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In recent years evidence has become available that drug response is a complex trait and as 
a consequence a one-size-fits-all approach in drug therapy is unsuitable. Indeed, a large 
inter-patient variability in drug efficacy exists and ranges between 25% to 80% (1). In 
addition to variable drug efficacy, individuals treated without tailoring of therapy may 
experience drug induced side-effects which in turn can lead to drug-related morbidity 
and mortality (2-4). Evidence that drug response is at least partly heritable has been 
available since the early 1930’s (5-10). In the following decades new discoveries in the 
emerging field of genetics and molecular biology have shown that drug efficacy, the 
absorption, distribution, metabolism and excretion of drugs and the risk of adverse drug 
events can be explained by genetics in some extent (11-14). Pharmacogenetics (PGx) is 
the area within the field of genetics that investigates the influence of heritability on drug 
response. Recent studies have shown that the use of PGx can lead to improved efficacy 
and a decrease in drug related morbidity and mortality (15-17). However, before PGx 
could be implemented in clinical care a number of barriers had to be addressed such as 
the lack of clinical grade tests, the lack of evidence-based therapeutic recommendations 
and the integration of PGx into the workflow of healthcare professionals (18). In the last 
decade numerous clinical grade test have become available, the Clinical Pharmacogenetics 
Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group 
(DPWG) have developed dosing guidelines for well-known gene-drug pairs and in the 
Netherlands the therapeutic recommendations of the DWPG are incorporated into 
electronic drug prescribing and -dispensing systems used by physicians and pharmacists 
in clinical practice. Currently, pharmacogenetic testing is used by secondary and tertiary 
care centers to optimize therapy with high risk medication (19). However, up to date the 
implementation of PGx in primary care has been low, while evidence suggests that patients 
treated in primary care could benefit from dose optimization based on genetic information. 
Unlike the field of oncology, where for example only approximately 5% of patients carry a 
genetic variant in DPYD that requires dose optimization of fluoropyrimidines (19, 20), the 
frequency of patients who receive suboptimal therapy as a result of drug-gene interactions 
is estimated to be larger. It has been shown that 28.6% of all patients in primary care use at 
least one drug metabolized by a polymorphic enzyme and 46 of the 53 guidelines issued 
by the DPWG in 2011 are related to drugs also used in primary care (21-23). These facts 
support the hypothesis that the adoption of PGx in primary care could lead to a health 
benefit for patients treated in the first line of health care.





The aim of this thesis is to investigate the adoption of PGx and the integration of genotype-
guided dosing in the workflow of physicians and pharmacists in primary care. This thesis 
is divided into five parts. The first part (Chapter 2) provides an overview of answers to 
frequently asked questions by clinicians related to the implementation of PGx. 
The second part of this covers the implementation of PGx in clinical practice and its 
impact on a national level. In Chapter 3 a novel test for the detection of 13 genetic variants 
in the pharmacogene CYP2D6, the Genochip CYP2D6 macro array, is compared to the 
gold standard in CYP2D6 genotyping (the Amplichip CYP450 test developed by Roche) 
to investigate whether the Genochip is ready for clinical implementation. Chapter 4 
investigates whether genotype guided dosing in primary care is feasible in a pilot study 
where 200 patients with an incident prescription for a subset of 10 drugs and historical 
use are genotyped in a panel based approach for CYP2C9, CYP2C19, CYP2D6, CYP3A5, 
DPYD, TPMT, SLCO1B1 and VKORC1 and received genotype guided dosing based on 
recommendations of the DPWG guidelines (the Implementation of Pharmacogenetics 
into Primary Care Project). In Chapter 5 an assessment of the clinical impact of PGx in 
primary care in the Netherlands is provided to predict how many patients that start with a 
drug currently described in the guidelines of the DPWG require an optimization of therapy. 
This study was performed with the frequencies of the eight pharmacogenes, obtained 
from the genotype results of the IP3 study, and combined with national prescription data 
from a selection of drugs which have a known gene-drug interaction with the selected 
panel of 8 genes. 
Part III covers the harmonization of PGx-test interpretation and therapeutic recommenda-
tions. Chapter 6 presents a counter argument to a proposition by Magnani et al. to reduce 
fluoropyrimidine dosing even further in heterozygous carriers of the DPYD*2A variant 
than currently described in the guidelines of CPIC and DPWG. In Chapter 7 is investigated 
which clinically relevant differences in terms of translation from genotype to phenotype 
and therapeutic recommendations exists between the guidelines of the CPIC and DPWG 
and whether they can be explained by the methodologies used by the two consortia. As a 
result of the efforts of the DPWG therapeutic recommendations for patients with known 
aberrant phenotypes are available at point-of-care through clinical decision support. 
However, it is currently unknown whether Dutch healthcare professionals feel prepared 
to guide treatment based on genetic information. 
Part IV investigates the knowledge, experience and attitudes towards PGx among (future) 
healthcare professionals. Chapter 8 describes a study to benchmark knowledge, experience, 
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and attitudes of Dutch pharmacists. In Chapter 9 the question is addressed whether 
PharmD have received enough training in their curriculum to feel informed about PGx. 
Part V contains the general discussion (Chapter 10) along with the English and Dutch 
summaries. 
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Drug response shows significant interpatient variability and evidence that genetics 
influences outcome of drug therapy has been known for more than five decades. However, 
the translation of this knowledge to clinical practice remains slow. Using examples from 
clinical practice six considerations about the implementation of pharmacogenetics (PGx) 
into routine care are discussed: the need for PGx biomarkers; the sources of genetic 
variability in drug response; the amount of variability explained by PGx; whether PGx 
test results are actionable; the level of evidence needed for implementation of PGx and 
the sources of information regarding interpretation of PGx data.
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Since the completion of the Human Genome Project, pharmacogenetics (PGx) has been 
heralded as one of the first clinical applications arising from this landmark project. Indeed, 
in 2001, it was envisioned that within 10 years physicians would use genomic information 
to guide the treatment of their patients (1, 2). However, currently we can conclude that 
adoption of PGx in clinical practice is limited and slow. Here, we present six considerations 
related to implementation of PGx in clinical practice. Each of the considerations is 
illustrated with clinical examples and potential strategies to improve implementation are 
discussed. 
Case example of the potential effect of genetic variability
Three 2-year-old children are prescribed 10–12.5 mg codeine orally every 4 to 6 h 
following a successful adenotonsillectomy (3, 4). The following day, the parents of one 
of the children consult the pediatrician because their child continues to experience 
pain. The pediatrician stops codeine and prescribes ibuprofen, which successfully 
lowers the pain (5-7). Routine follow-up with the second child shows a good response 
to codeine. On the third day after the adenotonsillectomy, the pediatrician receives 
a report by the paramedics who responded to an emergency call from the parents 
of the third child. The parents had found their child in the morning with decreased 
vital signs. The child had been wheezing and had developed fever the previous night. 
Efforts by the paramedics to resuscitate the child failed. Postmortem analysis showed 
blood levels of 0.70 mg codeine and 32 ng morphine per milliliter. Autopsy further 
revealed aspiration of food particles and bilateral consolidation in the lungs consistent 
with bronchopneumonia (8, 9). Genetic analyses showed that the cytochrome P-450 
(CYP) 2D6 genotypes could explain the different responses to codeine between the 
three children (5-9). This extreme example shows that variations in genes coding for 
metabolizing enzymes can lead to a significant difference in drug efficacy and safety. 
In this case, CYP2D6 genotype guided dosing may have prevented nonresponse of 
the first child and prevented the fatal outcome of the third child.
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Do we need (pharmacogenetic) biomarker to predict drug 
response?
In the current era of evidence-based medicine, patients are treated according to evidence-
based guidelines, which are ideally based upon results of multiple, double-blind, 
randomized controlled trials (RCTs). However, these RCTs often include highly selected 
individuals and participants are subjected to controlled procedures. In contrast, the actual 
patient population in clinical practice is highly heterogeneous and includes the elderly, 
patients with impaired organ function and patients with comorbidities (10). As a result, 
drug efficacy and toxicity in patients in clinical practice differs from outcomes of drug 
therapy observed in the clinical studies. Indeed, the variability of drug response among 
the major drug classes is high. It is estimated that drug efficacy ranges from 25 to 80%, 
with most of the drugs falling in the interval of 50–75% (11).
In addition, there is also the risk of adverse drug events. Although intense efforts are made 
by regulatory agencies to provide safe pharmacotherapy for the general population, it was 
reported that 1.8 million people were hospitalized for adverse drug events in the USA in 
1994 (12). Genetic variability contributes to this variability in drug toxicity and efficacy. It 
has been reported that 60% of all the drugs that caused adverse events were metabolized 
by enzymes that are under control of polymorphic genes (13). Furthermore, an analysis of 
607 patients from three US-based primary care centers showed that 28.6% used at least one 
drug that is metabolized by an enzyme that is under control of a polymorphic gene (14). 
The result of the variability in drug efficacy and toxicity is that it is difficult to prescribe the 
most effective and most safe drug to an individual patient. In fact, the current practice of 
prescribing could still be considered largely ‘trial and error.’ After diagnosis, a standardized 
drug and dosage are selected from a (evidence-based) guideline. The dose or drug choice 
may be individualized to some extent based upon the patients’ characteristics such as 
comorbidity, comedication, age or organ function. Then drug efficacy and toxicity are 
monitored by using (surrogate) markers such as blood pressure, cholesterol levels, tumor 
size or liver enzymes. When the therapy appears to be ineffective or causes side effects, 
the treatment is modified by adjusting the dose or selected drug.
Although this process of trial and error prescribing may be laborious and time consuming, 
it is not a problem for some treatments and conditions. For example, in the case of treatment 
of hypertension with antihypertensive drugs to lower the risk of cardiovascular disease, 
treatment efficacy can be monitored simply by measuring the blood pressure after 4 
weeks. Results from the Framingham study have shown that a hypertensive patient with 
additional risk factors has a risk of ≥ 20% of dying from cardiovascular disease in the next 
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10 years (15). Effective antihypertensive drug treatment results in a relative risk reduction 
of 20–25% over a 10-year time span and in a patient with a predicted Framingham risk 
of 25% antihypertensive treatment would lead to an absolute risk reduction of 5.0–6.3% 
(16, 17). It can be calculated that a 3-month delay of effective treatment due to trial 
and error prescribing would lead to an increase of only 0.13–0.16% in the absolute risk 
of cardiovascular-related death in 10 years. Therefore, a delay as a result of ineffective 
treatment has little, if any, effect on the reduction of cardiovascular events. Obviously, 
this is different in the field of oncology, where generally patients in a metastatic setting 
have a short life expectancy. For example, a 3-month delay due to difficulties in finding an 
effective and safe therapy is not acceptable in the treatment of metastatic colorectal cancer 
patients, with a median overall survival of only 24–36 months (18).
Therefore, it is of great importance to develop biomarkers for predicting drug response, 
especially in the following situations: where the drug effect is difficult to assess and presents 
after months to years; when treatment delay has important clinical consequences; in diseases 
with a poor prognosis and treatments with severe side effects.
In summary, drug response both with regard to efficacy and toxicity of frequently prescribed 
drugs is highly variable. Currently, pharmacotherapy is largely based on trial and error 
selection of drugs and dosages for individual patients. By using predictive PGx biomarkers, 
a more rational approach could be achieved and drug response could be predicted upfront, 
resulting in a safer and more efficacious drug treatment for the individual patient.
Which are the sources of genetic variability in drug response? 
Drug response is a combination of pharmacokinetics (PK) and pharmacodynamics (PD). 
PK describes the processes of absorption, distribution, metabolism and excretion and is 
generally referred to as ‘what the body does to the drug’. PD describes the processes when 
drugs, or their active metabolites, interact with their target, which can range from a receptor 
to a drug transporter. Changes in PK or PD contribute to variability of drug response, both 
with regard to efficacy and toxicity.
Genetic influence on pharmacokinetics 
Single nucleotide polymorphisms (SNPs), insertions and deletions in the genes that code 
for Phase I and II enzymes involved in PK can lead to reduced or even complete absence of 
enzyme activity. Although less common, increased enzyme activity has also been described, 
for example, due to allele multiplication (19). Consequently, these genetic variants can 
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lead to changes in plasma concentrations of drugs (14). Especially for drugs with a narrow 
therapeutic index, changes in the plasma drug concentration can easily result in failure of 
therapy or toxicity (see section ‘Case example of the potential effect of genetic variability’).
The effect of SNPs on drug PK can be exemplified by the fluoropyrimidines such as 
5-fluorouracil and capecitabine. These drugs are the cornerstones of treatment of many 
cancers, including colorectal and breast cancer. The most important metabolic step in the PK 
of fluoropyrimidines is the inactivation by the enzyme dihydropyrimidine dehydrogenase 
(DPD) in the liver. This enzyme is a product of the autosomal inherited DPYD gene and is 
responsible for > 80% of the metabolism of fluoropyrimidines (20). Normally, 10% of the 
patients who undergo fluoropyrimidine-based treatment experience severe toxicity and 
a significant number requires hospitalization for recovery (21). Diminished DPD activity 
is seen in up to 3% of the population, and treatment of an individual with diminished 
capacity to metabolize fluoropyrimidines can lead to severe or even lethal gastrointestinal, 
hematological or neurological toxicity (22-26). It has been shown that multiple SNPs in 
the DPYD gene can lead to an enzyme with a decreased or even absent activity (25-27). 
The IVS14+1G>A variant is the most studied variant and is present in an intron between 
exons 14 and 15 in the DPYD gene, where it causes the exon skipping of exon 14 and leads 
to a nonfunctional enzyme and decreased clearance of fluoropyrimidines (25, 26). Other 
relevant SNPs in DYPD that can lead to low or absent DPD activity are the 2846A>T and 
the 1236G>A mutations. The incidence of grade 3 to 4 diarrhea increases to 71% (p < 
0.01), 62% (p < 0.02) and 50% (p < 0.006), respectively, in patients heterozygous for the 
IVS14+1G>A, 2846A>T or 1236G>A mutation compared to 24% in patients with a wild 
type DPYD gene (28-31).
Genetic influence on pharmacodynamics 
Genetic variants in the genes coding for a receptor, a transporter or an enzyme can lead to 
a change in associated downstream signaling and biochemical processes. These differences 
can result in an altered drug response.
An example of how genetic variation may affect a drug’s PD is the SNPs in the ADRB2 
gene encoding the β2-receptor. β2-agonists are frequently prescribed drugs in patients 
with asthma and chronic obstructive pulmonary disease. The ADRB2 gene is located on 
q31-q32 of chromosome 5 (32). SNPs in ADRB2 have been correlated with a difference in 
downregulation, expression profiles and response to (ant)agonists of the β2-adrenoreceptor 
(33, 34). The SNPs 46G>A and 79C>G result in substitution of arginine to glycine at codon 
16 and glutamine to glutamic acid at codon 27, respectively (35). Homozygous carriers of 
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glutamic acid at codon 27 show a higher venodilatation after exposure to the β2-agonist 
isoproterenol (36). Multiple studies in children and adults with asthma have shown that 
homozygous carriers of arginine at codon 16 have a better airway response to albuterol 
compared to heterozygous carriers of arginine and homozygous carriers of glycine at 
codon 16 (33, 34).
Genetic influence on both pharmacokinetics & pharmacodynamics 
Obviously, since genetic variation in genes is abundant and for the majority of drugs 
multiple genes are involved in the PK and PD pathways, both variation in PK and PD will 
importantly contribute to variable drug response of most drugs. An example of a group of 
drugs where genetic variations in both PK and PD have been found related to variability 
in drug response is the coumarins. This group of drugs influences blood coagulation by 
targeting a metabolizing enzyme involved in the recycling of vitamin K (37-41).
The majority of the Phase I metabolism of coumarins occurs by the liver enzyme CYP2C9. 
Currently, over 30 genetic variants of the CYP2C9 gene have been described (42). The 
CYP2C9*2 (420C>T) and CYP2C9*3 (1075A>C) alleles both lead to changes in the 
amino acids in the catalytic site of the enzyme, resulting in lower or absent capacity to 
metabolize coumarins (43, 44). A case report by Steward et al. and a case-control study 
with 88 patients and 100 controls by Aithal et al. showed that patients with a variant allele 
of CYP2C9 require a lower maintenance dose than those with a wild type allele (45, 46). 
Four individual PGx studies with European patients confirmed these results (47-50). 
Coumarins target the enzyme vitamin K epoxide reductase multiprotein complex subunit 
1 (VKORC1). A genome-wide linkage study identified VKORC1 as the coding gene (51). 
Sequencing of VKORC1 in patients with a type 2 deficiency of vitamin-K-dependent clotting 
factors showed several genetic variants in the exome of the gene that were responsible 
for decreased activity of the enzyme (52). However, studies in European and American 
Caucasian patients using coumarins showed that variants in the promoter and an intron 
of VKORC1, the SNPs 1639G>A and 1173C>T, respectively, were more prevalent and 
showed better correlations with daily doses of coumarins than the found mutations in the 
exome (53-55). In the case of coumarins, the two genes coding for the enzymes CYP2C9 
and VKORC1 influence PK and PD, respectively, but both contribute to drug response.
Genetic influence on idiosyncratic drug reactions 
In some situations, adverse events are not related to the drug exposure. The frequency 
of these idiosyncratic (or type B) adverse events is lower than exposure-dependent (or 
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type A) adverse events and they are usually detected at a later stage in the process of drug 
development or after market approval. Indeed, between 1976 and 2005, 28 drugs were 
removed from the market because of serious idiosyncratic adverse events in the USA 
(56, 57). In recent years, genome-wide association (GWA) studies have identified genetic 
variants related to idiosyncratic reactions of several drugs (57, 58).
Flucloxacillin-induced liver injury is an example of a severe idiosyncratic drug reaction. The 
antibiotic flucloxacillin causes serious liver injury in < 1 in 10,000 patients. A GWA study 
of 51 cases of drug-induced liver injury (DILI) caused by flucloxacillin and 282 controls 
showed that SNPs in the genetic region of the HLA genes are a significant predictor of DILI. 
The strongest hit, a SNP located in the HCP5 gene, showed strong linkage disequilibrium 
with the B*5701 allele of HLA class I. Further analysis and replication in 16 additional 
DILI cases showed that individuals who carry the B*5701 allele have a much higher risk 
of flucloxacillin liver injury (an OR of 80.6) (59). Alleles that were identified in these 
GWA studies and candidate gene studies do not appear to influence PK or PD, but seem 
to modulate immune response to drugs. Similar associations between SNPs in HLA genes 
and toxicity have been reported for abacavir, allopurinol and carbamazepine (60-62).
How much variability is explained by pharmacogenetics? 
Fueled by the classic examples of Mendelian disorders, many clinicians consider PGx an 
on-or-off phenomenon. However, this phenomenon is rare and to date only a limited 
number of genes have been reported that have such an effect on the outcome of therapy. 
In addition to DPYD and several variants of HLA genes, the PGx biomarker TMPT, 
coding for the enzyme thiopurine methyltransferase and responsible for the metabolism 
of thiopurines, is one of the few examples where a large part of the observed variability in 
toxicity can be explained by genetic variants in a single gene. In general, not only genetics 
but also multiple nongenetic factors (i.e., age, organ function and weight) contribute to the 
complex phenotype of drug response and a single PGx biomarker may only be expected 
to explain a part of the observed interindividual variability in drug response. For most 
PGx biomarkers, the relative contribution in explaining interindividual response can be 
quantified as a percentage of explained variance symbolized by R2. Using these parameters, 
the clinical value of a PGx biomarker in selecting the right drug and the right dose can 
be estimated and compared to the performance of conventional clinical factors used to 
guide pharmacotherapy.
One of the first to quantify the effect of PGx on the variability in response was the group 
of Sconce et al. They investigated the effect of PGx variants on warfarin dose and showed 
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that genetic variants in VKORC1 and CYP2C9 could explain 17.5 and 15.0% of the variance 
in dose, respectively. Combination of the two genotypes with clinical factors such as age 
and height increased the explained variance in dose by the algorithm to 55% (See Table 
2.1) (55). For acenocoumarol and phenprocoumon the two genes CYP2C9 and VKORC1 
explain 4.5%, 27.2%, 4.6% and 34.1% of the variance in dose requirement respectively 
(63). Combination of CYP2C9 and VKORC1 status with other markers for response such 
as weight, height, sex, age and concomitant medication improved the explained variance 
to approximately 52.6% for acenocoumarol and 55.9% for phenprocoumon, respectively 
(Table 2.1) (63).
Similar potential for PGx biomarkers to explain a significant proportion of variability 
in response to medication is also observed in the field of rheumatology. Patients who 
are diagnosed with rheumatoid arthritis are treated with methotrexate (MTX), the most 
widely used disease-modifying antirheumatic drug (64, 65). However, only about half of 
Table 2.1: Explained variance in dose requirements, disease activity score response and ‡3 grade 
toxicity with and without clinical factors for three coumarins, methotrexate, fluoropyrimidines and 
irinotecan
Drug (Genetic) biomarker R2 Studied phenotype References
Warfarin CYP2C9
+ VKORC1





















Methotrexate AMPD1 + ATIC + ITPA + 
AMTHFD1
+ clinical factors (sex, Rf 

















AUC: Area under the curve; AMPD1: Adenosine mono- phosphate deaminase; ATIC: Aminoimidazole 
carboxamide ribonucleotide transformylase; DAS: Disease activity score; ITPA: Inosine triphosphate 
pyrophosphatase; MTHFD1: Methylenetetrahydrofolate reductase; RF: Rheumatoid factor.
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the patients show a good clinical response during treatment and in 30% of patients MTX 
treatment is stopped as a result of side effects (66, 67). In a study by Wessels et al., it was 
shown that the clinical factors such as sex, rheumatoid factor (RF) status, smoking and 
disease activity score (DAS) at baseline could explain approximately 25% of the variance in 
DAS response to MTX therapy in patients with newly diagnosed rheumatoid arthritis. In 
this study, genotypes for 17 SNPs in 13 candidate genes related to PK and PD of MTX were 
also correlated with the response in DAS after 6 months of treatment with MTX. SNPs in 
the genes adenosine monophosphate deaminase (AMPD1), aminoimidazole carboxamide 
ribonucleotide transformylase (ATIC), inosine triphosphate pyrophosphatase (ITPA) and 
methylenetetrahydrofolate reductase (MTHFD1) were significantly associated with a DAS 
response after 6 months of MTX therapy. Combined with the clinical factors, these four 
PGx biomarkers could explain approximately 35% of the variance in DAS response to 
MTX (Table 2.1) (68).
As described above, variation in the DPYD gene can explain an important part of observed 
toxicity to fluoropyrimidines. Indeed, multiple studies have shown that 23–38% of the 
occurrence of ≥ 3 grade toxicity of fluoropyrimidine treatment can be explained by 
genetic variants in the DPYD gene (Table 2.1) (69-72). Deenen et al. have shown that a 
dose reduction of 50% based on the IVS14+1G>A status can lead to a risk reduction of ≥ 
3 grade toxicity from 68% in historical controls to 15% while maintaining fluoropyrimi-
dine exposure comparable to fully dosed noncarriers of the IVS14+1G>A variants (73). 
However, as with the coumarin example, other clinical factors including treatment regimen 
and concomitant medication also contribute to the risk of toxicities (69, 74).
Another example of a drug–gene interaction where drug toxicity can be partly explained 
by PGx is the combination of the gene UGT-1A1 and irinotecan, an agent used in advanced 
colorectal cancer. Irinotecan is a prodrug that is metabolized in vivo by CYP3A into 
inactive metabolites and by carboxylesterase into the active metabolite SN-38. This active 
metabolite is responsible for the antitumor effect. SN-38 is glucuronidated in the liver by 
the enzyme UDP-glucuronosyltransferase (UGT) 1A1 to SN-38 glucoronide, which is 
excreted through bile and urine (75, 76). The UGT-1A1*28 gene carries a promoter region 
with a binding site consisting of six TA repeats, which allows the transcription factor IID 
to bind and upregulate expression of UGT-1A1*28. In carriers of the UGT-1A1*28 allele, 
the binding site contains seven TA repeats instead of the normal six and the expression of 
the UGT-1A1 enzyme is reduced (77). The reduced expression of this metabolic enzyme 
reduces the capacity of this individual to glucoronidate the active metabolite SN-38 which 
in turn can lead to accumulation and a higher chance of toxicity in the form of diarrhea 
and leukopenia than an individual with a wild type UGT-1A1 gene (78-81). A study by 
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Ramchandani et al. has shown that the decrease in absolute neutrophil count could be 
explained by 31%, while a combination of genotype with the area under the curve of SN-38 
resulted in an explained variance in absolute neutrophil of 49% (82).
Overall, these examples show that genetics can explain an important part of the variability 
in drug response. However, monogenetic influence on treatment variability is rare and 
the proportion of explained variance ranges considerably (5–55%) for different drug–gene 
combinations. Whether or not these numbers are clinically important is highly dependent 
on the studied phenotype and the examples also illustrate that PGx biomarkers should 
not be used as standalone markers for drug response, but should rather be combined with 
known clinical prediction for drug response to maximize the explained variance (R2). 
Are pharmacogenetic test results actionable? 
Typical outcomes of current PGx (GWA) studies include odds/hazard ratios (83, 84) and 
an increased risk or association with an improved or impaired response or negative drug 
effect (85, 86). However, these results are difficult to apply in treating individual patients.
Surveys among members of the Clinical Pharmacogenetics Implementation Consortium 
(CPIC) and members of the American Society for Clinical Pharmacology and Therapeutics 
in 2009 and 2010 have shown that there is a need for clear and curated peer-reviewed 
guidelines that help health care professionals to guide the interpretation of a PGx test 
result in a clinical context (87).
In daily practice, clinical factors such as kidney function are already used to adjust drug 
dosing and this information is typically available in guidelines or package inserts. Yet these 
guidelines rarely contain actionable information on the use of genetic biomarkers such as 
dose recommendations for a specific genotype. To make PGx test results actionable for 
clinicians, results from PGx studies have to be transformed from odds/hazard ratios to 
algorithms, decision trees or scoring systems.
An example of such a tool is the MTX scoring system developed by Wessels et al. to help 
rheumatologists select potential nonresponders from their patient population. The MTX 
scoring system includes the clinical factors such as gender, smoking status and DAS; the 
immunological biomarker RF and the MTHFD1, AMPD1, ITPA and ATIC genotypes. 
The system operates by assigning points for the presence of certain characteristics. For 
example, the presence of RF is scored by one point as well as the presence of variant alleles 
of MTHFD1, AMPD1 and ATIC, while the presence of the variant allele of ITPA scores 
two points. The cut-off values for responder and intermediate responder are set at ≤ 3.5 
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and < 6, respectively, while patients with a score of ≥ 6 are classified as nonresponders. 
Analyses with multiple cohorts have shown that this scoring system predicts the phenotype 
of responders or nonresponders in 79% (95% CI: 72–85%) of patients correctly (68).
Other examples of dosing algorithms can be found in the field of cardiology. In 2005, Sconce 
et al. evaluated the role of clinical and genetic factors on warfarin clearance in 297 patients 
using regression and selected age, height and CYP2C9 and VKORC1 genotypes for a new 
dosing algorithm. In a small cohort of 38 unrelated patients, the algorithm was validated 
and showed a regression of 0.80 (p < 0.001) between the modeled dose and the actual dose 
(55). For acenocoumarol and phenprocoumon, van Schie et al. developed loading and 
maintenance dose algorithms for these two drugs based on data from populations of 559 
and 375 genotyped patients, respectively, based on the parameters CYP2C9, VKORC1, age, 
height, weight and use of amiodaron. The algorithm of acenocoumarol was validated in 
an independent cohort of 707 patients in which all parameters necessary for the algorithm 
were collected. In the analysis, the algorithm shows an R2 of 52.7% for the genetic model, 
which is comparable with the R2 of 52.6% in the original study (88).
In conclusion, to make PGx test results actionable and to support clinical application, it 
is essential that results of PGx studies are presented as actionable dosing algorithms or 
decision trees.
What level of evidence is needed for implementation? 
The level of evidence that is required to implement PGx into clinical practice is highly 
debated (89-91). Current standards of evidence-based medicine require evidence for 
increased efficacy and safety or the same performance for lower costs, prior to the 
implementation of new techniques or treatments. If feasible, this evidence should best 
be obtained from RCTs (92, 93, 94-96). Thus, if PGx-guided therapy is considered an 
alternative compared to regular care, the evidence-based paradigm dictates the same level 
of evidence as is required for all other interventions and RCTs should be performed for 
each individual gene–drug combination.
However, there are also multiple arguments against the demand for RCTs for each gene–
drug combination. There is no valid pharmacological argument to consider gene–drug 
interactions any different from drug–drug interactions or dose adjustments for clinical 
factors such as for impaired liver or renal function and dosing recommendations. The latter 
two are typically exclusively based on observational data. Regulatory authorities do not 
require data from RCTs showing that these recommendations result in improved clinical 
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outcomes and in clinical practice dosages are frequently adjusted based on observational 
evidence (91).
A second argument against the demand for RCTs for every single gene–drug interaction 
is that they are highly expensive and thus simply impossible for every single drug–gene 
variant. For novel drugs, RCTs are paid for by the pharmaceutical company that holds 
the patent. However, for existing drugs the cost of conducting a RCT for a certain genetic 
variant may be considered too high. Furthermore, for many drugs that have a drug–
gene interaction the pharmacology is well known. For example, the majority of tricyclic 
antidepressants (TCAs) are metabolized by one or more highly polymorphic enzymes 
of the CYP family (97, 98). With the knowledge of the pharmacology of TCAs and the 
amount of clinical experience that has been obtained by clinicians with dosing based on 
blood levels, it appears to be a safe strategy to guide TCA dosing by PGx biomarkers (91, 
99). As an alternative to RCTs for each gene–drug interaction, some have argued that PGx-
guided therapy should be approved based on noninferiority (90). However, because PGx 
is a supplement on clinical care rather than an alternative for routine care, noninferiority 
is not the best option from a methodological point of view. Furthermore, noninferiority 
trials are much more sensitive to biases that dilute the differences between the index and 
control groups (100, 101).
Despite the ongoing debate about the necessity for an RCT for each gene–drug interaction, 
several RCTs for a number of PGx biomarkers have already been performed. Examples are 
the drug–gene pairs abacavir with HLA-B*5701 and the combination of coumarines with 
CYP2C9 and VKORC1. In the case of abacavir, it was shown that PGx-guided treatment 
results in lower risk of hypersensitivity. Subsequent studies also proved that screening for 
HLA-B*5701 is cost–effective (61, 102). However, for the pharmacogenetically guided 
dosing of coumarins the results are less clear. In recent years, multiple RCTs have been 
performed where PGx-guided anticoagulant therapy was compared to standard anticoagu-
lant therapy. While several RCTs with warfarin show results with a significant beneficial 
effect on time in therapeutic range (TTR), reports in 2007, 2009 and 2013 by Anderson et 
al., Gong et al. and Kimmel et al., respectively, contradict the positive studies (103-108). 
The results of the EU Pharmacogenetics of Anticoagulant Therapy (EUPACT) trials where 
PGx-guided therapy of acenocoumarol and phenprocoumon were compared to normal 
care only showed a modest effect on TTR in the first 4 weeks and no effect on the primary 
endpoint of TTR in the first 12 weeks. The EU-PACT results also contradict results from 
previous retrospective studies (63, 88). A clear explanation for this conflicting data remains 
to be found. A small effect size, a small window (<4 weeks) where PGx-guided therapy 
can make a significant difference, a difference in frequency of racial origin resulting in 
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differences in allele frequencies of CYP2C9 and the use of the genotype-guided algorithm 
on the first day of the loading dose have all been suggested (103-109).
In our opinion, a small number of positive RCTs with PGx biomarkers would be sufficient 
to provide evidence that genotype-guided strategy can lead to a better outcome of therapy. 
Once this proof of principle is established, additional RCTs might not be needed for each 
individual gene–drug combination. Then sufficient evidence for clinical utility in the 
form of observational evidence from well-designed and replicated studies should justify 
implementation of a PGx biomarker into patient care.
Sources for up-to-date information regarding interpretation of 
pharmacogenetic test results 
The interpretation of a PGx test result can be fairly straightforward only when a small 
number of variants with a well-established effect in one gene and one drug are involved. 
Based on the allelic variants carried by the individual, the dose can be adjusted (e.g., 
6-mercaptopurine and TPMT genotypes) with relative ease or the drug can be avoided 
(e.g., abacavir and HLA-B*5701). However, in clinical reality, the situation is often much 
more complex. For example, the effects of many genetic variants are not known and often 
drug metabolism involves multiple enzymes. In the case of the drug amitriptyline, which 
is metabolized by the enzymes CYP2D6 and CYP2C19, the majority of PGx studies on 
amitriptyline only focus on one of the enzymes. As a result, the prediction of the plasma 
concentration and effectiveness and tolerability of amitriptyline is difficult in individuals 
with polymorphisms in both CYP2D6 and CYP2C19 (99, 110). Moreover, when a patient 
uses multiple drugs, the interaction between gene–drug and drug–drug interactions rapidly 
becomes more complicated.
To facilitate clinicians with the interpretation of gene–drug interactions, the Dutch 
Pharmacogenetic Working Group (DPWG) developed PGx dose recommendations for 
26 drugs based on a systematic review of the literature in 2008 (111). In 2011, these guide-
lines were updated and contained 53 gene–drug interactions (112). In the US, a similar 
initiative was undertaken by the CPIC which was formed in 2009 and has since provided 
guidelines to translate results from genetic tests into results for 23 gene–drug interactions. 
The guidelines of both groups can be found on pharmgkb.org (113). The guidelines by 
the CPIC and the DPWG will greatly facilitate the sound interpretation of PGx test results 
and subsequent actions.
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In the last decade, PGx has transformed from the once anticipated revolution into a steady 
evolution. Research on SNPs in PK and PD candidate genes has provided us with several 
actionable variants that have been incorporated into clinical guidelines. In the past few 
years, technology has advanced significantly and more and more GWA studies and next 
generation sequencing (NGS) are published, reporting potential PGx biomarkers which 
can further explain the observed interindividual variability in drug response. In addition, 
although the number of newly found PGx biomarkers are relatively small compared to 
the number of genetic biomarkers for diseases, such as Alzheimer disease, depression, 
diabetes mellitus and cancer, it appears that the PGx biomarkers appear to have much 
larger effect sizes (114). However, the majority of these newly identified PGx biomarkers 
are still exploratory and it will take time and additional evidence to incorporate these 
findings into clinically actionable guidelines. In 2010, the first attempt was made to use 
whole genome sequencing data in a PGx context (115). A second assessment of whole 
genome sequencing data, including disease risk and PGx biomarkers, from 12 adults was 
recently reported (116).
Another way in which hypothesis-free genetic testing could further increase the number 
of useful PGx biomarkers is genotyping available material from drug registration trials. 
Linking PGx biomarkers to PK and PD data obtained in the same trials could simultaneously 
generate information about clinical validity and utility of PGx biomarkers and provide a 
scientific base for interventions in the population carrying the genetic variant (e.g., for a 
dose reduction in a patient carrying an allelic variant that decreases the metabolic rate of 
that drug). Adaptive signatures, adaptive thresholds or Bayesian adaptive two-stage Phase 
I/II trial designs could help explore and validate PGx biomarkers found through GWA 
studies and NGS. 
In addition, validated PGx biomarkers could be used to reduce the need for large and 
costly Phase III trials. In the case of a drug that only shows a modest effect on a composite 
clinical endpoint, a positive outcome of a Phase III trial is less likely, and especially if a 
small number of major side effects would occur during the trial this could prevent drug 
approval. Based on the role of the PGx biomarkers in the pharmacology of the drug (e.g., a 
genetic variation in the genome of the host leading to an altered metabolizing enzyme or a 
mutation in a tumor cell leading to an altered drug target) and whether the PGx biomarker 
is prognostic, predictive or both, the trial design incorporating the PGx biomarker can be 
adapted. In case the mechanism behind a predictive PGx biomarker is well understood 
and there is sufficient evidence that certain patients with (or without) the PGx biomarker 
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will not benefit from the drug therapy, an enrichment design could be used. In this trial 
design, the patient population is screened upfront and only patients who carry the specific 
PGx biomarker will be included and receive the new treatment or placebo (117, 118). An 
important aspect of this design is that the assay that is used for patient stratification is 
accurate and reproducible among participating centers. In case the clinical consequences 
of the status of the PGx biomarkers are not yet clear, alternative designs are more suitable. 
The sequential testing design is a method where a new treatment is tested in a general 
population of patients initially, and subsequently in a second RCT, the treatment is tested 
in a subgroup of patients with the PGx biomarker. A downside to the sequential testing 
design is the introduction of multiple testing (119, 120). In the biomarker, by treatment 
design patients are stratified according to the status of a predictive PGx biomarker and then 
randomized between treatment arms. This design is similar to the sequential design but 
encompasses each subgroup in a single RCT. The biomarker strategy design is a trial design 
in which patients are randomized into the arm where the given treatment is dependent on 
the status of a predictive PGx biomarker or into the arm where treatment is not dependent 
on the PGx biomarker. A downside to this design is the overlap between the two arms 
(each arm contains patients treated with a similar regimen) resulting in a larger trial (121, 
122). Finally, the adaptive accrual design is a two-stage trial where primarily only patients 
harboring the PGx biomarker are randomized over the treatment arms. When an interim 
analysis of the first stage is positive, all patients, regardless of the PGx biomarker status, 
are allowed into the second stage of the trial and with a negative result the trial is stopped 
(123). In a variant to this adaptive accrual design, the first and second stages are reversed 
(124). Overall, based on the type of PGx biomarker and the available evidence, a trial design 
encompassing a PGx biomarker is available with each design having pro and cons in the 
form of multiple testing, overlapping treatment arms or limiting the proof of treatment to 
a certain subgroup (125-127). Although these designs have not been applied frequently, 
there are a number of trials where these designs have contributed to registration of drug 
with a PGx biomarker in the package insert (e.g., trastuzumab, cetuximab, panitumumab, 
imatinib) (128-132). In some cases, PGx biomarkers even rescued drugs that initially failed 
to show efficacy in a ‘regular’ RCT (e.g., erlotinib) (133-135). With the decrease in drugs 
in development pipelines of the pharmaceutical industry, these alternate designs could 
prove useful, especially for drugs developed for targets at the biomolecular level such as 
in oncology (136).
At the other end of the spectrum of implementation, in primary care, the lack of clinical 
guidelines, a major barrier for the implementation of PGx, is being addressed by the ongoing 
efforts of the DPWG and the CPIC to create dosing guidelines that enable the translation 
of genetic laboratory test results into actionable prescribing decisions for specific drugs. 
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However, a limitation of these guidelines is that they only recommend what to do when a 
patient’s genotype is known and do not indicate which patients should be genotyped. For 
a few drugs such as abacavir and clopidogrel, indication for genotyping is in the package 
insert, but for many other drugs this is not clear.
Another important aspect is the PGx knowledge of health care professionals. A recent 
survey among US physicians concerning the adoption of PGx shows that 97.6% agrees 
that variation in a person’s genome can influence drug response. However, only 29% of the 
responding physicians had received formal education on PGx and an even smaller fraction 
(10.3%) felt adequately informed. This may be the reason why only 12.9% of the physicians 
had ordered a PGx test in the preceding year (137). A survey among Canadian pharmacists 
showed similar results. In this study, 96.6% of the surveyed pharmacists claimed that they 
would recommend a genetic test if it could help predict efficacy of a drug. Yet, only 7.7% 
of the pharmacists reported that they felt comfortable receiving and advising based on the 
test results (138). This would suggest that more education about PGx biomarkers and the 
respective dose/drug recommendations is needed.
In addition to the role of health care professionals in adoption of this technique, the 
willingness of patients is also important for successful implementation. Multiple surveys 
have shown that acceptance of PGx by patients is dependent on the confidentiality of the 
data and possibility of information being shared with third parties (139, 140). To date, it 
is still unclear who the manager of the patients’ genome is, who should perform which 
genetic tests and who should have access to this (pharmaco)genetic data. Some companies 
have already profited from this ambiguous situation by providing direct-to-consumer 
genetic testing.
In line with other clinical parameters that can influence the effects of drugs (e.g., kidney 
failure or an allergy to medication), genetic biomarkers should be incorporated in the 
patient’s medical file (electronic) so that only health care professionals have access to this 
information to adjust pharmacotherapy (e.g., alternate drug or alternate dose) based on the 
patients’ genetic data. Incorporation of genetic data in a patient’s electronic medical file has 
the advantage that the genetic information can be coupled with a centralized infrastructure, 
which holds guidelines on drug–gene–interactions and associated recommendations on 
choice or dose of a drug. In this way, PGx can be integrated into the workflow of physicians 
and pharmacists.
These arguments may lead to believe that implementation of PGx into clinical practice is 
still far away; however, the opposite is true. Due to the rapid advancements in the field of 
molecular biology, genotyping prices have decreased rapidly making them approachable. 
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Prospective genotyping is cost–effective for some PGx biomarkers, such as exemplified 
by DPYD with a price of €75 per test (73). In comparison, 3 years ago the assay had an 
estimated cost of €120 per test, which discouraged routine screening for variants of this 
gene (141, 142). Currently, 8 of the 80 centers in the Netherlands provide oncological care 
screen routinely for genetic variants in the DPYD gene.
Worldwide, several specialized centers and consortia at the forefront of clinical PGx have 
initiated large implementation programs (143). In 2011, St. Jude Children’s Research 
Hospital reported that a pharmacist-managed clinical PGx service for TPMT and CYP2D6 
was designed and implemented (144). The genotyping service was expanded in 2011 with 
CYP2C19 and SLCO1B1 and more are being added. Recently, it was reported that 1016 
patients had been successfully genotyped in the program and that 78% of the genotyped 
patients carried at least one high-risk allele showing that preemptive genotyping is feasible 
and clinically useful (145). In 2012, the University of Chicago initiated recruitment for 
their project of 1200 patients (146). The aim of this project is to determine whether 
incorporation of a preemptive PGx testing service into routine clinical care is feasible 
and produces clinically usable results. Recently, it was reported that already 608 patients 
were genotyped and these genotypes resulted in 367 signals from the genomic prescribing 
system. Based on these results, preemptive pharmacogenetic testing was considered a 
success (147). Results from the largest reported prospective genotyping program initiated 
by Vanderbilt University have been reported recently. Approximately 10,000 patients 
participating in the PREDICT program have been genotyped for a panel of five drug–gene 
interactions, including thiopurines and TPMT, clopidogrel and CYP2C19, simvastatin 
and SLCO1B1, tacrolimus and CYP3A5, and warfarin and CYP2C9 and VKORC1. Data 
indicate that 91% of the patients who were genotyped harbored one or more actionable 
variants and moreover that prospective testing reduced the testing burden in comparison 
with reactive genotyping (148). Although some of these programs are still in the research 
domain and do not represent standard clinical care, centers specialized in cardiology, 
oncology and transplantation medicine show that PGx can be used to prevent serious 
adverse drug reactions or guide drug treatment and that routine genotyping for clinical 
care is possible. Unfortunately, in comparison with secondary and tertiary centers, the 
implementation of genotype-guided therapy in primary care is still nonexistent. However, 
adoption of PGx by this field of medicine would probably lead to a major gain of health. 
The question then remains: Which patients are eligible for standardized genotyping? 
Algorithms to preemptively assess the patient’s exposure to medications that are known to 
have drug–gene interactions could provide an answer to the question which patients should 
be genotyped.
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Overall, we can conclude that due to the relatively low costs of genotyping techniques, 
available evidence-based guidelines and integration of genetic data and the guidelines in 
electronic health care systems, implementation of PGx into clinical care is feasible and 
will continue to be implemented in the coming years.
Five-year view
The application of novel approaches such as GWA studies and NGS will continue to 
provide the field of pharmacology with further knowledge and insights into mechanisms 
and genetic variants involved in drug efficacy and toxicity, which will be incorporated into 
clinical guidelines. The complex phenotype ‘drug response’ may be largely predictable 
using a combination of multiple genetic variants and other clinical parameters. In addition, 
epigenetic research will further help to better understand the molecular mechanisms 
underlying variability in drug response and safety.
Data from multiple RCTs investigating genotype-guided therapy will become available in 
the subsequent years and when positive will help clinicians to accept the proof-of-concept of 
PGx. The cost of genotyping techniques will further decline in the coming years, leading to a 
larger number of cost–effective PGx tests that improve drug efficacy and safety, making this 
an increasingly interesting option for health insurers. And with the cost of NGS expected to 
drop to a few hundred dollars, the personal genome may become a commodity. Ultimately, 
health care professionals will encounter an increasing number of patients with genetic 
information in their practice. 
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The aim of this study was to investigate the concordance between the novel GenoChip 
CYP2D6 macroarray and the AmpliChip, which is considered the gold-standard in CYP2D6 
genotyping. Germline DNA of 200 patients was genotyped with both the AmpliChip and 
the GenoChip CYP2D6 macroarray. 198 samples (99%) showed concordance. In two 
discordant samples the AmpliChip identified a *41 allele while the GenoChip CYP2D6 
macroarray did not. Sanger Sequencing showed that the 2988G>A mutation and thus the 
*41 allele was not present in both samples. We conclude that that the GenoChip CYP2D6 
macroarray is a valid method for detecting genetic variants of CYP2D6 in a Caucasian 
population.
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Cytochrome P450 (CYP) 2D6 is a highly polymorphic gene that is involved in the metabolism 
of 20–25% of the currently marketed drugs (1, 2). Currently more than 80 variants of this 
gene have been described including single nucleotide polymorphisms (SNPs), insertions 
and deletions of single or multiple nucleotide(s) and deletion or duplication of the entire 
gene [http://www.cypalleles.ki.se/] (3-5). Based upon the presence of genetic variants in 
the CYP2D6 gene, a diplotype can be assigned and translated into extensive metabolizer 
(EM), intermediate metabolizer (IM), poor metabolizer (PM) or ultra-rapid metabolizer 
(UM) phenotype to predict the metabolizing capacity of an individual. In 2005 the FDA 
approved the AmpliChip® (Roche, Indianapolis, US) for clinical use. This platform enables 
to test for 32 variant alleles of CYP2D6 and 2 variant alleles of CYP2C19 and is considered 
the gold standard in CYP2D6 genotyping. However, in clinical practice the use of the 
AmpliChip is limited, potentially due to its relatively high costs. Recently, a macroarray 
for CYP2D6 genotyping (GenoChip CYP2D6) was developed by PharmGenomics GmbH 
(Mainz, Germany) which has a lower cost per test, does not require expensive equipment 
and is easy to handle. The concept of the macroarray is the formation of a visible pattern 
on the bottom of the GenoChip CYP2D6 tube using biotin labeled primers, immobilized 
oligonucleotides and a streptavidin-horseradish peroxidase complex. This pattern then can 
be captured using a colorimetric camera. The array can detect *3, *4, *6, *7, *8, *9, *10, 
*11, *17, *29 and *41 alleles using the SNPs rs35742686, rs3892097, rs5030655, rs5030867, 
rs5030865, rs5030656, rs1065852, rs5030863, rs28371706, rs59421388 and rs28371725 
along with deletion (*5) and duplication of the gene. These are the most prevalent alleles 
with increased, decreased or absent function (6-8). The aim of this study was to investigate 
the concordance between the Genochip CYP2D6 macroarray and the AmpliChip. 
Materials and methods
DNA samples were obtained from the CYPTAM study (CYPTAM: NTR1509) (9). In brief, 
the CYPTAM is a prospective multicenter study including 671 female patients with breast 
cancer in the Netherlands and Belgium. In this study, whole blood samples of 656 patients 
were collected and DNA was isolated with the Magna Pure system (Roche Diagnostics). 
The samples were analyzed with the AmpliChip CYP450 array to test for 32 variant alleles 
of CYP2D6 and successful genotyping result was produced for 642 patients. The first 200 
CYPTAM samples successfully genotyped with the AmpliChip were cross-validated using 
the PharmGenomics GenoChip CYP2D6 DNA macroarray kit to test for the alleles *3, *4, 
*6 , *7, *8, *9, *10, *11, *17, *29, *41, gene deletion (*5) and gene multiplication according 
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to the protocol supplied by the manufacturer. Briefly, each DNA sample was amplified 
using three separate PCR mixes (A, B & C) with biotinylated PCR primers. Mix A was 
used for amplification of *3, *4, *6, *7, *8, *9, *10, *11, *17, *29, *41. Mix B and C were 
used for detection of gene deletion (*5) and duplication (*xN), respectively. PCR products 
were analyzed by gel electrophoresis using a 0.7 % agarose gel to detect the presence of a 
4.6 kb fragment in mix A and a 3.5 kb and a 3.2 kb for mix B and C respectively. An aliquot 
of 3 µl of each PCR product was then transferred to a single reaction tube containing 60 
µl denaturizing mixture and incubated for 2 minutes at 95 °C. Following this step the 
denatured DNA was transferred to the GenoChip CYP2D6 macroarray where it binds 
to the oligonucleotide probes immobilized on the bottom of the GenoChip CYP2D6 
array tube. By adding a streptavidin-horseradish peroxidase complex and the substrate 
tetramethyl benzidine a precipitation was formed which resulted in a visible pattern that was 
captured using a colorimetric camera (see Figure 3.1). Finally, the patterns were analyzed 
using the software provided by the manufacturer. Diplotypes obtained with the GenoChip 
CYP2D6 and AmpliChip were converted to genotype predicted phenotypes (gPhenotypes) 
using the AmpliChip package insert CYP2D6 genotype to phenotype translation table. 
The inter-observer difference in the gPhenotypes was analyzed with a Cohen’s Kappa 
analysis using SPSS version 20 (SPSS, Inc., Illinois, USA) and a κ-value larger than 0.95 
was considered good concordance. After the primary comparison of the two genotyping 
methods the DNA of samples with discordant calls were analyzed using Sanger Sequencing 
along with DNA of positive controls. The DNA of the discordant samples and controls 
was amplified using 5 pMol forward (5’-GCTGGCTGGCAAGGTCCTA-3’) and reverse 
(5’-GGTGTCCCAGCAAAGTTCA-3’) primers using a PCR reaction with 15 minute pre-
Figure 3.1: A schematic display of the GenoChip CYP2D6.
On the bottom of the GenoChip array oligonucleotides specific to the selection of SNP’s are present. During 
incubation target SNP’s are immobilized on the bottom the chip. The hybridized oligonucleotides are 
labelled using a streptavidin-Horseradish peroxidase conjugate and finally tetramethyl benzidine is added 
to form a localized pattern. Courtesy of PharmGenomics GmbH.
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step of 95 °C, 40 cycles of 95 °C - 55 °C - 72 °C of 30 seconds each, and post step of 10 minutes 
at 72 °C. 1 µl of each of the PCR products were Sanger sequenced using 10 pMol of forward 
primer. Data was analyzed using Chromas Software (Technelysium, Brisbane, Australia).
Results
Genotype comparison
The call rate of both the AmpliChip and the GenoChip CYP2D6 was 100%. The con-
cordance between the 200 samples tested with the GenoChip CYP2D6 and AmpliChip 
was 99 % for the 13 tested CYP2D6 variants. Results for the alleles *3, *4, *6, *7, *8, *9, *10, 
*17, *29, gene-deletion (*5) and gene-duplications were 100% concordant. The AmpliChip 
identified *2 (n = 61) and *35 (n = 18) alleles that are not included in the tested alleles 
on the GenoChip CYP2D6 array (both alleles are defined as fully functional alleles). A 
discordance was observed for the *41 allele. The GenoChip CYP2D6 identified 34 *41 alleles 
compared to 36 *41 alleles identified by the AmpliChip (see Table 3.1). In two samples 
(3002 and 8008) the AmpliChip identified the *41 allele where the GenoChip CYP2D6 
did not, resulting in *29/*41 and *1xN/*41 compared to *1/*29 and *1/*1xN diplotypes 
(see Table 3.1), respectively.
Comparison of genotype predicted CYP2D6 phenotypes
Based on the used translation table 160 EMs, 21 IMs, 17 PMs and 2 UMs were identified 
by the AmpliChip. In 6 patients a duplication of the CYP2D6 gene was observed resulting 
in 2 patients with a genotype predicted Phenotype (gPhenotype) of UM (*1/*1xN and 
*1/*35xN). Three patients with a duplication with diplotypes of *1xN/*4 (n = 2) and 
*1xN/*41 were classified as EM and one patient with a *4/*4xN diplotype was classified 
as PM. A deletion of CYP2D6 was observed in 26 patients resulting in 14 patients with 
EM gPhenotype, 3 patients with IM gPhenotype and 9 patients with PM gPhenotype. 
The translation of the called diplotypes by the GenoChip CYP2D6 using the CYP2D6 
genotype to phenotype translation table resulted in 160 EMs, 20 IMs, 17 PMs, 3 UMs. In 
two samples (sample 1035 and 5002) the array identified a “*4 mutation heterozygous” 
and a “gene duplication”. This result could not be interpreted unequivocally and could 
represent both *1xN/*4 or *1/*4xN diplotype. However, both diplotypes translate into the 
extensive metabolizer category according to the used translation table. For patient 3002 
genotyping with the GenoChip CYP2D6 array resulted in an EM gPhenotype instead of an 
IM gPhenotype, while for patient 8008 the gPhenotype EM changed to UM. The discordant 
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Table 3.1: Genotyping results of both methods
Diplotype interpreted 













*1/*1xN 3a UM *1/*1xN 1 2a
UM *1/*35xN 1
*1xN/*41 or *1/*41xN 0a EM *1xN/*41 1a  
*1/*3 2 EM *1/*3 1 2
EM *2/*3 1
*1/*4 51 EM *1/*4 31 51
EM *2/*4 18
EM *4/*35 2
*1xN/*4 or *1/*4xN 2 EM *1xN/*4 2  
*1/*5 14 EM *1/*5 8 14
EM *2/*5 4
EM *5/*35 2
*1/*6 2 EM *1/*6 1 2
EM *2/*6 1
*1/*9 3 EM *2/*9 2 3
EM *9/*35 1
*1/*10 3 EM *1/*10 3  
*1/*17 1 EM *1/*17 1  
*1/*29 1a EM *1/*29 0a  
*1/*41 21 EM *1/*41 12 21
EM *2/*41 7
EM *35/*41 2
*3/*3 1 PM *3/*3 1  
*4/*4 5 PM *4/*4 5  
*4/*4xN 1 PM *4/*4xN 1  
*4/*5 9 PM *4/*5 9  
*4/*6 1 PM *4/*6 1  
*4/*9 4 IM *4/*9 4  
*4/*10 2 PM *4/*10 2  
*4/*41 7 IM *4/*41 7  
*5/*9 1 PM *5/*9 1  
*5/*41 2 IM *5/*41 2  
*9/*41 2 IM *9/*41 2  
*10/*10 1 IM *10/*10 1  
*29/*41 0a IM *29/*41 1a  
*41/*41 1 IM *41/*41 1  
  200 Total 200  
The genotyping results of the AmpliChip containing *2 and *35 alleles are clustered with *1 alleles as the 
GenoChip CYP2D6 does not call the *2 and *35 variants. a Differences in genotyping results excluding *2 
and *35 allele.
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diplotypes of these two samples and the associated change in gPhenotypes led to the change 
in the distribution of 160 EMs, 21 IMs, 17 PMs and 2 UMs that were interpreted from 
the CYP2D6 diplotypes obtained with the AmpliChip to 160 EMs, 20 IMs, 17 PMs and 
3 UMs were interpreted from results of the Genochip (see also Table 3.1). The Cohen’s 
Kappa analysis of the gPhenotypes of 200 patients showed a high measure of concordance 
(κ = 0.971, p < 0.001) between the two genotyping methods.
Sanger Sequencing
The Sanger Sequencing results of the two discordant samples showed a homozygous GG 
(homozygous wildtype) at position 2988 for both samples 3002 and 8008 (see Figure 
3.2). The three selected control samples showed 2850CC/2988GG, 2850CT/2988GA and 
2850TT/2988AA in the Sanger Sequencing analysis (see Figure 3.3). Based on the results 
from this analysis it can be concluded that the 2988G>A variation was not present in both 
samples and these two patients did not carry the *41 allele. 
Discussion
The GenoChip CYP2D6 showed a high degree of concordance with the AmpliChip in 
CYP2D6 genotyping. Of the 200 tested samples, a difference in alleles called by both 
methods was only seen in two samples both with discordance in calling the *41 allele. 
However, Sanger sequencing confirmed the results obtained by the GenoChip CYP2D6 
that the *41 allele is not present. The Cohen’s Kappa analysis of the gPhenotypes showed 
a high degree in concordance. 
Although there are multiple techniques for CYP2D6 genotyping available, the analysis of 
this gene remains complex, as exemplified by a number of reports where a genetic analysis 
did not produce a result that was usable in the clinical setting (10-12). In line with the 
findings from this study, problems with *41 genotyping with the AmpliChip have also been 
reported previously. In a study of 107 genomic DNA samples genotyped for five loci 12 
discordant CYP2D6 diplotypes were observed of which two were identified as *41 allele by 
the AmpliChip, while the other methods did not (13). In a study of 83 samples comparing 
the AmpliChip with a Long Range PCR platform combined with Sanger sequencing it 
was observed that in 9 discordant samples *2 alleles were miscalled as *41 alleles by the 
AmpliChip (14).
These erroneous results of the *41 allele can be explained by the panel that is interrogated 
for the *41 allele and the change in definition of the *41 allele over time. The AmpliChip 
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uses a combination of the presence of the 1661G>C, 2850C>T and 4180G>C SNPs and 
the absence of the -1584C>G SNP, while the GenoChip CYP2D6 calls the *41 allele solely 
based on the 2988G>A SNP. This SNP was first reported in 2004 (after the completion 
of the development of the AmpliChip) and is currently considered the most indicative 
SNP for the *41 allele by The Human Cytochrome P450 Allele Nomenclature Committee 
[http://www.cypalleles.ki.se/] (3, 7). The haplotypes which were previously genotyped 
as *41 and lacked the 2988G>A SNP were then reclassified as *2L and *2M which both 
share the -1584C, 2850C>T, 1661G>C and 4180G>C with the *41 haplotype (3, 15, 16). As 
observed in the Sanger sequencing results of the two discordant samples and the selected 
controls the 2988G>A SNP is not present in samples 3002 and 8008, which justified the 
genotyping result of the GenoChip CYP2D6 in these two samples (see Figure 3.2 and 3.3). 
In a clinical setting the observed difference in genotyping result can affect drug therapy. 
Using the translation table provided in the package insert of the AmpliChip the difference in 
called diplotypes would lead to alternate gPhenotypes for patient 3002 (IM instead of EM) 
and 8008 (EM instead of UM) and as results these two patients would receive a different 
dose or drug (e.g. nortriptyline) based on the results of the AmpliChip or GenoChip 
CYP2D6 respectively (17, 18).
A limitation of this study was that a direct comparison of the genotyping results reported 
by both methods was not possible. The first reason hindering a direct comparison of the 
diplotypes is that the GenoChip CYP2D6 reports if a variant allele is present or not and 
does not provide a diplotype like the AmpliChip. In 1.0 % of the GenoChip results, the 
diplotype could not be unequivocally interpreted. For example, the result “heterozygous *4 
variant detected” and “duplicated allele detected” can be interpreted as both the *1xN/*4 
or the *1/*4xN diplotype (see Table 3.1). The *1xN/*4 diplotype can be translated into the 
gPhenotypes in EM in patients with a duplicate of *1 and UM in case of patients with 3 or 
more copies of *1. Depending on the applied translation table the *1/*4xN diplotype can 
also be interpreted in multiple gPhenotypes. Using the Dutch consensus on interpretation 
of CYP2D6 diplotypes the *1/*4xN would be interpreted as IM, while the translation table 
provided in the package insert of the AmpliChip would result in EM (18). 
A second reason impeding a direct comparison of the genotyping results is the difference 
in the panel of alleles tested by both methods. The AmpliChip platform tests for the 
*2 and *35 alleles that have no effect on CYP2D6 enzyme activity and have no clinical 
consequences, whereas the GenoChip CYP2D6 does not test for these variants. Although 
the gPhenotype calls for individuals harboring the *2 or *35 allele are similar between the 
methods, a direct comparison of the diplotypes is not possible.
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To perform the statistical analysis both obtained CYP2D6 diplotypes were translated to 
gPhenotypes using the translation table provided in the package insert of the AmpliChip. 
This translation from diplotype to gPhenotypes could potentially mask differences between 
samples with a discordant diplotype. For example if a patient would be classified as *1/*1 
by one method and as *1/*10 by the other the gPhenotype would still be EM in both cases. 
However, in the case of the miscalled *41 allele by the AmpliChip a difference in gPhenotype 
was observed for patients 3002 and 8008. If chosen for the CYP2D6 genotype to phenotype 
translation table by Hicks et al., where patient carrying two decreased functional alleles 
(e.g. *10/*10 or *29/*41) would still be classified as EM, this would lead to the gPhenotype 
distribution of 160 EM’s, 16 IM’s, 17 PM’s, 3 UM’s and 2 unknown genotypes for both 
methods, masking the found difference in diplotype between patient 3002 and 8008 (17). 
Although there are already many genotyping techniques available for CYP2D6, this study 
is the first report to show a direct comparison between a macroarray and the AmpliChip 
in a Caucasian population. The advantages of the GenoChip CYP2D6 are that the array 
does not require expensive equipment, has a relatively low cost per test and is easy to 
handle. The array tests for the most prevalent CYP2D6 alleles with increased, decreased or 
absent function (6-8). However, it could be improved by adding a manner to specifically 
detect which allele is duplicated. In individuals who are carriers of a variant allele and a 
duplication of an allele, the interpretation of the results of the GenoChip CYP2D6 can 
lead to multiple diplotypes (e.g. *1xN/*4 or *1/*4xN). 
Conclusion
Based on this comparison it can be concluded that the GenoChip CYP2D6 is a valid method 
for detecting genetic variants of CYP2D6 in a Caucasian population. 
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Despite the nationwide availability of pharmacogenetic (PGx) guidelines in electronic 
medication surveillance systems in The Netherlands, PGx guided prescribing is still 
uncommon in primary care. We set out to investigate the adoption of pharmacist initiated 
PGx testing in primary care. Community pharmacists were offered a free PGx test covering 
40 variants in 8 genes to test patients receiving an incident prescription (iRx) of a selection 
of 10 drugs. Results of the PGx test along with predicted phenotypes and a therapeutic 
recommendation based on the Dutch Pharmacogenetics Working Group (DPWG) 
guidelines were transferred to the pharmacist and physician. Adoption was defined as the 
percentage of eligible patients that received genotyping. From November 2014 – July 2016, 
200 patients were included with an adoption of 18.0%. Of the included patients 57.5% 
received an IRx for atorvastatin, 14.5% started with simvastatin and 28.0% received an 
incident prescription for amitriptyline, (es)citalopram, nortriptyline, or venlafaxine. 90% 
of the patients carried at least one actionable PGx test result in the selected PGx-panel. In 
31.0% of the incident prescriptions a combination between a drug with a known gene-drug 
interaction and an actionable genotype was present and a therapeutic recommendation 
was provided. The provided recommendations were accepted by the clinicians in 88.7% of 
the patients. Pharmacist initiated implementation of PGx in primary care is feasible, and 
the frequency of actionable gene-drug interactions for the selected drugs is high.
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In recent years many of the hurdles hindering the successful application of pharmacogenetics 
(PGx) have been addressed (1, 2). The Clinical Pharmacogenetics Implementation 
Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) both have 
published a range of guidelines on relevant gene-drug interactions providing PGx-test 
interpretation and therapeutic recommendations for patients with a known genotype (2-4). 
Several pharmacogenetic implementation projects have been initiated in specialized and 
secondary care centers. Results have not only shown the feasibility of clinical pharmaco-
genetics but also highlighted the high frequency of clinically actionable genotypes in the 
general population underscoring the potential for the use PGx to improve pharmacotherapy 
(5-11). Currently, PGx testing is not routinely implemented in primary care (12). However, 
studies have shown that of the drugs with a known gene-drug interaction 25 are among 
the most frequently used medications in the USA by patients in a home setting. Examples 
of these drug include statins, TCA’s, SSRI and SNRI’s (13). Therefore, PGx-informed 
decision making has a high potential to lead to optimized pharmacotherapy in primary 
care. Indeed, preliminary studies in primary care setting have shown that PGx informed 
prescribing leads to a reduction in hospitalization, appears to be cost-effective and that 
gene-drug interactions may appear to be independent risk for hospitalization (14-17). 
In the Netherlands the infrastructure for using PGx information to guide pharmacotherapy 
is well developed. The DPWG guidelines are fully integrated into available clinical decision 
support (CDS) nationwide through the G-standard (https://www.knmp.nl/producten-en-
diensten/gebruiksrecht-g-standaard/informatie-over-de-g-standaard/the-gstandaard-the-
medicines-standard-in-healthcare), and readily available as pop-up alerts (see Figure 4.1) 
during drug prescribing and dispensing (3, 4). With their dedication to safe and effective 
pharmacotherapy pharmacists are leading candidates to act on a patients’ genotype. Patients 
also appear to be positive towards PGx-testing initiated within a community pharmacy 
setting (18). Based on the availability of PGx guidelines integrated in the workflow of 
healthcare professionals and the positive attitude to pharmacy delivered PGx we set out to 
investigate whether genotype guided dosing in primary care using a PGx test panel in the 
Netherlands is feasible. Additionally, we wanted to investigate the frequency of actionable 
genotypes in a panel of the genes CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, SLCO1B1, 
TPMT and VKORC1 and to study the frequency of gene-drug interactions in primary care. 




Study design and setting
The Implementation of Pharmacogenetics into Primary care Project (IP3) was designed as 
a prospective multicenter observational study of routine clinical practice with the objective 
to test the feasibility of pharmacist initiated pharmacogenetics testing in primary care. 
Secondary aims were to investigate the frequency of actionable phenotypes, the frequency 
of incident prescriptions with a combination between a drug with a known gene-drug 
interaction and the associated actionable genotype, and the effects of gene-drug interactions 
on pharmacotherapy in both the period of empirical treatment prior to inclusion (i.e. 
without the knowledge of the patients’ genetic make-up) and during genotype-guided 
dosing in separate analyses. The central Medical Ethics Review board of the Leiden 
University Medical Center (LUMC) in Leiden, The Netherlands approved the protocol. 
Endpoints
The primary endpoint was the adoption rate of PGx testing. This was defined as the number 
of genotyped patients divided by the total number of eligible patients in the timeframe 
of the study. Secondary endpoints included the frequency of actionable genotypes, the 
number of patients with a combination of an actionable genotype in combination with 
Figure 4.1: Example of an alert generated through Clinical Decision Support.
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a drug with a known gene-drug interaction, the number of drug related interventions 
(defined as stopping of the medication, switching to another drug, switching to a different 
dose), the number of visits to the pharmacy, and the drug dose. The medication history of 
the included patients was collected from the electronic patient records in the pharmacy. 
In order to compare drug dosages of different drugs defined daily dosages (DDD) were 
used. To account for changing dosages over time, a time-weighted average was calculated 
for each of the drugs of inclusion. 
To study the effects of genotype guided dosing on the secondary endpoints follow-up on all 
secondary outcomes was prospectively collected from the point of inclusion until the end of 
the study in which general practitioner and pharmacist had knowledge of actionable PGx 
test results. In a similar analysis the effects of actionable genotypes on secondary outcomes 
during the period where individuals had been treated empirically by general practitioners 
and pharmacists without the knowledge of the patients’ genotype was studied. The follow-
up concerning the secondary endpoints was collected prospectively for the period in which 
general practitioner and pharmacist had knowledge of actionable PGx test results. For 
the retrospective analysis the DDD, number of visits to the pharmacy and drug related 
interventions were collected. Patients (see below) were identified through weekly searches 
in the electronic drug dispensing systems. Treating pharmacists informed eligible patients 
about the project. When the patient agreed to participate, written informed consent was 
obtained and a saliva sample for DNA extraction was collected.
Patients
Adult (18 years or older) patients with an incident prescription (defined as no prescription 
for the incident drug within the preceding 12 months) for at least 28 days for amitriptyline, 
atomoxetine, atorvastatin, (es)citalopram, clomipramine, doxepin, nortriptyline, simvas-
tatin or venlafaxine in participating primary healthcare centers in the vicinity of Leiden 
were invited to participate in the study and offered free genetic testing. To investigate the 
impact of PGx informed prescribing historical data were used. Therefore, patients needed 
to have at least one prescription for one of the 10 selected drugs for a period of at least 
28 days other than the incident prescription in the preceding year. After identification of 
the patients through automated queries the participating pharmacists manually checked 
whether patients fulfilled the in- and exclusion criteria. Finally, patients not recruited 
within 14 days after dispensing the incident prescription were excluded.




Saliva was collected using the Oragene DNA OG-250 (DNA Genotek Inc, Ottawa, 
Ontario, Canada) and sent to the department of Clinical Pharmacy & Toxicology at the 
LUMC. DNA was isolated according to the protocol of the manufacturer. Genotypes 
of CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, SLCO1B1, TPMT and VKORC1 (see 
Supplementary Document S4.1) were determined using the Drug Metabolizing and 
Transporters (DMET) Plus Array (Affymetrix, Santa Clara, CA). CYP2D6 copy-number 
variation was detected with qPCR (Thermo Fisher Scientific, Massachusetts, USA). The 
DMET test was further supplemented with the DPYD 1236G>A and 2846A>T variants 
which were routine tests in the LUMC at the time of study execution (19). The genotypes 
of the 8 genes in the pharmacogenetic profile were translated into genotype predicted 
phenotypes using the DPWG guidelines. Finally, a report for the general practitioner 
and pharmacists was generated which contained the genotypes, the genetic predicted 
phenotypes along with a therapeutic recommendation to continue current therapy in case 
of a wildtype genotype or to adjust pharmacotherapy in case of a combination between an 
actionable genotype and the prescribed drug. The report was transferred to the treating 
clinicians with the request to record the genetic profile in automated electronic drug 




The primary endpoint of this study was the extent of adoption of PGx-testing expressed 
as the percentage of eligible patients that received genotyping in a percentage. 
Secondary endpoints 
To explore whether gene-drug interactions resulted in a difference in the time-weighed 
DDD’s a multinomial generalized estimating equation (GEE) was carried out using the 
categorized DDD’s from the prescribed drug at inclusion (amitriptyline, atomoxetine, 
atorvastatin, (es)citalopram, clomipramine, doxepin, nortriptyline, simvastatin or 
venlafaxine) as dependent variable, and the occurrence of a gene-drug interaction as an 
independent variable. The GEE model was chosen because of the hierarchical structure in 
the data for the prospective collected DDD’s of the drug prescribed at the time of inclusion 
with genotyped guided dosing. In addition, a multilevel log-linear Poisson analysis was 
carried out to determine whether a relationship was present between the actionable 
phenotype and number of switches in dose after inclusion. Furthermore, a multilevel log-
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linear Poisson analysis was carried out to determine between actionable phenotype and 
the number of visits to the pharmacy in the prospective collected follow-up.  
In three separate analyses, the retrospectively collected follow-up from the period before 
inclusion was analyzed in a similar manner. The categorized DDD’s from one of the ten 
selected drugs used before inclusion were analyzed using a multinomial GEE with the 
categorized DDD’s as dependent variable and presence of a gene-drug interaction as an 
independent variable. Multilevel log-linear Poisson analyses were carried out to analyze 
the effect gene-drug interactions on the number of switches in dose applied and the 
number of visits before inclusion. Sensitivity analyses for all the multilevel models were 
performed to investigate whether factors such as gender, age, weight, height and automated 
dose dispensing were confounding factors. Model specifications included an exchangeable 
correlation structure and a robust estimator. In all models the patient was used as the lowest 
level clustered within prescribing physician.
Results
Characterization of included patients & incident prescriptions
In total 200 patients were included in this study. The characteristics of the patients are 
presented in Table 4.1. The included study population contained 103 (51.5%) females 
and 97 (48.5%) males with mean age was 62 ± 11 years ranging from 27 up to 87. The 
majority of patients (92.5%) reported that both parents were of Caucasian descent (see 
Table 4.1). The majority of the patients received an incident prescription for a statin i.e. 
atorvastatin (n = 115) or simvastatin (n = 29). The remainder of the patients were included 
on amitriptyline (n = 15), citalopram (n = 7), escitalopram (n = 3), nortriptyline (n = 17) 
or venlafaxine (n = 14) (see Table 4.1).
Adoption of PGx
The adoption of PGx testing by healthcare professionals (primary endpoint) was 18.0% 
(see also Figure 4.2). In the 20 month recruitment period, 1,864 patients with an incident 
prescription for one of the 10 drugs and historical use of one of the other nine drugs were 
identified. Of those patients 483 were not eligible for inclusion. Reasons included duration 
of prescription < 28 days, use of the incident drug in the preceding 12 months, no use of 
one of the other nine selected drugs in the previous year, previously included in the study, 
or was too young (< 18 years). Furthermore 267 patients were not considered eligible by the 
pharmacists. Reasons included palliative treatment, no permanent address, not capable of 
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providing written informed consent.. Of the 1,114 eligible patients 652 were not contacted 
by the pharmacist within two weeks after the patient picked up the incident prescription. 
Of the 462 patients that were contacted 207 consented to the study, whereas 255 patients 
did not agree to participate. Of the 207 patients that agreed to participate in the study 7 
were excluded because they did not sign informed consent, failed to provide a saliva sample 
or the saliva contained too little DNA and the patient refused to provide a new sample.
Table 4.1: An overview of the characteristics of the included patients
Gender (M / F) 97 / 103
Age (year)
Mean (Std. error) 62 ± 11
Range 27–87
Length (cm)
Mean (Std. error) 172 ± 10
Weight (kg)
Mean (Std. error) 81.6 ± 17
Reported ethnicities of both parents (%)
Both Caucasian descent 92.5
Both Asian descent 3.0
Both Arabic descent 1.5
Both Somali descent 0.5
Mixed descent 2.5
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Occurrence of actionable genotypes & gene-drug interactions
Ninety percent of the genotyped patients carried at least one actionable genotype with one 
and two actionable genotypes per patient being the most frequent with an occurrence of 
28.5% and 32.5% respectively. The remainder of the patients carried up to five actionable 
genotypes out of the panel of eight tested genes (See Table 4.2). The frequencies of different 
genotype predicted phenotypes for each of the eight genes are presented in Table 4.3. For 
31.0% of the patients a combination between a drug with a gene-drug interaction and 
actionable genotype was present requiring action from the healthcare professionals. The 
majority of the combinations of drugs with known gene-drug interactions and genotypes 
consisted of a gene-drug pair between the SLCO1B1 gene with the drug atorvastatin (n = 
Figure 4.2: Overview of patient flow.
Step 1 – Not eligible: identified prescription was no incident prescription (n = 5), incident prescription too 
short (n = 469), no historical use of other drug (n = 5), already included or asked (n = 3), < 18 years of age 
(n = 1).
Step 2 – Not deemed suitable by pharmacists: Medirol (automated dosing dispensing system) (n = 79), 
patient not capable of providing informed consent (n = 8), patient did not have a known home address (n 
= 2), patient received end-of-life care (n = 2), unknown (n = 176).
Step 3 – Not contacted: patient was missed (n = 429), pharmacists was too busy (n = 29), patient unreachable 
(n = 26), pharmacists on vacation (n = 16), unknown (n = 152).
Step 4 – Patient did not agree to participate (n = 255).
Step 5 – Not included: patient not show up on intake (n = 1), informed consent form not signed (n = 1), 
patient posted sample after six months (n = 1), index drug not visible anymore in CDS (n = 1), patient 
refused request for 2nd sample (n = 3).
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35). The frequencies of other combinations were CYP2C19 with (es)citalopram (n = 3), 
CYP2D6 with amitriptyline (n = 6), CYP2D6 with nortriptyline (n = 7), CYP2D6 with 
venlafaxine (n = 8) and SLCO1B1 with simvastatin (n = 3). Patients with combination of 
an actionable genotype and associated drug were not significantly different from patients 
without this gene-drug pair regarding gender, age, length and weight. In an exploratory 
analysis medication surveillance based on a pharmacogenetic profile did not result in a 
significant change in time weighed DDD’s (OR 1.14, CI 0.68–1.92, p = 0.614), interventions 
performed on the medication (OR 1.33, CI 0.92–1.93, p = 0.128) or the number of visits 
to the pharmacy (OR = 0.93, CI 0.63–1.36, p = 0.695). Medication surveillance based on 
genomic information resulted in 32 additional alerts for drugs other than the drugs of 
inclusion in 25 patients during the follow-up period.
Medication use during genotype-guided dosing & guideline adherence
An average follow-up of 15.6 months (ranging from 6 to 25 months) of medication use with 
electronic medication surveillance using genetic predicted phenotypes from the determined 
panel was prospectively collected. The mean treatment period for the drug of inclusion was 
357 days ± 221 (defined as the period between the projected end date of the last prescription 
and the start date). In 40.5% of the patients the medication of inclusion was stopped before the 
end of the follow-up period which was higher but not significantly different between patients 
with and without a gene-drug interaction combination between an actionable genotype and 
associated drug (48.4% vs. 37.0%. p = 0.128). Follow-up on the patients with such as gene-drug 
pair upon inclusion showed that in 55 (89%) of the cases with a relevant combination of an 
actionable genotype with a relevant drug the healthcare professionals adhered to the DPWG 
guidelines by switching the patient to another drug, adjusting the dose, guarded a maximum 
dose or performed additional monitoring as instructed per the DPWG guidelines. In 1 case 
(1.6%) the healthcare professionals did not adhere to the guidelines which was motivated 
by the fact that patient had tolerated the treatment in the period between inclusion and the 
moment where the genetic profile in combination with the therapeutic recommendations 
was provided to the healthcare professionals. In 5 cases (7.8%) the gene-drug pair between 
CYP2D6 and venlafaxine was present while treatment continued and 1 case (1.6%) the dose-
maximum for escitalopram as recommended by the DPWG was surpassed.
Impact of gene-drug interactions on pharmacotherapy in empirical dosing
One of the goals of this study was to investigate the effect of gene-drug interactions on 
pharmacotherapy during the period where healthcare professionals did not have access 
to the patients’ pharmacogenetic profile. To study this research question patients were 
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required to have received at least one prescription of one of the ten selected drugs in the year 
before inclusion (other than the drug of the incident prescription). The majority of patients 
(63.0%) had received a prescription for simvastatin before inclusion in the study which in 
108 patients was stopped for a switch to atorvastatin. 57 patients received a prescription 
for an antidepressant in the year preceding inclusion, most frequently citalopram (n = 
19). In 33 cases the drug was still prescribed during follow-up (for example a patient who 
was included because of an incident prescription for an antidepressant continued statin 
treatment for hypercholesterolemia). In the retrospective analyses of the medication use 
in the period during empirically dosing the occurrence of gene-drug interactions did not 
lead to a significant difference in time weighted DDD’s (OR = 0.67, CI 0.35–1.29, p = 
0.235), interventions (OR = 1.27, CI 0.93–1.75, p = 0.133) or visits to pharmacies (OR = 
1.08, CI 0.64–1.83 p = 0.764). 
Discussion
This study demonstrates that genotype guided dosing in primary care is feasible. The 
IP3 project allowed healthcare professionals to gain experience with individualizing 
pharmacotherapy based on genetic variation in the setting of their own practice. During 
this implementation study healthcare professionals adopted PGx testing in 18.0% of all 
eligible patients. The results of this study further show that actionable genotypes in the 
tested panel of eight genes are quite common in our group of primary care patients. The 
majority of patient’s caries at least one actionable genotype. Moreover, in 31% of the patients 
a combination of drug with a known gene-drug interaction with an actionable genotype 
was present at the time of inclusion.    
Overall, the IP3 study is the first studies outside the US to evaluate a PGx panel approach 
to guide individualized pharmacotherapy using CDS in a primary care setting. Similar 
initiatives implementing PGx panel testing in a primary care setting in the US have been 
reported by research groups including Brixner et al., Elliot et al., Finkelstein et al. and Perez 
et al. (14-17). In the study performed by Brixner et al. the effect of panel-based genomic 
screening with 6 genes on the health resource utilization after starting pharmacotherapy 
with a selection of 61 drugs was studied. The research team compared a cohort of 205 
patients who received pharmacogenetic screening with 820 untested patients. Results 
showed that the screened cohort had a lower rate of hospitalizations (relative risk (RR) 
of 0.61, 95% confidence interval (CI) = 0.39–0.95, p = 0.027), a lower rate of visits to the 
emergency department (RR = 0.29, 95% CI = 0.15–0.55, p < 0.001) and a higher rate 
of visits to the outpatient clinic (RR = 1.97, 95% CI = 1.74–2.23, p < 0.001). With this 
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decrease in hospitalizations and visits to emergency departments the authors concluded 
that prescribing using genomic information could potentially lead to cost-savings (14). 
Elliot et al. showed in a prospective, open-label, randomized clinical trial in a hospital-
based home health agency that a pharmacogenetic screening in patients aged 50 years or 
older results in a lower rate of re-hospitalizations per patient at 60 days (RR = 0.48, 95% 
CI = 0.27–0.82, p = 0.007) and a lower rate of emergency visits per patient at 60 days 
(RR = 0.58, 95% CI = 0.34–0.99, p = 0.045). In a pilot study using a nested case-control 
approach Finkelstein et al. showed that frequently hospitalized older adults have more 
major drug-gene interactions compared to adults who are rarely hospitalized (p < 0.05). 
Finally, Perez et al. showed in a double-blind, parallel, multi-center randomized controlled 
trial in which 316 adult patients diagnosed with major depressive disorder were included 
that genotyping using a PGx panel that the response rate to anti-depressant treatment in 
the PGx-guided group was significantly higher compared to conventional therapy (Odd 
Ratio (OR) = 1.62, 95% CI 1.00–2.61, p = 0.0476). Additionally, the side-effect burden 
measured by the Frequency, Intensity and Burden of Side Effects Rating Burden sub 
score was significantly higher in to the control group compared to the PGx-guided group 
(OR = 2.06, 95% CI 1.09–3.89, p = 0.026). These studies indicate that a panel approach 
can reduce adverse drug reactions, improve drug efficacy and is probably cost-effective. 
When the current study is compared to the frequencies obtained in the pilot of Elliot et 
al. similarities in the frequencies of actionable genotypes can be seen for CYP2C9 (37.5% 
vs. 29.8%) and CYP2D6 (47.0% vs. 42.9%) (15).
Unlike the other four studies no significant effects of gene-drug interactions on dosages, 
interventions and visits were found in this study. This can be explained by the fact that 
this study was not powered to detect effects of gene-drug interactions on the secondary 
endpoints. An additional explanation for the lack of an effect of genotyping on the 
secondary endpoints can be found in considerable number of patients with an incident for 
atorvastatin. According to the guidelines of the DPWG a patient should be switched to an 
alternate cholesterol lowering therapy in case the patient is carrier of the TC variant of the 
SLCO1B1 and additionally uses co-medication that inhibits CYP3A4 (3, 4). In 35 of the 62 
patients with a gene-drug interaction observed in this study the drug-gene interaction was 
a combination between the SLCO1B1 521 TC or CC genotype and the drug atorvastatin 
and a check on drug-drug interactions mediated through CYP3A4 was executed by the 
pharmacist. However, only in 7 cases inhibition of activity of CYP3A4 by another drug 
was found, whereas in the remaining 28 cases no action was required. This dilution by the 
SLCO1B1 and atorvastatin gene-drug interaction could have been restricted by applying 
a cap on the number of individuals included for each drug which is currently applied in 
the U-PGx protocol (20).
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Another limitation was that our study setting was aimed to resemble routine clinical 
practice, while for the study informed consent was required, and resulted in a higher 
time investment from the participating pharmacists compared to ordering a PGx test 
within routine care. This may have negatively affected the adoption rate. Additionally, the 
healthcare professionals did not receive any financial compensation for the time required 
for the inclusion of patients and the inclusion of patients had to be performed alongside 
their regular work in clinical practice. In some cases, eligible patients may not have been 
contacted as healthcare professionals could not include patients as their regular clinical 
tasks had to be performed. Similar to previous studies this project has shown that a 
significant portion of patients in primary care is open to pharmacogenetic testing (18, 21, 
22). Additionally, this study has shown that individualizing medication based on genetic 
make-up is possible. However, the body of evidence supporting large scale implementation 
of a preemptive PGx panel approach in primary care is still lacking. Large implementation 
projects such as the U-PGx program are designed to provide an answer to this question (20). 
Conclusion
A pharmacist initiated implementation of PGx in primary care is feasible, and the frequency 
of actionable gene-drug interactions is high.  
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Supplementary Document S4.1: Overview of tested PGx variants
Gene Allele Reference sequence + variant RS-number
CYP2C9 *2 NG_008385.1:g.3608C>T rs1799853
CYP2C9 *3 NG_008385.1:g.42614A>C rs1057910
CYP2C19 *2 NG_008384.3:g.19154G>A rs4244285
CYP2C19 *3 NG_008384.3:g.17948G>A rs4986893
CYP2C19 *17 NG_008384.3:g.-806C>T rs12248560
CYP2D6 *2A M33388:g.-1584C>G rs1080985
CYP2D6 *10 M33388:g.100C>T rs1065852
CYP2D6 *12 M33388:g.124G>A rs5030862
CYP2D6 *11 M33388:g.883G>C rs201377835
CYP2D6 *17 M33388:g.1023C>T rs28371706
CYP2D6 M33388:g.1661G>C rs1058164
CYP2D6 *6 M33388:g.1707delT rs5030655
CYP2D6 *4 M33388:g.1846G>A rs3892097
CYP2D6 *40 M33388:g.1863_1864insTTTCGCCCCTTTCGCCCC rs72549356
CYP2D6 *20 M33388:g.1973_1974insG rs72549354
CYP2D6 *19 M33388:g.2539delAACT rs72549353
CYP2D6 *3 M33388:g.2549delA rs35742686
CYP2D6 *38 M33388:g.2587delGACT rs72549351
CYP2D6 *9 M33388:g.2615delAAG rs5030656
CYP2D6 M33388:g.2850C>T rs16947
CYP2D6 *7 M33388:g.2935A>C rs5030867
CYP2D6 *44 M33388:g.2950G>C rs72549349
CYP2D6 *41 M33388:g.2988G>A rs28371725
CYP2D6 *29 M33388:g.3183G>A rs59421388
CYP2D6 *42 M33388:g.3259_3260insGT rs72549346




CYP3A5 *3 NG_007938.1:g.12083G>A rs776746
CYP3A5 *6 NG_007938.1:g.19787G>A rs10264272
DPYD *2A NM_000110.3:c.1905+1G>A rs3918290




TPMT *2 NM_000367.4:c.238G>C rs1800462
TPMT *3B NM_000367.4:c.460G>A rs1800460
TPMT *3C NM_000367.4:c.719A>G rs1142345
VKORC1 NM_206824.2:c.173+1000C>T rs9934438
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Pharmacogenetics (PGx) is currently implemented in hospitals to optimize therapy with 
high-risk drugs. However, many drugs investigated by Dutch Pharmacogenetics Working 
Group and the Clinical Pharmacogenetics Implementation Consortium are used in primary 
care and actionable phenotypes for the associated genes (CYP2C9, CYP2C19, CYP2D6, 
SLCO1B1 and VKORC1) are common. The goal of this study was to estimate the clinical 
impact of implementation of a preemptive PGx-panel (n = 8) related to drugs used in 
primary care for 2016. In 23.6% of all incident prescriptions of 45 drugs (n = 856002 
prescriptions/year) an actionable gene-drug interaction was present according to the 
guidelines of the DPWG. More importantly, these gene-drug interactions would result in 
a dose-adjustment or switch to another drug in 1 out of 19 (= 5.4%) incident prescriptions. 
Consequently, with an anticipated near future where healthcare professionals will be 
regularly confronted with results of PGx panels, adjusting pharmacotherapy based on this 
information will become a routine task in drug prescribing and dispensing.
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The current use of prescription drugs is suboptimal. Many patients suffer from poor drug 
efficacy which in turn can lead to cessation of therapy or disease progression. Another 
significant portion of patients experience serious drug adverse events with possible 
hospitalization or even death as a result of the current one-size-fits-all approach (1, 2). 
In recent decades it has become clear that the interpatient variability in drug efficacy and 
-toxicity can be (partially) explained by genetic-variation between individuals (3). Therefore, 
in 2005, the Royal Dutch Pharmacists Association formed the Dutch Pharmacogenetics 
Working Group (DPWG) to aid in the personalization of pharmacotherapy based on an 
individual’s genetic make-up. The DPWG has created a set of evidence based guidelines (n 
= 86) which has been fully integrated into the electronic drug prescribing and dispensing 
systems and are available through clinical decision support (4-6). Currently, in The 
Netherlands PGx testing is mostly performed for single gene-drug pairs. For example, 
testing for DPYD before starting therapy with capecitabine or 5-fluorouracil is routine care 
in the Netherlands and supported by a consistent body of evidence (7, 8). The impact of 
PGx in this drug-gene combination is considered high as DPD deficient patients receiving a 
normal dose of capecitabine have a high risk for severe toxicities (7). Nowadays, genotyping 
platforms allow for simultaneous characterization of multiple genes. This approach has 
been evaluated in multiple studies in secondary centers (9-14). Results indicate that > 
95% of all individuals carry at least one actionable phenotype when tested for a panel of 
12 genes (including e.g. CYP2C9, CYP2C19, CYP2D6, SLCO1B1 and VKORC1) (15, 16). 
This panel-based approach has also been favorably evaluated in a number of small pilot 
studies in a primary care setting (17-19). 
Most drugs frequently prescribed in primary care are not considered high risk. However, the 
combination of a high prescription volume and a high frequency of actionable phenotypes 
of the associated genes may also have result in a high impact (20, 21). In this study we set 
out to make a quantitative estimate of the potential impact of implementing PGx in primary 
care by calculating the number of action prescriptions in The Netherlands that comprise a 
gene-drug pair that is considered actionable by the DPWG. Additionally, we investigated 
the frequency of prescriptions where a change in choice of drug or dosage would have 
been required at the start of therapy as described in the guidelines of the DPWG based on 
a prediction of their genetic predicted phenotype. 




Selection of drug-gene-interactions and classification of therapeutic recommen-
dations
The methodology for guideline development of the DPWG has been described in detail 
previously (4-6). For this study, the DWPG guidelines were reviewed for drugs with 
an actionable therapeutic recommendation for a least one phenotype. Therapeutic 
recommendations were classified in no action, lower dose, higher dose, alternate drug, 
additional clinical monitoring of the patient, optional lower dose, optional higher dose and 
a maximum dose threshold. Additionally, the guidelines were checked to see whether the 
therapeutic recommendations were dependent on patient characteristics such as age and 
concomitant use of other medication. For citalopram and escitalopram the therapeutic 
recommendations are dependent on the age of the patient as a lower dose is recommended 
for patients ≥ 65 years of age (4, 5, 22). Secondly, for SLCO1B1 and atorvastatin the 
therapeutic recommendation depends on concomitant use of a CYP3A4 inhibiting drug i.e. 
amiodaron, verapamil or diltiazem. Patients with a SLCO1B1 521TC or CC genotype and a 
CYP3A4 inhibitor are advised to switch to rosuvastatin or pravastatin, whereas in patients 
without a CYP3A4 inhibitor only increased monitoring for muscle pain is recommended. 
Source of nationwide prescription data
The Foundation of Pharmaceutical Statistics (SFK) collects data on dispensed drugs from 
~95% of all the community pharmacies in the Netherlands (23). To this end, patients are 
assigned an anonymous identification number that allows tracking within the participating 
community pharmacies (23). The SFK database also holds data on patient characteristics 
(gender and date of birth), dates on starting/stopping of medication by each patient, 
prescribed dosages, drug formulation, concomitant use of other medication which can be 
extracted for research (23). For this study dispensing data concerning incident prescription 
for the period January 1st – December 31st, 2016 were obtained. For citalopram, escitalopram 
and atorvastatin additional information concerning age of the patients and concomitant 
medication was also collected (4, 5, 22).
Frequencies of genetic predicted phenotypes
To estimate the potential clinical impact of implementation of preemptive testing for a 
panel consisting of 8 genes related to drugs used in primary care frequency data obtained 
in the “Implementation of Pharmacogenetics into Primary Care Project” (IP3) study 
were used as a representation of the national population (see Figure 5.1). In short, for 
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the IP3 study 200 patients receiving an incident prescription for a selection of 10 drugs 
with a known gene-drug interaction were genotyped for a panel of 8 genes and 40 genetic 
variants using the Affymetrix DMET platform supplemented with a CYP2D6 copy-number 
variation (CNV) assay. The genetic test results were translated to actionable phenotypes 
(e.g. extensive, intermediate, poor metabolizer or EM, IM and PM respectively) according 
to the interpretation tables provided by the DPWG guidelines, and communicated to the 
general practitioner and pharmacist to perform genotype guided dosing using clinical 
decision support (21). 
Estimating the clinical impact of PGx in primary care
Frequencies of actionable phenotypes for the eight genes from the IP3 were inferred for 
the Dutch population and combined with the prescription data obtained from the SFK. 
After exclusion of drugs not registered in the Netherlands (warfarin) or primarily used in 
secondary care (5-fluorouracil, capecitabine and tegafur) a selection of 45 drugs remained 
(see Table 5.1). This final selection was used to estimate the occurrence of actionable 
Figure 5.1: Overview of the frequencies of the phenotypes sorted to gene.
Green: extensive / normal metabolizer (CYP’s, DPYD, TPMT) / normal transporter activity (SLCO1B1) / normal 
sensitivity (VKORC1). Orange: intermediate metabolizer (CYP’s, DPYD, TPMT). Red: poor metabolizer (CYP’s) / 
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gene-drug pairs in daily practice in community pharmacies by multiplying the estimated 
frequency of actionable phenotypes for each gene with the observed incident prescriptions 
of the related drugs (see Table 5.2).
Results
For this analysis incident prescription data for the selection of 45 drugs were available from 
1882 pharmacies (94.4% of total). In 2016, a total of 3338464 unique patients received a total 
of 3628597 incident prescriptions for the selected 45 drugs (see Table 5.1). The distribution 
of the phenotypes for the 8 genes is presented in Figure 5.1. Based on the frequencies of the 
actionable phenotypes of the eight genes and the amount of 3628597 incident prescriptions 
it can be estimated that in 856002 incident prescriptions (23.6%) a gene-drug pair is 
present (see Table 5.2). In ~195691 incident prescriptions (1:19; = 5.4%) the gene-pair 
requires immediate action by the prescribing physician or dispensing pharmacists by 
lowering the dose (n = 43616), increasing the dose (n = 1315) or switching to an alternate 
drug (n = 150761). For the remainder of the prescriptions where an actionable gene-drug 
pair is present (n = 660311) no immediate action is required, however more intensified 
monitoring for side effects is recommended (n = 250980), guarding a lower maximum 
threshold of the prescribed dose designated by the DWPG for specific phenotypes (n = 
26924) or a potential decrease (n = 90543) or increase (n = 291863) of the dose in case 
of observed over- or undertreatment respectively (see Table 5.2). In case all patients 
treated in primary care received pre-emptive screening for the panel of eight genes ~12 
per 1000 incident prescriptions would have required an intervention for the selected 45 
drugs. Additionally, healthcare professionals would be required to monitor patients more 
intensively for side-effects or failure of treatment in ~42 per 1000 incident prescriptions 
of the drugs included in the selection.
CYP2C19 & (es)citalopram
For the selective serotonin reuptake inhibitors (SSRI) citalopram, escitalopram and 
sertraline the DPWG has provided a lower maximum dose for intermediate and poor 
metabolizers compared to extensive metabolizers (4, 5, 22). However, in contrast to 
sertraline the maximum dosages for citalopram and escitalopram have alternate thresholds 
for patients < 65 years of age vs. ≥ 65 years. In 41338 of the 56580 incident prescriptions 
for citalopram (= 73.1%) the patient was below the age of 65 whereas in 15424 cases the 
patient was 65 years or older (= 26.9%). From these data it can be inferred that in 8888 
prescriptions a patient with an IM phenotype of age under 65 should have received a 
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Table 5.1: An overview of the total of incident prescriptions for drugs with an actionable DPWG 
recommendation dispensed in Dutch pharmacies that supply data to the SFK sorted to ATC-code












C07BB02 METOPROLOL MET THIAZIDEN 1908
C10AA01 SIMVASTATIN 187362
C10AA05 ATORVASTATIN 111840
C10BA02 SIMVASTATINE & EZETIMIBE 4888







M01AE52 NAPROXEN & ESOMEPRAZOL 673
N02AA05 OXYCODON 464799
N02AA55 OXYCODON & NALOXON 82
N02AJ06 CODEIN & PARACETAMOL 69300
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dose restriction of 30 mg and in 3277 prescriptions a patient with an IM phenotype of age 
65+ should have been restricted to a maximum dose of 15 mg. For PMs the dose should 
have been maximized to 20 mg in individuals of < 65 years old (n = 1240 prescriptions) 
and 10 mg for age 65+ (n = 457 prescriptions) respectively. In case of escitalopram the 
dose-restriction should have been 15 mg (n = 4607 prescriptions) and 7.5 mg (n = 651 
prescriptions) for patient with the IM phenotype in the groups < 65 and ≥ 65 respectively. 
In 643 prescriptions of escitalopram the patient would likely have been PM and be younger 
than 65 years of age, thus requiring a dose restriction of 10 mg, whereas in 91 prescriptions 
the patient would likely have been PM and have been ≥ 65 years, thus requiring a dose 
restriction of 5 mg (see Table 5.2). 
SLCO1B1 & atorvastatin
The frequency of patients with a reduced transport capacity mediated as a result of genetic 
variation in the SLCO1B1 gene was found to be 25.5% of which 23.5% was the result of the 
521TC genotype and 2.0% the result of a 521CC genotype. In 2016 a total of 113749 incident 
prescriptions for atorvastatin or atorvastatin combined with ezetimibe were dispensed. 
Based on genotype data from our previous study, in 29006 prescriptions the patient would 
likely carry the 521TC or the 521CC genotype. For these individuals, an additional check 
for concomitant use of inhibitors of CYP3A4 is required as per the DWPG guidelines and 
in case of presence of a CYP3A4 inhibitor healthcare professionals are recommended to 
switch to an alternate drug. Of the 29006 prescriptions where the patient carried a poor 
SLCO1B1 phenotype a CYP3A4 inhibitor was not present in 28085 of the prescriptions 
and the patient should have been informed to monitor for signs of myopathy. Based on 
SFK data it could be observed that in 921 prescriptions the patient concomitantly used 
a drug that was a known inhibitor of CYP3A4 and the patient should have received an 
alternate therapy for management of their cholesterol or the inhibiting drug should have 
been stopped (see Table 5.2). 
Discussion
This study provides an estimate of the potential nation-wide clinical impact of a pre-
emptive pharmacogenetic panel for 8 genes approach in primary care in The Netherlands. 
Based on frequencies of actionable phenotypes gathered in a pilot study of 200 patients 
and nationwide prescription data (n = 3628597) we inferred that in 23.6% of the incident 
prescriptions of the selected 45 drugs a gene-drug pair is present. If genetic testing of the 
selected 8 genes had been performed in this population, we estimate that for 5.4% of the 
Chapter_5_Paul.indd   101 21-9-2018   11:08:24
Chapter 5
102
incident prescriptions an intervention at the start of therapy would have been required 
and in 18.2% of the incident prescriptions more intense clinical monitoring of the patient 
would be required according to the guidelines of the DPWG.
A strength of this study is that the dataset used to calculate the frequency of gene-drug 
pairs compasses 1882 pharmacies (94.4% of total) and reflects all community pharmacies 
in the Netherlands (23). This allows for a detailed view of the medication use of the 
total population treated in primary care and provides accurate data of the number of 
incident prescriptions of one of the PGx drugs where patients have not yet reached their 
maintenance therapy as a result of empirical dosing by general practitioners. In a similar 
study by Samwald et al. prescription data from a combination of sources (private insurance, 
Medicaid or Medicare) were used. Whereas the dataset used in that study encompasses a 
considerable larger number of patients, it is at risk for selection bias as it is restricted to 
selected groups within the population of the U.S (24). 
Although the data in this analysis encompasses 94.4% of the pharmacies in the Netherlands 
and provides a detailed view of drug use in primary care, other sections of pharmaceutical 
care are not represented in this dataset. A majority of the 5.6% of pharmacies that do not 
supply data to the database of the SFK are mainly outpatient pharmacies (community 
pharmacies as part of a hospital). In comparison with community pharmacies the outpatient 
pharmacies often dispense more specialized pharmacotherapy, for example HIV-therapy. 
This may result in a higher frequency of drug-drug interactions through CYP3A4 and 
higher frequency of relevant drug-drug-gene interactions for statins. The number of 
incident prescriptions where a patient uses a CYP3A4 inhibitor may likely be an under-
estimation of the reality. 
As a result of the use of a PGx panel with a limited number of pharmacogenes this may lead 
to an underestimate of the potential impact of PGx in primary care. After the initiation of 
the IP3 pilot study the DPWG has published additional guidelines on gene-drug pairs other 
than the 8 genes existing on the DMET but not included in this panel (e.g. CYP1A2 and 
CYP2B6). In addition, the chosen platform in the pilot study does not encompass all genes 
deemed relevant by the DPWG such as FVL and HLA genes. As a result, the estimation 
performed in this study is likely to be conservative. Similar to the U-PGx project current 
genotyping initiatives using a pre-emptive panel approach should use a platform which 
provides an extensive panel and is flexible to allow for adjusting if new guidelines are 
published by CPIC or the DPWG (25).
Currently, the implementation of PGx in primary care remains low in the Netherlands, 
despite the existence of guidelines containing therapeutic recommendations and their 
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integration into the workflow of healthcare professionals (4, 5, 26). In part, this may be 
explained by the fact that not all healthcare professionals are aware of the existence of 
clinical decision support in electronic medications surveillance systems. A recent survey 
among pharmacists showed that 65.4% was aware that clinical decision support contained 
therapeutic recommendations for genetic predicted phenotypes (26). The potential of PGx 
has grown, but probably other healthcare professionals (such as physicians) are not all 
aware of the state in which PGx is already available in their workflow. Finally, the clinical 
utility and cost-effectiveness of pre-emptive panel-based screening for pharmacogenetic 
variants has only been shown in small pilot studies, but large clinical trials providing the 
required evidence are still lacking (17-19). Initiatives such as the U-PGx (www.upgx.eu) 
which will try to provide an answer to these questions are currently ongoing (25). 
Based on the data presented in this study it can be concluded that approximately one in 
every four incident prescriptions of a selection of the 45 drugs included in the DPWG 
guidelines present with a gene-drug interaction. If all patients with an incident prescription 
for one the drugs of this selection would have been genotyped, 1 out of every 19 incident 
prescriptions would require a dose adjustment or switch at the start of therapy. 
Conclusion
With an anticipated near future where healthcare professionals will be confronted with 
results of PGx panels adjusting pharmacotherapy as a result of relevant gene-drug 
interaction will likely become a routine task in drug prescribing. 
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splice site variant: the need for further 
revision of dose and schedule
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Magnani et al. report the results of a prospective study in which they screened fluoropy-
rimidine naive patients with gastrointestinal, breast and head and neck cancers who were 
about to receive a fluoropyrimidine containing regimen (XELOX, FOLFOX etc.) for the 
IVS14+1G>A variant in the DPYD gene (1). For heterozygous carriers of this allele the 
fluoropyrimidine dose was reduced by 50%, as recommended by the guidelines published 
by the Dutch Pharmacogenetics Working Group (DPWG) (2). Toxicities were recorded 
during the first two chemotherapy cycles. In 4 of the 180 screened patients a heterozygous 
IVS14+1G>A variant was found. Despite the 50% dose reduction, 3 of these 4 patients 
developed severe toxicities that required hospital admission and discontinuation of treat-
ment during the first treatment cycle. Based on these data Magnani et al. suggest that 
even larger dose reductions are required for patients with the IVS14+1G>A variant than 
recommend in the DPWG guidelines. In this letter we would like to comment on some of 
the conclusions that Magnani and colleagues make in their article.
The DPWG recommendation to start fluoropyrimidine treatment with a 50% reduced dose 
followed by dose titration in response of toxicity in carriers of the IVS14+1G>A variant is 
based on systematic review of evidence from 3,773 fluoropyrimidine treated patients from 
17 published studies. The data include prospective genotype guided dosing studies, pro-
spective observational studies and case-control/case series with retrospective genotyping. 
Outcomes of these studies range from grade III or IV toxicity, DPD activity, dihydrouracil/
uracil plasma ratio and 5-FU plasma clearance. The overall quality of evidence for this 
gene-drug interaction was at least scored as moderate (≥ 3 on a 5 point scale, with 0 being 
the lowest and 4 being the highest) and the clinical relevance was scored as an F on a 7 
point scale (with AA having the lowest impact and F having the highest impact) (see Table 
6.1) (2). Recently, the Clinical Pharmacogenetics Implementation Consortium (CPIC) 
published their guideline for DPYD genotypes and fluoropyrimidine dosing (3). They 
report that approximately 50% of the heterozygous carriers of a low activity allele develop 
severe toxicity compared to a general population risk of 10–40%. Based on a systematic 
literature review, CPIC recommends a dose reduction of at least 50% in heterozygous 
carriers of the IVS14+1G>A variant, in line with to the DPWG recommendation (3). 
Moreover, an interim analysis of the largest prospective study to date (n = 1,700) of DPYD 
adjusted fluoropyrimidine dosing showed that carriers of the IVS14+1G>A allele (n = 17) 
could safely be treated with a median dose of 48% (24–91%) of the recommended dose. 
By reducing the dose to 50% of the recommended dose for carriers of the IVS14+1G>A 
variant, the risk of grade ≥ 3 toxicity was reduced from 68% (in historical controls) to 15% 
which was comparable with the toxicity risk in the fully dosed non-carrier group (4). Also, 
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it was observed that the exposure to fluoropyrimidines in the genotype-guided heterozygote 
IVS14+1G>A variant group was comparable to fully dosed non-carriers (4). Therefore, 
we believe that a 50% dose reduction for patients with this genotype is supported by the 
best available evidence. A larger dose reduction, as suggested by Magnani et al., might 
further reduce the occurrence of toxicity in the heterozygous IVS14+1G>A population, 
but probably also at the cost of not fully benefiting from the fluoropyrimidine therapy (3).
We agree with Magnani et al. that for the prevention of all fluoropyrimidine induced 
toxicity genotype-guided dosing using only the IVS14+1G>A genotype (in addition to 
adjustments for clinical variables as bodyweight, renal function, etc.) might not be sufficient 
and screening for additional variants is warranted. Yet, the incidence of severe toxicity in 
patients with genotype-guided dosing reported in their paper is strikingly high compared 
to other studies (75% vs. 15%) (1, 4). A recent meta-analysis shows that the sensitivity and 
specificity of IVS14+1G>A genotyping for the prediction of overall grade ≥ 3 toxicity were 
5.2% and 99.2% respectively, while the sensitivity and specificity of 2864A>T genotyping 
for the prediction of overall grade ≥ 3 toxicity were 5.4% and 99.2% respectively (5). Other 
SNPs in DPYD (such as 1236G>A), other genes including ABCB1, MTHFR and TYMS, 
environmental factors or co-administered drugs have all been implicated in fluoropyrimi-
dine induced toxicity (3). Therefore, several other methods to detect DPD deficiency have 
been tested including measurement of DPD activity in peripheral blood mononuclear 
cells, a 13C-uracil breath test, measurement of dihydrouracil (DHU) concentrations after 
an oral uracil loading dose, determination of the U/DHU ratio, and 5-FU therapeutic drug 
monitoring (TDM). However sensitivity, specificity and cost-effectiveness for all of these 
phenotyping methods remain to be elucidated.
As a final note we would like to add that the guidelines of the DPWG were developed to 
provide guidance to the treating physician and pharmacist when they are confronted with 
patients that have been genotyped at a previous occasion. At the time these guidelines were 
developed the evidence to justify prospective screening was limited. As seen in the research 
by Deenen et al. and Terrazino et al. there is now indeed sufficient evidence to prospec-
tively screen patients who are about to receive fluoropyrimidines for the IVS14+1G>A 
variant in the DPYD gene and adjust the fluoropyridine dose based on the genotype. This 
genotype-guided dosing is now already implemented in a number of hospitals in the 
Netherlands including ours.
We conclude that the currently available evidence supports a 50% dose reduction followed 
by dose titration based upon toxicity for known heterozygous carriers of the DPYD 
IVS14+1G>A allele treated with a fluoropyrimidine.   
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Both the Clinical Pharmacogenetics Implementation Consortium (CPIC®) and Dutch 
Pharmacogenetics Working Group provide therapeutic recommendations for well-known 
gene-drug pairs. Published recommendations show a high rate of concordance. However, as 
a result of different guideline development methods used by these two consortia, differences 
between the published guidelines exist. The aim of this paper is to compare both initiatives 
and explore these differences, with the objective to achieve harmonization.
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An important barrier for the implementation of pharmacogenetics in clinical practice is the 
translation of the results of a genetic test into clinical action (1-3). Kirchheiner et al. were 
among the first to extract dosing recommendations based on pharmacokinetic (PK) data 
of patients with known CYP2D6 and CYP2C19 genotypes (4). Anticipating a proximate 
future in which both pharmacists and physicians would be confronted with patients with 
a known genotype, two consortia, the Dutch Pharmacogenetics Working Group (DPWG) 
and the Clinical Pharmacogenetics Implementation Consortium (CPIC®), provide widely 
recognized therapeutic recommendations for specific gene-drug pairs (5-32). 
The DPWG was founded by the Royal Dutch Pharmacists Association (KNMP) in 2005 
and in the last decade has reviewed 86 potential gene-drug pairs of which 47 guidelines 
provide therapeutic recommendations for one or more aberrant phenotypes (see Table 7.1 
and Box 7.1 for additional information) 
Table 7.1: Characteristics of the two consortia
CPIC DPWG
Founded 2009 2005
Type of membership Open for application of new 
members with a clinical interest 
in pharmacogenetics, N=206 as of 
March 2017
By invitation, N = 14
Composition Multidisciplinary Multidisciplinary
Objectives 1. To address the barriers 
to implementation of 
pharmacogenetic tests into 
clinical practice
2. To provide guidelines that 
enable the translation of genetic 
laboratory test results into 
actionable prescribing decisions 
for specific drugs
1. To develop pharmacogenetics-
based therapeutic (dose) 
recommendations
2. To assist drug prescribers and 
pharmacists by integrating 
the recommendations into 
computerized systems for drug 
prescription and automated 
medication surveillance
Number of gene-drug 
pairs covered
40 86 
Number of gene-drug 
pairs with therapeutic 
recommendation
40 47
Frequency of scheduled 
updates
As needed, reviewed at least every 
2 years
If needed, max 4 years
Funding National Institutes of Health Royal Dutch Pharmacist's 
Association and H2020 contract 
number 668353-I
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The CPIC, established in 2009 as a joint project between the Pharmacogenomics Research 
Network (PGRN) and the Pharmacogenomics Knowledgebase (PharmGKB), has a similar 
goal to provide actionable, genotype-based prescribing recommendations for known 
gene-drug pairs (see Table 7.1) (3). To date, CPIC has published 19 guidelines (eight that 
have been updated since the original publication) covering 40 gene-drug pairs which are 
publicly available through both the PharmGKB (https://www.pharmgkb.org/) and CPIC 
websites (https://cpicpgx.org/) (8-33). The aim of this paper is to compare both initiatives 
and explore differences in the methodology and therapeutic recommendations of both 
consortia. 
Methodology of comparison
The process of guideline synthesis was compared based on the information provided in 
papers describing the two initiatives (5, 34). A list of gene-drug pairs evaluated by both 
DPWG and CPIC was created. CPIC guidelines published up to March 2017 were extracted 
from https://cpicpgx.org/guidelines/. Information on DPWG guidelines was extracted 
from the G-standard on the 1st of March 2017. For each gene-drug pair, guidelines were 
systematically compared for used terminology (used for the determination of allele function 
and phenotypes), allele classification / genotype, dose recommendations, evidence, and 
clinical relevance scores. Differences in allele classification were labeled as a category I 
Integration of therapeutic recommendations of the DPWG into clinical care
The DPWG guidelines are available at point of care in the Netherlands through all 
electronic prescribing and medication surveillance systems and continuously updated 
and distributed through the G-standard. The G-standard is the Dutch national drug 
database which contains information used in medication surveillance. The information 
of the G-standard supports the prescribing, dispensing, ordering and reimbursement 
of drugs and is used by physicians, pharmacists, health insurers, government and 
drug wholesalers in the Netherlands (https://www.knmp.nl/producten-en-diensten/
gebruiksrecht-g-standaard/informatie-over-de-g-standaard/the-g-standaard-the- 
medicines-standard-in-healthcare). English versions of the DPWG guidelines have 
been published in 2008 and 2011 in the international literature, and a subset is currently 
available at the PharmGKB website: https://www.pharmgkb.org/.
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difference and differences in genotype to phenotype translation were labeled as a category II 
difference. Relevant differences in therapeutic recommendations were defined as different 
therapeutic strategies (e.g., no adjustment vs. changes in dose vs. alternate therapy) or 
a ≥ 20% difference in the recommended dose between the two guidelines for a specific 
genotype. The found relevant differences were then subdivided based on the attributed 
explanation for the differences. Discordances in therapeutic recommendations presumably 
explained by differences in the methodologies of the two consortia were allocated to 
category III, discordances presumably explained by a time-effect were classified as category 
IV, and discordances in recommendations which were presumably explained by differences 
in clinical practice between nations were allocated to category V.
Methodology of CPIC
To select relevant gene-drug pairs, the CPIC uses a survey-based approach supplemented 
with nominations from members and external experts and is informed by actions such as 
the U.S. Food and Drug Administration labeling (3). The CPIC also takes into account the 
actionability of a gene-drug pair (i.e., genetic information should/could be used to change 
prescribing of affected drug) and the degree of testing for variations in the gene. For each 
new gene-drug pair, the CPIC coordinator forms a multidisciplinary writing committee 
consisting of experts with a relevant track record of related publications and/or other 
expertise. To assist in the literature search, compiling and evaluation of identified evidence, 
a scientific curator from PharmGKB is added to the team. The curator and coordinator are 
responsible for drafting the gene background information, phenotype assignments, and 
compilation of the tabular materials necessary for clinical implementation of the guideline 
(34, 35). Clinical studies, case studies, pre-clinical studies and in vitro information of the 
drug(s) of interest with a genetic variant are evaluated and are systematically rated as weak, 
moderate or high. Based on this body of evidence, as well as the evidence for the alternative 
therapy being recommended, the writing committee derives clinical recommendations 
stratified by phenotype. Each recommendation is scored using a system based on that by 
Valdes et al. as Strong, Moderate, Optional, or No Recommendation (36). A draft of the 
guideline is written by the committee and reviewed by other CPIC members. Feedback 
from this process is incorporated into the guideline before it is subjected to external peer 
review (34, 35). The guideline is considered for update whenever new evidence impacts 
prescribing recommendations (see Figure 7.1). 
Chapter_7_Paul.indd   129 21-9-2018   11:07:01
Chapter 7
130
Figure 7.1: A comparison of the methodology for guideline synthesis of the two consortia.
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Methodology of DPWG 
To select relevant gene-drug pairs, curators from the DPWG perform systematic searches 
in PubMed on known gene variants that affect drug pharmacokinetics and pharmacody-
namics. For each gene-drug pair identified papers are rated by two independent DPWG 
members based on a scoring system (37). Based on the scores the DPWG assesses whether 
a gene-drug pair is indeed present and whether a therapeutic (dose) recommendation is 
required. Recommendations can include a dose adjustment or a therapeutic strategy (i.e., 
therapeutic drug monitoring or stricter clinical monitoring of patients). Dose-adjustments 
are calculated using PK-data from available papers with evidence rated 3 or 4 on a 0–4 
point scale. All evidence is condensed into a final report containing the DPWG conclu-
sion whether a gene-drug pair is indeed present, whether action is required and if so, 
the therapeutic recommendation. These reports are then integrated into a database for 
electronic medication surveillance, the G-standard, which feeds all available electronic 
drug prescribing and dispensing systems in the Netherlands (5, 6). Gene-drug pairs are 
updated if needed but at least every four years (see Figure 7.1).
Differences in methodology
An overview of the characteristics and objectives of both consortia is presented in Table 
7.1, and the methodology of both consortia in selection of relevant gene-drug interactions, 
literature review and guideline synthesis are in Figure 7.1. Although the initial selection 
of the relevant gene-drug pairs was different, the general process of guideline synthesis 
by the DPWG and the CPIC is highly similar. Both consortia use professional curators to 
systematically search and evaluate scientific evidence (36, 37). Yet, there are some minor 
differences. DPWG reviews the level of evidence and the level of clinical relevance on 
separate scales using a five-point (0–4) and seven-point (AA-F) scale, respectively, while 
the CPIC rates the level of evidence on a three-point (weak-moderate-high) scale (36, 37).
A second difference is the sources of information considered for guideline development. 
The DPWG only provides a recommendation if data from at least one clinical study 
of good or moderate quality are available, whereas the CPIC also considers data from 
preclinical studies and case-reports. A third difference is the process used to synthesize a 
dose recommendation. The DPWG applies a quantitative method, whereas CPIC applies 
an approach based on expert consensus. 
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Differences in terminology for allele function and phenotype 
assignment 
Differences in the terminology used to describe allele function also exist. An example is the 
difference in the word used to describe an allele that has a “greater than normal function”. 
The CPIC uses the term “increased function”, whereas the DPWG uses “gain-of-function”. 
A similar difference in terminology is seen for alleles with decreased function (see Table 
7.2). With the publication of the first therapeutic guideline of CYP2D6, CPIC opted for the 
historical term “extensive metabolizer” to describe individuals who carry one or two alleles 
which encode for a fully functional enzyme (8, 15). However, based on the results from 
the recent CPIC term standardization project, normal metabolizer will replace extensive 
metabolizer in all new and updated CPIC guidelines (38). The term extensive metabolizer 
is also used by the DPWG in the published guidelines and is currently still used in clinical 
practice (5-7). In this comparison the term normal metabolizer will be used to describe 
individuals who were previously (CPIC) or are currently (DWPG) categorised as extensive 
metabolizers (see Table 7.2). The CPIC term standardization project also resulted in the 
addition of phenotypes such as CYP2C19 rapid metabolizer with a functional definition 
of “increased enzyme activity compared to normal metabolizers, but less than ultra-
rapid metabolizers” and the SLCO1B1 increased function with a functional definition of 
“increased transporter function compared to normal function” (38). 
Table 7.2: Discordances in terminology for allele function and phenotypes
Category Functional definition Consortium Term
Allele Greater than normal function CPIC Increased function
DPWG Gain-of-function*
Allele Less than normal function CPIC Decreased function
DPWG Decreased activity*
Phenotype Individuals who carry two alleles which 
encode for a fully functional enzyme or indi-
viduals with a combination of an allele which 
encodes for a fully functional enzyme and 




Phenotype An individual carrying one normal function 
allele and one increased function allele
CPIC Rapid metabolizer
DPWG -
*In this article the terminology of the CPIC will be used.
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Differences in allele classification and genotype to phenotype 
conversion 
Both CPIC and DPWG provide therapeutic recommendations at the phenotype level. 
As a result, a genotype-predicted phenotype (gPhenotype) needs to be inferred from 
the results of the genetic test. This process requires “translation tables” provided by both 
consortia. For the genes CYP2C9, CYP2C19, CYP2D6 and DPYD, differences in both the 
classification of alleles (category I) and the translation of genotype to phenotype (category 
II) can be observed. 
CYP2C9
Based on a publication from 2004, the DPWG guideline categorizes the CYP2C9*8 allele as 
a “gain-of-function” allele (39). CPIC categorizes the same allele as a “possible decreased 
function” allele based on 2 more recent reports by Liu et al. and Allabi et al. (40, 41). The 
allele frequency of CYP2C9*8 is ~0% in Caucasians and 4.70% in African-Americans 
(42, 43). As a result of the low allele frequency, this difference in allele classification does 
not appear to have clinical consequences for Caucasians. However, in African-American 
patients this difference could result in different therapeutic recommendations. 
CYP2C19
Both consortia recognize the CYP2C19*17 allele as an allele with a function greater than 
normal and categorize the genotypes *17/*17 as “ultra-rapid metabolizer” and *2/*17 and 
*3/*17 as intermediate metabolizers, respectively. However, a difference exists between the 
genotype to phenotype translation of the *1/*17 genotype. In guidelines of CPIC published 
before July 2016 the diplotype *1/*17 is categorized as the phenotype ultra-rapid metabolizer 
(24, 26, 44-50), while the DPWG classifies this diplotype as normal metabolizer based 
on the same literature (5, 6, 44-50) (see Table 7.3). As of July 2016 CPIC introduced the 
additional phenotype “rapid metabolizer” to fill the need to distinguish between individuals 
with a *1/*17 and *17/*17 on a phenotype level. This new phenotype was introduced in 
the CPIC guideline providing information and therapeutic recommendations on the gene-
drug interaction of CYP2C19 and voriconazole (32, 38). 
Based on the *17 allele frequency of 18% among African populations and 18–24% among 
Caucasian populations, this difference in genotype to phenotype translation can result in 
a difference in treatment recommendations for many individuals (6, 24). For example, a 
prescription with amitriptyline for a patient with a CYP2C19*1/*17 genotype results in a 
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recommendation to switch to an alternate therapy based on the CPIC guideline, while the 
DPWG guidelines advise the normal starting dose for the same genotype (6, 24).
DPYD
CPIC provides fluoropyrimidine dosing recommendations for normal/high, intermediate, 
and deficient dihydropyrimidine dehydrogenase (DPD) activity phenotypes based on 
DPYD genotypes (14). In contrast the DPWG uses an activity-score (AS) to accommodate 
the increasing number of DPYD allelic variants and their difference in function (see Table 
7.3) (7, 51). Further differences can be seen in the amount of variants that are discussed 
in the guidelines. For example, the 496A>G, 1156G>T, 1651G>A, and 1845G>T variants 
are not mentioned in the CPIC guideline, while the IVS10-15TC variant is mentioned 
without a classification of the status. In contrast, the DPWG indicates that the variant 
alleles 496A>G and IVS10-15TC are only associated with toxicity in a single study and the 
1156G>T, 1651G>A and 1845G>T variant alleles are mentioned as cause of toxicity in case 
reports. Inversely, the 1129-5923C>G is mentioned by the CPIC, but not by the DPWG.
Finally, a difference between the two guidelines exists in the evidence supporting the allele 
classification of the *13 and the 1236G>A/haplotype B3 variant. CPIC reports that there 
is a clear association of the *13 allele with reduced clearance of capecitabine and 5-FU 
in addition to evidence from case-reports (14). In contrast, DPWG concludes that the 
Table 7.3: Discordances in genotype to phenotype translation
Gene Genotype / activity score Classification*
CYP2C19 *1/*17 CPIC: Rapid metabolizer (24;26;44-50)
DPWG: Normal metabolizer (5;6;44-50)
CYP2D6 AS 1.0 CPIC: Normal metabolizer (15;16)
DPWG: Intermediate metabolizer (5-7)
CYP2D6 AS 2.5 CPIC: Ultra-rapid metabolizer (15;16)
DPWG: Normal metabolizer (5-7)
DPYD 2846AT / 1236GA CPIC: Normal metabolizer (14)
DPWG: AS 1.5 / Intermediate metabolizer (7;14;51)
DPYD e.g. (*2A + (2846AT or 
1236GA))
CPIC: Intermediate metabolizer (14)
DPWG: AS 0.5 / Intermediate metabolizer (7;14;51)
* As a result of a consensus in a CPIC project to standardize terms for PGx test results the CPIC has adopted 
the term normal metabolizer to replace the historical term extensive metabolizer as experts participating 
in the CPIC project found it less confusing for clinicians. In this comparison the term normal metabolizer is 
used (See Table 7.2) (38).
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evidence supporting a decreased activity of the *13 allele is limited and only described in 
case-reports (7).
Inversely, the DPWG categorizes the 1236G>A/haplotype B3 as a reduced function variant 
with a body of evidence similar to the 2846A>T variant (7). In contrast, CPIC mentions 
this variant without assigned status, similar to the IVS10-15TC variant (14).
CYP2D6
Both consortia classify the CYP2D6*36 allele as a variant allele; however, there is a 
difference in the interpretation of the functionality of this allele between the two consortia. 
The DPWG classifies the activity of the *36 allele as reduced (52-57), while the CPIC 
classifies the allele as non-functional based on four articles published after 2002 (58-61). 
The difference in allele classification of functionality can potentially be explained by the 
distinction between the single variant which has no residual CYP2D6 activity and the 
*36 +*10 tandem allele with residual activity (of the *10 allele). In contrast, the DPWG 
still uses the old classification of the *36 and has not yet made a difference between the 
single and tandem variants. Due to the low allele frequency of the *36 and the *36+*10 
tandem in African Americans and Europeans (0.00–0.98%) this difference in allele status 
will not have much clinical consequences for these populations. However, in patients 
from Asian descent the frequency of these two variant alleles of CYP2D6 is much higher, 
1.52% (0.00–16.40) and 26.41% (22.45–32.65) for the single and tandem variant of the *36, 
respectively, and this could have implications for the therapy of Asian individuals carrying 
the single variant of CYP2D6 (6, 26).
A second more important difference between the DPWG and the CPIC guidelines concerns 
the translation of the genotype to the CYP2D6 phenotype. Both consortia use the AS of 
CYP2D6 proposed by Gaedigk et al. to attribute the scores of 0, 0.5, 1.0, and N to alleles 
with no function, decreased function, normal function, and alleles with normal function 
and a duplication of N times, respectively, to calculate a gene-activity score for CYP2D6. 
Although DPWG and CPIC agree on the diplotype score of 0 for poor metabolizers, they 
use a different conversion of the AS to the intermediate metabolizer gPhenotype (62, 63). 
The DPWG has assigned the scores of 1.0 (combination of a functional and a non-functional 
allele or a combination of two alleles with reduced function) and 0.5 to intermediate 
metabolizer phenotype and the scores of 1.5 and 2.0 to the normal metabolizer phenotype 
(57), whereas CPIC assigned the scores of 1.0–2.0 to the normal metabolizer phenotype 
and the score of 0.5 to the intermediate metabolizer phenotype, respectively (see Table 
7.3 and Figure 7.2) (15, 16). 
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Due to the relatively high frequency of null alleles as the *3, *4 and *5 among African, 
American and European populations, and the high occurrence of the *10 allele among 
Asian individuals, a large group of patients will have an AS of 1.0. These patients will be 
classified as either normal metabolizers or intermediate metabolizers and may receive 
different treatment recommendations. The different translation of CYP2D6 genotype to 
phenotype between the DPWG and CPIC guidelines has a potentially significant impact 
on the treatment with drugs of individuals with an AS of 1.0 (see Figure 7.2).
Therapeutic recommendations
A total of 40 and 86 gene-drug pairs were reviewed by CPIC and the DPWG, respectively. 
For 27 gene-drug pairs both CPIC and DPWG provide guidelines which were included 
in the comparison. For 5 gene-drug pairs the rating of the evidence and the therapeutic 
recommendations were equal. For 8 gene-drug pairs, differences in the rating of the 
body of evidence supporting the same therapeutic recommendation were observed, 
but no clinical relevant differences in the therapeutic recommendations were identified 
(see Table 7.4). An example of this difference is the therapeutic recommendation for the 
Figure 7.2: Phenotype translation and nortriptyline dose recommendations of the CPIC and DPWG 
based on CYP2D6 activity scores.
Solid bars: CPIC interpretation of phenotype and dosing recommendation. Dotted bars: DPWG interpreta-
tion of phenotype and dosing recommendation. Red: poor metabolizer, Orange: intermediate metabolizer, 
Green: normal metabolizer, Blue: ultra-rapid metabolizer. Note: CPIC provides no specific dose adjustment 
for amitriptyline but recommends to consider increasing the dose and using therapeutic drug monitoring 
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CYP2C19 intermediate metabolizer and clopidogrel. Both consortia recommend to switch 
to a different platelet inhibitor for the CYP2C19 intermediate metabolizer phenotype but 
the rating of the available evidence by CPIC and the DPWG are moderate and strong, 
respectively (6, 20). For 16 of the 27 gene-drug pairs with a total of 31 individual gene-
drug-phenotype combinations, relevant differences (see definition) were observed in 
the therapeutic recommendations. In the case of 6 gene-drug pairs relevant differences 
in therapeutic recommendations were seen for only one aberrant phenotype, whereas 
for 8 gene-drug pairs differences were seen for two aberrant phenotypes and for 2 gene-
drug pairs differences were seen in > 2 aberrant phenotypes. All discordant therapeutic 
recommendations can be found in Table 7.4. Some of the discordances will be highlighted 
below.
CYP2C19 & CYP2D6 + Tricyclic antidepressants
The DPWG has provided individual therapeutic recommendations for CYP2D6 and the 
tricyclic antidepressants (TCAs) amitriptyline, clomipramine, doxepin, nortriptyline, 
and imipramine, as well as CYP2C19 and imipramine based on AUC and steady-
state concentrations (7). CPIC additionally provides recommendations for CYP2C19 
and amitriptyline, clomipramine, doxepin, and trimipramine as well as CYP2D6 and 
desipramine, while the DPWG has not (yet) provided therapeutic recommendations 
because the consortium has categorized these gene-drug pairs as low clinical impact based 
on the scientific literature (7). As a result of the used methodology, the CPIC has provided 
equal therapeutic recommendations for the TCAs amitriptyline, clomipramine, doxepin, 
imipramine and trimipramine to avoid these drugs in CYP2C19 ultra-rapid, rapid and poor 
metabolizers. In addition, the same therapeutic recommendation of a 25% dose reduction 
is provided for CYP2D6 intermediate metabolizers and a recommendation to avoid TCAs 
in CYP2D6 ultra-rapid and poor metabolizers (Table 7.4). 
Other differences in the therapeutic recommendations for TCAs can be seen in the dosing 
recommendations for CYP2D6 ultra-rapid metabolizers. In this case, CPIC recommends 
to avoid using a TCA due to the potential lack of efficacy and to consider an alternative 
drug not metabolized by CYP2D6. If a TCA is warranted, CPIC recommends to consider 
titrating to a higher target dose and using therapeutic drug monitoring to guide dose 
adjustments. In contrast, the DPWG provides specific, PK-based dosing advice. If a TCA 
is warranted, the DPWG recommends starting dosages for amitriptyline, clomipramine, 
doxepin, imipramine, and nortriptyline (see Figure 7.2) of 125%, 150% , 200%, 170% and 
160% of the normal starting doses, respectively, followed by a recommendation to utilize 
therapeutic drug monitoring (6, 7, 24) (Table 7.4).
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As mentioned previously, the DPWG uses an AS for DPYD while the CPIC uses phenotypes 
of normal/high, intermediate and deficient activity (soon to be changed to normal, 
intermediate, and poor metabolizers, respectively, in the next DPYD guideline update based 
on the results of the CPIC term standardization project) (14, 51). The gene activity model 
scores alleles with a reduced function as 0.5, while fully dysfunctional alleles are classified 
as 0. The AS model allows scores of 1.5 and 0.5 in addition to the scores of 2.0 (EM), 1.0 
(IM) and 0.0 (PM) (see Table 7.3). Both guidelines include an initial 50% dose-reduction 
for intermediate metabolizers (AS = 1) and a recommendation to switch to an alternative 
drug for poor metabolizers (AS = 0). The DPWG also contains a recommendation for 
25% and 75% dose reduction of the starting dose for the AS of 1.5 and 0.5, respectively 
(7, 14) (Table 7.4). 
TPMT + thiopurines
In the guidelines of the DPWG the dosing advice for azathioprine and 6-mercaptopurine 
are a 50% dose-reduction and 90% dose-reduction for TPMT intermediate metabolizers and 
poor metabolizers, respectively. The CPIC recommends a mean starting dose of 50% (range 
30–70%) and 10% of the conventional dose for TPMT intermediate metabolizers and poor 
metabolizers, respectively. Thrice weekly dosing instead of the normal daily dosing is also 
recommended for poor metabolizers. In the case of thioguanine the DPWG recommends 
a slightly (15%) smaller dose reduction for intermediate metabolizers compared to the 
30–50% dose reduction and thrice weekly dosing advised in the CPIC guideline (Table 7.4). 
Analysis of differences
From the 19 guidelines published by CPIC (covering 40 gene-drug pairs) and 86 guidelines 
by the DPWG, 27 guidelines cover the same gene-drug pairs. Based upon the comparison 
of the guidelines, there is substantial agreement between the recommendations given 
by the two consortia. However, for 13 gene-drug pairs there are differences (≥ 20%) 
in therapeutic recommendations for one or more aberrant phenotypes. Most of the 
observed differences in therapeutic recommendations probably result from differences 
in applied methodologies. In some cases this results in a situation where CPIC provides a 
recommendation for a gene-drug combination based on an expert consensus formed for 
a group of drugs (e.g. TCAs), whereas the DPWG finds the evidence for certain individual 
gene-drug combinations insufficient and is unable to calculate a dosing recommendation 
(e.g. CYP2C19 and amitriptyline). In other cases both consortia recognize a gene-drug 
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interaction, but come to a different dosing recommendation for a certain phenotype as 
a result of the used methodology (e.g. the CYP2C19 poor metabolizer and imipramine). 
A second explanation of the differences between the CPIC and DPWG are the result of 
a “time effect,” as literature searches are performed at different time points by the two 
consortia and new articles are published continuously (category IV, see Table 7.4). For 
example, a difference exists in the therapeutic recommendation for fluvoxamine between 
the guideline for CYP2D6 and CYP2C19 genotypes and dosing of SSRIs of CPIC from 2015 
and the DPWG guideline for fluvoxamine. This difference can partially be explained by 
the article of Suzuki et al. which was not included in the DPWG guidelines because it was 
published after the literature search of the DPWG (64). This article showed a significant 
effect of CYP2D6 genotype on fluvoxamine steady-state concentration. This example 
underscores the need to update existing recommendations.
Additionally, differences in therapeutic recommendations are sometimes the result of 
differences in clinical practices between countries (category V, see Table 7.4). An example 
of this difference can be seen in the recommendations for the gene-drug combination of 
CYP2C19 and voriconazole (6, 7, 32). The CPIC recommends to choose an alternative agent 
that is not dependent on CYP2C19 metabolism in poor and ultra-rapid metabolizers and a 
standard regimen in intermediate metabolizers. Therapeutic drug monitoring is mentioned 
as a factor that can warrant a change in dosing regimen or choice of drug similar to other 
clinical factors (e.g. drug-drug interactions or impaired renal/hepatic function) that can 
lead to change in selection of therapy or dose adjustments. Therapeutic drug monitoring 
is only mentioned specifically in the therapeutic recommendation for a poor metabolizer 
in the event that voriconazole is considered more appropriate than alternative agents. In 
contrast, the DPWG provides the recommendation to start with a standard of care dosing 
and always follow-up with therapeutic drug monitoring in case of poor and intermediate 
metabolizers. In case ultra-rapid metabolizers a 50% increase of the starting dose is 
recommended followed by therapeutic drug monitoring. These differences between the 
guidelines clearly show a difference in the place of therapeutic drug monitoring within 
voriconazole therapy between the different practice settings.
Another example of differences as a result of clinical practice can be seen in the recom-
mendations for coumarins. The DPWG and CPIC both provide recommendations for 
the gene-drug pairs of CYP2C9 and VKORC1 and warfarin. In addition the DPWG also 
provides therapeutic recommendations for acenocoumarol & phenprocoumon which are 
mainly used in the Netherlands (6, 7, 17, 18). The CPIC provides recommended daily 
maintenance dosing regimen for warfarin in mg/day based on specific algorithms, while 
the DPWG guidelines only provides a decrease in the loading dose. In the Netherlands, 
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patients using coumarins are strictly monitored by anticoagulation clinics using the interna-
tional normalized ratio (INR). With this strict control of the INR, the need for a predicted 
daily coumarin dose based on pharmacogenetic information is limited. Due to the large 
difference in the monitoring of patients the added clinical value of pharmacogenetics is 
different in both settings, resulting in other therapeutic recommendations of the DPWG 
and CPIC, respectively.
Specifically for CYP2D6, differences in the translation of genotypes to phenotypes that exist 
between the guidelines of the two consortia can be explained by the different interpretations 
of certain genotypes throughout literature. For the gene CYP2D6, some consider an AS of 
1.0 an intermediate metabolizer, while the package insert of the Amplichip categorizes this 
score as a normal metabolizer (56). In part this is due to variability in how AS is translated 
into phenotype for different probe drugs. Studies using tramadol, dextromethorphan and 
sparteïne as the probe drug show no difference in the kinetic profile between individuals 
with and AS of 1.0 and individuals with an AS of 2.0 (54, 55, 65-69). In contrast, using 
trimipramine, doxepine, haloperidol and debrisoquine as the probe drug shows a 
significant difference between individuals with an AS 1.0 and 2.0 (54, 70-75). Specifically 
for CYP2D6, it can be concluded that the use of different model substrates have led to 
mixed interpretations of genotypes which in turn have led to different interpretations of 
the AS of 1.0 by the two consortia. In fact, an international team of CPIC and DPWG 
members has recently agreed to try to impose standards on how AS are interpreted into 
phenotypes for major CYP2D6 substrates. 
As previously mentioned, the differences between guidelines can potentially lead to dif-
ferences in dosages or choice of drugs for patients with the same genotype. In case of 
some discordances a minor update (e.g., an update of the status of the CYP2C9*8 and 
CYP2D6*36 alleles in the DPWG guidelines) (category I, IV) can solve discrepancies, while 
in some cases harmonization is warranted to create uniform interpretations of genotypes 
into phenotypes (category II). 
Finally, the difference in publication strategy should also be addressed. A current disadvan-
tage of the DPWG guidelines is the limited availability in English. In addition, the available 
English versions date back to 2011 and do not contain the most recent information. 
Currently, as a part of the EU granted Ubiquitous Pharmacogenomics (U-PGx) project, the 
DPWG is working on the English translation of their therapeutic recommendations and it 
is anticipated that in the near future these documents will be made available to clinicians 
of other nations in the form of European guidelines which further strengthens the need 
for harmonization with CPIC (http://upgx.eu/) (76).
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In conclusion, this comparison shows that the CPIC and the DPWG guidelines are generally 
similar in terms of allele classification, genotype to phenotype translations and therapeutic 
recommendations for most gene-drug pairs. However, some differences between the 
guidelines of the two consortia exist and should be harmonized where possible, especially 
in the case of different allele classifications and genotype to phenotype translations. 
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To benchmark Dutch pharmacists knowledge, experience, and attitudes towards PGx 
with a specific focus on the effects of awareness of the Dutch Pharmacogenetics Working 
Group guidelines. A web-based survey containing 41 questions was sent to all certified 
Dutch pharmacists. 667 pharmacists completed the survey (18.8%). Virtually all responders 
believed in the concept of PGx (99.7%). However, only 14.7% recently ordered a PGx test 
(≤ 6 months), 14.1% felt adequately informed and 88.8% would like to receive additional 
training on PGx. Being aware of the DPWG guidelines did not have any significant effect 
on knowledge or adoption of PGx. Dutch pharmacists are very positive towards PGx. 
However, test adoption is low and additional training is warranted.
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The field of pharmacogenetics (PGx) has progressed significantly with a large number of 
studies showing the relation between heritability and drug-response. In the United States 
and European Union currently 137 and 77 labels of registered drugs contain information 
on PGx respectively (1, 2). Moreover, initiatives by the Dutch Pharmacogenetics Working 
Group (DPWG) and Clinical Pharmacogenetics Implementation Consortium (CPIC) have 
provided guidelines containing drug/dose recommendations for a significant number of 
drug-gene-interactions (DGI’s) (3-5). 
With their knowledge on pharmacology, reputation as medication experts, and overview of 
drug use by their patient’s, pharmacists are alleged to play a key role in the implementation 
of PGx into clinical care (6). However, despite their excellent position, pharmacists may not 
yet feel fully prepared for this task. A survey among Canadian pharmacists indicates that 
although they have high expectations towards PGx, only 7.7% felt comfortable interpreting 
and advising patients based on PGx test results (7). Similar results were found in a survey 
among US physicians where 10.3% of the responders felt adequately informed about PGx 
testing (8). Both these results stress the existence of a knowledge gap hindering the clinical 
uptake of PGx.
In The Netherlands, PGx guidelines developed by the DPWG providing clear cut recom-
mendations for patients with a known genotype are available at point-of-care by incorpora-
tion into computerized systems for drug prescription, dispensing, and automated medica-
tion surveillance (Figure 8.1) (3). These computerized systems are used by all pharmacists 
working in a clinical setting in the Netherlands (in both primary and secondary care). 
The availability of DPWG guidelines in the routine workflow of healthcare professionals 
through interruptive clinical decision support (CDS) may reduce the perceived knowledge-
gap and result in a higher clinical uptake of PGx (9, 10). The aim of this study was to 
benchmark Dutch pharmacists about knowledge, experience, and attitudes towards PGx. 
We specifically focused on investigating if the incorporation of DPWG recommendations 
on DGI’s into CDS leads to reduction in the perceived knowledge gap, a reduction in the 
need of additional training on the subject and higher adoption of PGx testing. 
Methods
Study design
A nationwide web-based cross-sectional survey was performed using the survey tool 
NetQ (11). Community, hospital and outpatient pharmacists in the Netherlands were 
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invited to participate by an email sent via their professional societies, with a reminder after 
two weeks. Community pharmacists were defined as pharmacists working in a primary 
healthcare setting outside of a hospital. Hospital pharmacists were defined as pharmacists 
working in a secondary healthcare setting within a hospital. Outpatient pharmacists were 
defined as pharmacists dispensing to outpatients from a pharmacy located in a hospital. 
Participants had the opportunity to complete the survey in the period from 15 November 
2014 until 1st of January 2015. Responding to the invitation was completely voluntary and 
results were processed anonymously.
Questionnaire
A questionnaire was constructed by adapting two published surveys and translating the 
questions to Dutch (7, 8, 12, 13). A brief introduction explaining the terms pharmacogenetics 
& pharmacogenomics and the topics that would be surveyed preceded the questionnaire. 
The questionnaire consisted of a total of 41 questions (Supplementary Document S8.1). 
Figure 8.1: An example of an pop-up generated through clinical decision support.
A typical alert generated by automated medication surveillance after prescription of nortriptyline to a 
patient known to be a poor metabolizer of CYP2D6 (condensed & translated from Dutch).
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The survey responses of the participants were automatically tabulated and stored within 
NetQ [101]. Incomplete surveys were excluded from the analysis. Age was recoded into a 
six-level categorical variable (≤ 29, 30–39, 40–49, 50–59, and ≥ 60 years). Practice setting 
was recoded into a three-level variable: community pharmacy + other, outpatient pharmacy, 
hospital pharmacy. 
Due to the low rate of responses in some answer categories the results of the questions 
7–13 and 38 were condensed for the univariate and multivariate analysis into a two-level 
(Q 7–13) and three-level (Q38) scale respectively (8). 
The univariate analyses were performed using a χ2 test (excl. Q36). Variables that showed a 
significant association in the univariate analysis were included in the multivariate analyses. 
For the univariate and multivariate analysis of past adoption the variable future adoption 
was not included and for the analyses’ of future adoption the group of past adopters were 
excluded (8). Data was analysed with SPSS version 20 (SPSS, Inc., Illinois, USA) and p < 
0.05 was considered statistically significant.
Results
Characterization of responders
In total 3,550 pharmacists were invited to complete the questionnaire (596 hospital 
pharmacists, 171 outpatient, 2,780 community pharmacists and other). Of the invited 
pharmacists, 727 participants responded to the link and 667 (18.8%) completed the survey. 
Of the 667 responders 54.3% was female. Age was distributed bimodally with a median 
age of 41. The practice setting of the majority of the responders was community-based 
(69.6%), while 24.6% and 4.8% worked in a hospital or outpatient pharmacy respectively 
(Table 8.1). Of note, in the Netherlands pharmaceutical care in a secondary healthcare 
setting is delivered by hospital pharmacists. Unlike other countries, specialization does 
not focus on areas of medicine but on the different task within hospital pharmacy i.e. 
drug manufacturing, quality control, therapeutic drug monitoring, drug dispensing etc. 
In the primary healthcare setting drugs are dispensed to patients either by community 
pharmacies or outpatient pharmacies. Examples of “other” practice settings consisted of 
regulatory bodies, industry, and (temporarily) non-practising pharmacists.
The response rate among hospital pharmacists was significantly higher than the response 
rate among pharmacists working in the community + other or outpatient setting (27.5% 
vs. 16.9% and 18.4% respectively, p < 0.001). In the Netherlands all pharmacists receive 
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six year university training resulting in a Pharm D degree. Afterwards pharmacists can 
enroll in a two or four year post-graduate specialty training to obtain a registration as 
community or hospital pharmacist respectively. Of the responders 12.7% were in a post-
graduate residency programme to obtain a license. During their PharmD program or 
their postgraduate training 39.7% and 24.4% of the responders received any form of PGx 
training respectively (Supplementary Document S8.1, S8.2).
Belief in concept of PGx and expectations towards PGx testing
Virtually all responders (99.7%) believed that the genetic profile of a patient can influence 
the response to medication (Figure 8.2). To assess their expectations towards PGx testing 
pharmacists were asked three questions. On the question whether a PGx test could prevent 
their patients from taking the wrong dose or drug 80.8% of the responders answered at 
least 2 on a scale from 0 (no expectation) to 3 (high expectation). Using the same 4 point 
scale 84.9% responders answered ≥ 2 on the question whether PGx could detect which 
drug or dose will be more efficacious in their patient and 81.3% answered ≥ 2 on the 
question whether a PGx test will allow detection which drug or dose will cause less side 
effects (Figure 8.3 and Supplementary Document S8.1). 










≥ 60 51 7.6
Possession of specialty
Yes 549 82.3





Community + other (*) 471 70.6
* For statistical purposes the group of responders working in a community setting (n = 464) and the group 
of responders working in a setting other than community, outpatient or hospital (n = 7) were combined.
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Figure 8.2: Key findings of this study to benchmark the knowledge of -, experience with - and 
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Figure 8.3: Expectations of pharmacists towards PGx testing.
Red = I have no expectations that PGx …, orange = I have low expectations that PGx …, yellow = I have 
high expectations that PGx …, green = I have very high expectations that PGx … (the size of the bar is 
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Adoption of PGx 
In the Netherlands all pharmacists in clinical practice (community, outpatient and hospital 
setting) are allowed to order PGx tests directly or recommend PGx testing to the prescribing 
physicians. In this survey only 98 responders (14.7%) reported ordering or recommending 
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a PGx test in the last six months (Figure 8.2). The majority did so to improve the drug 
therapy of a patient (92.9%) and stated that the PGx test improved drug efficacy (52.0%), 
reduced toxicity (74.5%), improved the patients’ understanding of their disease (18.4%), 
or improved the adherence of the patient to the treatment (6.1%). Of these past adopters 
of PGx testing 79.6% expected to order or recommend equal or more PGx test in the next 
six months, while 12.2% stated that they expect to order less PGx test in the near future. 
Of the 569 responders (85.3%) who did not order or recommend a PGx test in the last 
six months 71.7% stated that they did not expect to do so in the next six months. Overall, 
27.1% of the surveyed pharmacists expected to order or recommend a PGx test in the 
next six months. Of the responders who had not adopted PGx testing or did not anticipate 
ordering or recommending a PGx test in the coming six months, the majority (60.3%) 
indicated a lack of knowledge and information on PGx testing as primary reason. Other 
main reasons for not ordering or recommending a PGx test consisted of “not dispensing 
drugs where PGx is relevant” (25.6%) or uncertainty regarding reimbursement of PGx 
(14.0%). From the PGx test adopters 8 stated that they did not expect to order  a PGx in 
the next six months. Reasons given by these past adopters to not order a PGx test in the 
near future consisted of a lack of knowledge, resistance of patients towards PGx testing, 
alternate methods for monitoring of patients and limited clinical relevance.
Working in a hospital setting (OR 9.44, CI 4.13–21.57, p < 0.001) was the only variable 
independently associated with past use of PGx testing. Feeling informed about PGx testing 
(OR 1.99, CI 0.99–3.99, p = 0.052), the use of genetic laboratories as sources of information 
for availability of PGx tests and application in treatment (OR 2.16, CI 0.99–4.71, p = 
0.054) and the use of other sources of information to guide drug treatment (OR 2.92, CI 
0.98–8.71, p = 0.054) showed a trend towards significance with past adoption of PGx testing. 
Being aware of the existence of the DPWG guidelines (OR 1.00, CI 0.38–2.67, p = 0.999) 
and their integration in the electronic prescription and dispensing systems (OR 1.23, CI 
0.57–2.69, p = 0.596) did not show an independent associations with past use of adoption 
(Supplementary Document S8.3). The multivariate analysis for future adoption indicated 
that working in a hospital setting (OR 5.85, CI 2.67–12.82, p < 0.001) or outpatient setting 
(OR 3.01, CI 1.05–8.57, p = 0.039), feeling comfortable to recommend a PGx test to a patient 
to predict whether a drug is effective in their case (OR 2.18, CI 1.03–4.64, p = 0.043), using 
post-academic education as source of information for availability of pharmacogenetic tests 
and how to apply them in pharmacotherapy (OR 2.91, CI 1.36–6.23, p = 0.006) and having 
high worries that there is no suitable drug for their patients (OR 1.31, CI 1.06–1.611, p = 
0.011) were independently associated with future adoption of PGx testing (Supplementary 
Document S8.3). Differences between adopters, future adopters and non-adopters can be 
seen in Supplementary Document S8.4.
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Attitude towards own ability to interpret PGx test results
Currently, 48.4% of the participants would feel comfortable to recommend a PGx test to 
predict drug efficacy. However, if the PGx test could also reveal information about disease 
risk only 7.8% would feel comfortable to do so. Of the surveyed pharmacists, 27.0% would 
feel qualified to receive PGx test results of a patient, interpret them and advise a patient or 
treating healthcare professional on the choice of drug or dose based on the results (Figure 
8.2). Reflecting the questions informing about education and training, the majority of 
pharmacists (66.3%) would see themselves qualified after receiving training on the subject. 
Participants were also asked if they would recommend a drug treatment despite a PGx test 
result indicating non-response or severe side effects for their patient. Approximately half of 
the responders (49.0%) would not recommend the treatment, while a slightly smaller group 
(47.5%) would recommend the drug treatment provided it concerned a life-threatening 
disease. Only 3.4% would recommend the drug irrespectively of the results of the PGx 
test or condition of the patient. 
Access to and use of PGx information 
Although approximately half of the pharmacists received some sort of PGx training (see 
above) only 14.1% felt adequately informed about the availability of PGx tests and how 
to apply PGx in relation to drug therapy. Furthermore, almost all responders (88.8%) 
indicated they would like additional training on PGx (Figure 8.2). Responders indicated 
using the summary of product characteristics (SmPC), the European drug package insert 
(78.7%), internet (63.2%), colleagues (38.8%), post-academic courses (30.6%), genetic 
laboratories (24.0%) or other such as the Informatorium Medicamentorum (IM), a 
handbook published by the The Royal Dutch Pharmacist’s Association (KNMP) containing 
the DPWG recommendations in addition to information on drug dosages, (contra)
indications, drug-drug-interactions, (25.6%) as sources of information for availability 
of PGx tests and application in treatment. Concerning the evidence for adoption of PGx 
testing recommendation by a guideline (93.0%), scientific publication (81.3%), approval or 
recommendation by regulatory authorities (80.4%) were seen as high value by responders, 
while less responders indicated recommendation by opinion leaders as high value (46.7%). 
The majority of the participants (88.0%) would use the IM to make a choice about the drug 
and dose in case of a patient with genotype results. Other sources indicated to guide drug 
treatment included the SmPC (61.0%), scientific literature (58.3%), Farmacotherapeutisch 
Kompas (FK), a handbook containing information on drug dosages, (contra)indications, 
drug-drug-interactions published by The National Health Care Institute in the Netherlands 
(34.2%), regulatory authorities (25.9%) or a colleague (22.9%). Only 10 pharmacists (1.5%) 
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had encountered a patient who had ordered a genetic test on their own account in the 
preceding six months (Supplementary Document S8.1). 
74.1% of the responders were aware of the existence of the DPWG dosing guidelines and 65.4% 
was aware that these guidelines were incorporated in CDS systems (Figure 8.2). Responders 
who were aware of the guidelines and their integration in the CDS systems, were more likely 
to be early adopter (p < 0.001) and more likely to feel informed about PGx testing (p < 0.001). 
A subgroup analysis of pharmacy specialties showed that only hospital pharmacists were 
more likely to feel informed about PGx testing if they were aware of the DPWG guidelines 
(p < 0.05). In the multivariate analysis of “feeling informed about PGx testing” working in a 
hospital setting (OR 3.67, CI 1.57–8.55, p = 0.003), not being in need for additional training 
(OR 2.96, CI 1.38–6.33, p = 0.005), scoring “undecided” or “(very) important” for approval 
or recommendation of a PGx test by regulatory authorities (OR 42.28, CI 3.59–498.48, p 
= 0.003 and OR 14.38, CI 1.33–155.55, p = 0.028), still advising the only available drug to 
treat your patient’s disease if a pharmacogenetic test revealed ineffective or leads to severe 
side effects (OR 8.54, CI 2.25–32.42, p = 0.002) and still advising the only available drug to 
treat your patient’s life-threatening disease if a pharmacogenetic test revealed ineffective or 
leads to severe side effects (OR 0.46, CI 0.24–0.86, p = 0.015) were independently associated 
with feeling informed about PGx testing. No independent association between being aware 
of the DPWG guidelines (OR 1.36, CI 0.51–3.65, p = 0.537) and their incorporation in the 
electronic medication systems (OR 1.84, CI 0.82–4.13, p = 0.139) with feeling informed 
about PGx testing was observed (Supplementary Document S8.3). 
In a similar multivariate analysis factors associated with the perceived need of extra PGx 
training were studied. The analysis revealed that feeling qualified to receive PGx test 
results of a patient, interpret them and advise upon PGx test results after training (OR 
3.70, CI 1.41–9.76, p = 0.008) and feeling not informed about PGx testing (OR 2.40, CI 
1.17–4.90, p = 0.016), using the SmPC as source of information to guide drug treatment 
(OR 1.85, CI 1.05–3.26, p = 0.032) were independently associated with the need for 
additional training on PGx related subjects. Being aware of the existence of the DPWG 
guidelines (OR 0.89, CI 0.41–1.95, p = 0.770) and the incorporation in CDS (OR 1.03, CI 
0.51–2.08, p = 0.927) showed no significant association with a reduced need for training 
(Supplementary Document S8.3).
Worries related towards PGx testing, privacy and coverage
Participants were asked a total of eight questions concerning worries related to conse-
quences of PGx test results, privacy of PGx data and coverage of PGx tests by insurance 
Chapter_8_Paul.indd   174 21-9-2018   11:06:15
Pharmacists’ perception of PGx in the context of a CDS system
175
8
companies. Four questions assessed potential concerns related to PGx using a 4-point scale 
ranging from 0 (no worries) to 3 (very worried). To the question inquiring to whether 
a PGx test might reveal that there is no suitable drug available for their patients 28.3% 
of the participants answered that they were at least moderately worried (score ≥ 2). Of 
the responders 52.9% was at least moderately worried that a PGx test might reveal that a 
patient has risk factors for another disease. Furthermore, 70.0% of the responders was at 
least moderately worried that results of a PGx test could come in hands of an unauthorized 
individual and the majority of the responders (91.4%) was at least moderately concerned 
that a health-insurance company could infer a patients’ genotype based on the prescribed 
drug or dose (Figure 8.4). 
In line with the four previous questions, 76.9% of the responders are more concerned 
about the loss of privacy of patients’ PGx test results than the results from any other 
laboratory or diagnostic test. With regard to privacy of the data responders agreed that the 
treating physician (99.3%) and the pharmacist (97.3%) should have access to the PGx test 
results, while nurses, psychologists and dieticians should not. The opinion whether other 
health-care professionals should be able to access PGx data was mixed (Supplementary 
Document S8.2). With regard to unfavourable results almost two-thirds of the responders 
(63.7%) thought that a PGx test with negative test result could have a possible adverse 
psychological effect on a patient and/or the patients’ family. The final question of this 
Figure 8.4: Worries of pharmacists towards PGx testing.
Green = I have no worries that …, yellow = I have low worries that …, orange = I have high worries that 
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section related to coverage of PGx by health-insurers. Virtually all responders (99.7%) 
stated that health-insurance companies should provide coverage for PGx tests, however 
there is a mixed opinion whether PGx should always be covered (69.1%) or only in specific 
occasions (30.6%).
Differences between pharmacy specialties
Survey results of the different practice settings were compared and significant differences 
were observed between the three groups. The group of responders working in a community 
+ other setting contained relatively more individuals of age ≥ 50 (p = 0.003). Hospital 
pharmacists had received post-graduate training on PGx during their specialization more 
often compared to the community + other and outpatient setting (60.4% vs. 12.7% vs. 
12.5%, p < 0.001), were more often aware of the DPWG guidelines (91.5% vs. 67.3% vs. 
84.4%, p < 0.001) and their integration in the CDS systems (79.9% vs. 60.3% vs. 65.6%, 
p < 0.001) compared to the other two groups. Furthermore, hospital pharmacist felt 
comfortable to recommend PGx testing more often (74.4% vs. 40.1% vs. 37.5%, p < 0.001), 
felt qualified to receive PGx testing results, interpret them and advise a patient based on 
PGx test results more often (59.1% vs. 16.3% vs. 18.8%, p < 0.001) and felt less need for 
training on the subject (24.4% vs. 7.0% vs. 6.2%, p < 0.001) compared to the community 
pharmacy + other and outpatient setting. Other differences between specialties can be 
seen in Supplementary Document S8.2.
Discussion
This survey shows that Dutch pharmacists are generally very positive towards PGx. Virtually 
all responders believe that indeed drug response can be at least partially explained by 
genetic variation and the majority of the participants have high expectations of PGx. We 
hypothesized that incorporation of the DPWG guidelines in automated CDS systems would 
lead to higher adoption of PGx, while simultaneously reducing the need for additional 
PGx training (9). However, the results from the current study show that being aware of the 
availability of the DPWG guidelines was not independently associated with feeling informed 
about PGx testing or past adoption of PGx testing. Furthermore, the percentage of PGx test 
adoption is comparable to the findings of a survey among physicians in the US (14.7% vs. 
12.9%), where mostly information on DGI’s is not readily available in CDS systems. Similar 
to the US, there appears to be a knowledge gap present among the Dutch pharmacists, as 
only 14.1% of the responders in this survey feels adequately informed about PGx testing. 
Similar to the association between feeling informed and adoption of PGx testing found 
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in the study by Stanek et al. (p < 0.001) our survey shows a trend towards an association 
between feeling informed and PGx test adoption (8). The combined data from both these 
studies indicate that a lack of knowledge about availability of PGx tests and their application 
in drug therapy is one of the remaining barriers for clinical implementation of PGx into 
clinical practice. The current study confirms that a large amount of responders would like 
additional training on the subject and that being aware of the availability of the DPWG 
guidelines was not associated with a reduced need for additional PGx training. A similar 
need for training (96.6%) is seen in a survey performed among 284 pharmacists in Canada, 
with a similar electronic drug prescribing and dispensing system as used in the US (7). 
It appears that PGx implementation programmes should be accompanied by extensive 
training programmes as currently implemented in the 1200 patient project and the 
programmes PG4KDS, eMERGE-PGx, PREDICT and U-PGx (14-18). In all, the results 
from this study combined with findings from previous studies refute our hypothesis that 
nationwide availability of interruptive CDS containing dosing advices on DGI’s leads to 
higher adoption of PGx and reduces the need for additional training.
Our results indicate a need of more education about PGx. Only 39.7% and 24.4% of the 
responders received training on PGx-related subjects in their PharmD program or their 
postgraduate training respectively. A stronger embedding of PGx in the curricula of 
pharmacists in training could be a manner to prevent a potential knowledge gap in future 
generations of pharmacists. An example could be by integrating PGx into courses that train 
PharmD students in medication surveillance as in our opinion PGx should be an integral 
part of this area within pharmacy practice. Post-academic education is also considered 
important by the responders for disseminating PGx knowledge, and was associated with 
adoption of PGx in the near future (OR 2.91, CI 1.36–6.23, p = 0.006). However an ideal 
setting for a PGx training for (community & outpatient) pharmacists remains to be 
established. Additional research in the form of targeted surveys, structured interviews and 
/ or focus groups could further provide a more detailed answer how specific demands for 
PGx related information and education can be met.
The current cross-sectional study evaluated both the current attitude of Dutch pharmacists 
towards PGx and their own perceived abilities to interpret PGx data, as well as actual 
adoption of PGx testing by pharmacists. The data indicate that approximately 80% of the 
pharmacists are moderately hopeful that PGx could prevent patients receiving wrong drug 
or doses; could detect which drug or dose is the most effective for a patient and that PGx 
could minimize the risk of adverse advents. The survey of de Denus et al. shows similar 
ratings of 80.0%, 82.6% and 79.1% of Canadian pharmacists who are at least moderately 
hopeful on these subjects respectfully. Dutch pharmacists also have similar worries 
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(moderate to high) compared with their Canadian colleagues (7). 
The results from this survey further show that adoption of PGx is particularly low in the 
community pharmacy setting, although previous research has shown that implementation 
of PGx in primary care is feasible (19). In the Netherlands, pharmacists working in primary 
care are considered the gatekeepers of patients’ medication records. Prescriptions from 
multiple prescribers for the same patient converge in community or outpatient pharmacies. 
Therefore, community and outpatient pharmacists are the designated healthcare 
professionals to perform medication surveillance based on therapeutic recommendations 
from the G-standard, the nationwide electronic drug database. In our opinion PGx is an 
integral part of medication surveillance and therefore these pharmacists should understand 
a PGx test result at a phenotype level and to be able to optimize therapy based on CDS 
alerts. In addition, as experts in the area of pharmacology pharmacists could take a leading 
role in genotyped guided therapy by recommending or ordering test when this is indicated.
The low adoption might be explained by the lack of consensus on which specific patients 
should be tested. For several drug treatments typically applied in the hospital setting i.e. 
fluoropyrimidine derivatives or purine-antimetabolites, there is high quality evidence 
from prospective studies showing that genotyping for mutations in DPYD and TPMT 
improves outcome of drug treatment (20, 21). However, for many drugs frequently used in 
primary care such evidence is still lacking. In addition, currently available pharmacogenetic 
guidelines by the DPWG and the CPIC only provide recommendations for patients with a 
known genotype and do not indicate which patients should be genotyped. Future versions 
of the DPWG guidelines containing information on when genotyping is indicated in 
combination with clinical rules or pre-test alerts could further help with the implementation 
of PGx testing.
For this cross-sectional survey a voluntary basis was used introducing the potential risk 
of bias as strongly opinionated (both in a positive and in negative manner) or experienced 
individuals are more likely to respond introducing selection bias. From “The Dutch 
Foundation for Pharmaceutical Statistics (SFK)”, an organization which gathers data from a 
panel which includes 95% of the community and outpatient pharmacies in the Netherlands, 
demographic data on pharmacists working in the community and outpatient setting 
was obtained. The distribution of responders to this survey working in a community or 
outpatient setting between the different age groups (≤ 29, 30–39, 40–49, 50–59, and ≥ 60 
years) differed significantly from the distribution of all Dutch pharmacists among these 
age groups (p < 0.001). In the surveyed population a higher relative count of pharmacist 
was found in the combined group of 20–39 (44.0% vs. 37.8%) compared to the combined 
group of 40+ (56.0% vs. 62.2%) in a chi2 analysis (p = 0.009). The male / female ratio and 
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the ratio between specialty trained and in training did not differ significantly (22). The 
age distribution of responders working in a hospital setting among the five age groups 
also differed significantly from the age distribution of the whole population of hospital 
pharmacists over the five age groups (p < 0.001). Responders were also significantly younger 
compared to all pharmacists working in a hospital setting when the age groups were 
combined in the groups 20–39 (56.2% vs. 45.1%) and 40+ (43.5% vs. 54.9%) and analysed 
with a chi2 analysis (p < 0.012). Demographic data on the population of hospital pharmacists 
was obtained from the professional society of hospital pharmacists, (www.nvza.nl) (23). 
Likewise, no differences in gender and the ratio between specialty trained and in training 
were observed. Therefore, our data may not be fully applicable to the older pharmacists. 
The percentage of responders among the hospital pharmacists was significantly higher 
compared to the other two groups. In the Netherlands, several hospitals have prospective 
genotyping programmes for TPMT and DPYD and hospital pharmacists may therefore have 
more experience with PGx testing (24). As a result, our estimate of adoption of PGx among 
the whole population of Dutch pharmacists may be too optimistic. However, compared 
to the two previous surveys our study shows a higher response rate (18.8% vs. 2.59% and 
6.76%) that reduces the risk of selection bias (7, 8).  
Conclusion
This survey shows that adoption of PGx among Dutch pharmacists is still low and despite 
the nationwide availability of interruptive CDS containing the DPWG guidelines Dutch 
pharmacists still perceive a lack of knowledge on the subject that remains to be an important 
barrier for PGx test adoption. 
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Q1: What is your gender?  Male 305 45.7
 Female 362 54.3
N %
Q2: What is your age?  20–29 105 15.7
 30–39 209 31.3
 40–49 144 21.6
 50–59 158 23.7
 ≥ 60 51 7.6
N %
Q3: Are you in possession of 
a specialty or are you in train-
ing for a specialty?
 Yes, I am in possession of a specialty 549 82.3
 Yes, I am in training for specialty 85 12.7
 No, I do not possess a specialty and are not in 
training for a specialty
33 4.9
N %
Q4: What is your practice setting?  Community pharmacy 464 69.6
 Hospital pharmacy  164 24.6
 Outpatient pharmacy 32 4.8
 Other … 7 1.0
N %
Q5: Which department carries 
out the majority of the phar-
macogenetic test for diagnos-
tic purposes?
 Hospital pharmacy laboratory 19 11.6
 Clinical chemistry laboratory 30 18.3
 Human genetics laboratory 11 6.7
 Samples are determined externally 87 53.0
 Samples are not determined in the hospital 
and not determined externally
8 4.9
 Other ... 4 2.4
 Hospital pharmacy laboratory 5 3.0
 Unknown 19 11.6
Belief and expectations towards PGx
N %
Q6: Do you believe that a patient’s genetic profile may influ-
ence his/her response to drug therapy?
 Yes 665 99.7
 No 2 0.3
N %
Q7: Do you expect that pharmacogenetic testing will prevent 
your patient from taking the wrong medicine (or the wrong 
dose)? (0 = no expectations… / 3 = very high expectations …)
 0 11 1.6
 1 117 17.5
 2 310 46.5
 3 229 34.3
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Q8: Do you expect that pharmacogenetic testing will allow 
detecting which drug (or which dose) will be more efficacious 
in your patient? (0 = no expectations… / 3 = very high expec-
tations …)
 0 5 0.7
 1 96 14.4
 2 309 46.3
 3 257 38.5
N %
Q9: Do you expect that pharmacogenetic testing will allow 
detecting which drug (or which dose) will cause less side 
effects in your patient? (0 = no expectations… / 3 = very high 
expectations …)
 0 11 1.6
 1 124 18.6
 2 313 46.9
 3 219 32.8
Worries toward PGx testing
N %
Q10: Are you worried that a PGx test might show there is no 
suitable drug for your patient? (0 = not worried / 3 = very 
worried)?
 0 268 40.2
 1 210 31.5
 2 150 22.5
 3 39 5.8
N %
Q11: Are you worried that a PGx test could reveal that your pa-
tient also has risk factors for another disease that he/she does 
not know about? (0 = not worried / 3 = very worried)?
 0 92 13.8
 1 162 24.3
  2 236 35.4
 3 177 26.5
N %
Q12: Are you worried that a health insurance could obtain in-
formation about an individual’s genotype based on the drug/
dose prescribed? (0 = not worried / 3 = very worried)
 0 25 3.7
 1 32 4.8
 2 116 17.4
 3 494 74.1
N %
Q13: Are you worried that one of your patient’s PGx test 
results could be passed to an unauthorized person? (0 = not 
worried / 3 = very worried)
 0 53 7.9
 1 147 22.0
 2 187 28.0
 3 280 42.0
N %
Q14: Do you think that your patient’s unfavorable test results 
could have adverse psychological consequences on him and 
his family?
 Yes 425 63.7
 No 105 15.7
 No opinion 137 20.5
N %
Q15: Are you more concerned about the loss of privacy of 
a patient’s genetic information from the results of pharma-
cogenetic tests than from the results of other laboratory or 
diagnostic tests?
 Yes 154 23.1
 No 513 76.9
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N % N %
Q16: Among the following 
health professionals, which 
ones should have access to 
patients’ pharmacogenetic 
information (select all that 
apply)
 Physician 662 99.3 5 0.7
 Pharmacist 649 97.3 18 2.7
 Genetic counsellor 517 77.5 150 22.5
 Clinical chemist 319 47.8 348 52.2
 Nurse practitioner 113 16.9 554 83.1
 Psychologist 41 6.1 626 93.9
 General nurse 13 1.9 654 98.1
 Social worker 1 0.1 666 99.9
 Dietician 27 4.0 640 96.0
N %
Q17: Do you believe that health insurers should provide full 
coverage for pharmacogenetic tests?
 Always 204 30.6
 Sometimes 461 69.1
 Never 2 0.3
PGx test adoption
N %
Q18: At any time in the past 6 months, have you ordered or 
recommended a pharmacogenetic test?
 Yes 98 14.7
 No 569 85.3
N %
Q19: Within the past 6 months, with what average 
frequency have you ordered or recommended a 
pharmacogenetic test?
 1 time /mo. 77 78.6
 2–5 times /mo. 22 22.4
 >5 times /mo. 7 7.1
 N/A
Yes No
N % N %
Q20: At any time in the 
past 6 months, have you 
ordered or recommended a 
pharmacogenetic test for … 
(select all that apply)
 A patient 91 92.9 7 7.1
 Yourself 2 2.0 96 98.0
 A colleague or friend 5 5.1 93 94.9
 A family member? 3 3.1 95 96.9
 Other 3 3.1 95 96.9
 N/A
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N % N %
Q21: Pharmacogenetic 
tests have benefited 
your patients by … 
(select all that apply)
 Improving drug effectiveness 51 52.0 47 48.0
 Reducing drug toxicity 73 74.5 25 25.5
 Increasing patients’ under-
standing of their disease/therapy
18 18.4 80 81.6
 Improving patients’ adherence 
to therapy
6 6.1 92 93.9
 No tests ordered 6 6.1 92 93.9
 Patients have not benefited 11 11.2 87 88.8
 Other 51 52.0 47 48.0
N %
Q22: Do you anticipate ordering or recommending more, 
less or no pharmacogenetic tests for patients within the 
next 6 months
 More PGx tests 78 79.6
 Less PGx test 12 12.2
 No tests 8 8.2
N %
Q23: Do you anticipate ordering or recommending a pharma-
cogenetic test for a patient within the next 6 months?
 Yes 181 27.1
 No 486 72.9
Yes No
N % N %
Q24: If you have 
not ordered or 
recommended a 
pharmacogenetic 
test in the past 6 
months, or do not 
anticipate ordering
one in the next 6 
months, please 
indicate the main 
reason why (select 
one):
 Concern over privacy 10 1.7 567 98.3
 Little-to-no or uncertain value in 
testing
8 1.4 569 98.6
 Lack of insurance coverage for 
testing
81 14.0 496 86.0
 Not enough knowledge about 
testing/genomic markers
348 60.3 229 39.7
 Patients’ resistance to genetic 
testing
11 1.9 566 98.1
 I do not dispense drugs with PGx 
tests available or recommended
148 25.6 429 74.4
 Other 184 31.9 393 68.1
 N/A
N %
Q25: Currently, various (pharmaco)genetic tests are available 
directly to consumers. At any time in the past 6 months, has a 
patient brought into your office the results of a genome-wide 
scan obtained on his or her own?
 Yes 10 1.5
 No 657 98.5
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Q26: What kind of genetics test(s) 
had these patients performed?
A “whole genome scan” is a scan 
of the patient’s DNA that reveals 
markers associated with diseases 
and/or altered response to drug 
therapy
 A test of a single (pharmaco) gene 2 8
 A test of multiple (pharmaco)genes 4 6




Q27: At which University did you obtain your 
PharmD?
 University of Groningen 221 33.1
 University of Leiden 38 5.7
 University of Utrecht 357 53.5
 University of Amsterdam 32 4.8
 Other 19 2.8
N %
Q28: Was PGx instruction included in your graduate pharmacy 
education curriculum?
 Yes 265 39.7
 No 402 60.3
N %
Q29: Was PGx instruction included in your postgraduate 
specialty training ?
 Yes 163 24.4
 No 504 75.6
N %
Q30: Do you feel that you are adequately informed about the 
availability of genetic testing and its application
in the context of drug therapy?
 Yes 94 14.1
 No 573 85.9
N %
Q31: Would you like to participate in extra training on 
pharmacogenetics
 Yes 592 88.8
 No 75 11.2
Attitude towards own ability to interpret PGx test results
N %
Q32: Would you feel qualified to receive your patient’s 
pharmacogenetic testing results, interpret them and 
advise your patient on a treatment choice?
 Yes 180 27.0
 Yes, but after having had 
training on the subject 442 66.3
 No, this is not my re-
sponsibility 45 6.7
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Q33: Would you feel comfortable to recommend 
pharmacogenetic testing to your patients if those 
tests could predict that a specific drug could be 
efficacious in their case?
 Yes 323 48.4




Q34: If a pharmacogenetic test revealed that the 
only available drug to treat your patient’s disease is 
ineffective or leads to severe side effects, would you 
still advise your patient to take that medicine?
 Yes 23 3.4
 No 317 45.7
 Yes, only if he/she had a 
life-threatening disease 327 49.0
N %
Q35: Would you feel comfortable to recommend 
genetic testing to your patients if those tests could 
reveal which diseases are liable to affect them in the 
future
 Yes 52 7.8
 Yes, but only if that 
disease could be treated 84 12.6
 No 339 50.8
 Undecided 192 28.8
Access to and use of PGx information
N %
Q36: Do you obtain extra information on genetic testing and 
its application in the context of drug therapy?
(if “No" proceed to Q38)
 Yes 258 38.7
 No 409 61.3
Yes No
N % N %
Q37: Where do you obtain 
information on genetic 
testing and its application 
in the context of drug 
therapy? (select all that 
apply)
 Drug labeling (package 
insert)
203 30.4 464 69.6
 Internet 163 24.4 504 75.6
 Genetic testing laboratory 62 9.3 605 90.7
 Colleague 100 15.0 567 85.0
 Post-academic education 
and pharmacotherapeutic 
meetings
79 11.8 588 88.2
 Other 66 9.9 601 90.1
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Q38: What level of evidence is of 
importance to you in consideration 
of ordering a pharmacogenetic test
Authority approval of 
recommendation
 Very unimportant 7 1.0
 Unimportant 10 1.5
 Un-decided 114 17.1
 Important 310 46.5
 Very important 226 33.9
Speciality guidelines  Very unimportant 4 0.6
 Unimportant 3 0.4
 Un-decided 40 6.0
 Important 328 46.9
 Very important 292 43.8
Scientific journal  Very unimportant 4 0.6
 Unimportant 5 0.7
 Un-decided 116 17.4
 Important 374 56.1




leaders or respected 
colleagues
 Very unimportant 3 0.4
 Unimportant 30 4.5
 Un-decided 256 38.4
 Important 328 49.2
 Very important 50 7.5
Yes No
N % N %
Q39: Where do you obtain 
information to make a 
choice about the drug and 
dose in case of a known 
genotype?
 Drug labeling (package 
insert)
407 61.0 260 39.0
 Registration authority 173 25.9 494 74.1
 Scientific literature 389 58.3 278 41.7
 Colleague 153 22.9 514 77.1
 Pharmaceutical Compass 228 34.2 439 65.8
 Informatorium Medicamen-
torum
587 88.0 80 12.0
 Other … 37 5.5 630 94.5
N %
Q40: Were you aware that in the Netherlands dosing 
guidelines are available with information on the choice and 
dose of drugs based on the genotype of a patient?
 Yes 474 74.1
 No 173 25.9
N %
Q41: Were you aware that in the Netherlands medication 
surveillance based on the genotype of a patient in 
incorporated in the automated drug dispensing systems?
 Yes 436 65.4
 No 231 34.6
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Community + other Outpatient Hospital
N % N % N %
Response p < 0.001
Yes 471 16.9 32 18.4 164 27.5
No 2316 83.1 142 81.6 432 72.5
2787 100.0 174 100.0 596 100.0
Age p = 0.003
20–29 71 15.1 8 25.0 26 15.9
30–39 130 27.6 12 37.5 67 40.9
40–49 99 21.0 7 21.9 38 23.2
50–59 128 27.2 5 15.6 25 15.2
≥ 60 43 9.1 0 0.0 8 4.9
471 100.0 32 100.0 164 100.0
Do you expect that…
PGx will allow detect of which drug or 
dose will be more efficacious p = 0.017
0 2 0.4 0 0.0 3 1.8
1 57 12.1 6 18.8 33 20.1
2 225 47.8 9 28.1 75 45.7
3 187 39.7 17 53.1 53 32.3
471 100.0 32 100.0 164 100.0
At any time in the past 6 months, 
have you ordered or recommended a 
pharmacogenetic test p < 0.001
No 454 96.4 30 93.8 85 51.8
Yes 17 3.6 2 6.2 79 48.2
471 100.0 32 100.0 164 100.0
Do you anticipate ordering or 
recommending a pharmacogenetic 
test for a patient within the next 6 
months p < 0.001
no past testing, no future testing 407 86.4 23 71.9 48 29.3
no past testing, future testing 47 10.0 7 21.9 37 22.6
past testing 17 3.6 2 6.2 79 48.2
471 100.0 32 100.0 164 100.0
Supplementary Document S8.2: Comparison between specialties
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Community + other Outpatient Hospital
N % N % N %
At which University did you obtain 
your PharmD
p = 0.015
Groningen 153 32.5 8 25.0 60 36.6
Utrecht 241 51.2 22 68.8 94 57.3
Leiden 29 6.2 1 3.1 8 4.9
Amsterdam 30 6.4 0 0.0 2 1.2
Other 18 3.8 1 3.1 0 0.0
471 100.0 32 100.0 164 100.0
Was education on PGx included in 
your postgraduate specialty training p < 0.001
No 411 87.3 28 87.5 65 39.6
Yes 60 12.7 4 12.5 99 60.4
471 100.0 32 100.0 164 100.0
Would you like to participate in extra 
training on pharmacogenetics p < 0.001
No 33 7.0 2 6.2 40 24.4
Yes 438 93.0 30 93.8 124 75.6
471 100.0 32 100.0 164 100.0
Would you feel qualified to receive 
your patient’s pharmacogenetic 
testing results, interpret them and 
advise your patient on a treatment 
choice p < 0.001
No 34 7.2 2 6.2 9 5.5
Yes 77 16.3 6 18.8 97 59.1
Yes, after training 360 76.4 24 75.0 58 35.4
471 100.0 32 100.0 164 100.0
Would you feel comfortable to 
recommend pharmacogenetic testing 
to your patients if those tests could 
predict that a specific drug could be 
efficacious in their case p < 0.001
No 134 28.5 11 34.4 19 11.6
Yes 189 40.1 12 37.5 122 74.4
Undecided 148 31.4 9 28.1 23 14.0
471 100.0 32 100.0 164 100.0
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Community + other Outpatient Hospital
N % N % N %
Do you feel that you are adequately 
informed about the availability of 
genetic testing and its application in 
the context of drug therapy p < 0.001
No 444 94.3 31 96.9 98 59.8
Yes 27 5.7 1 3.1 66 40.2
471 100.0 32 100.0 164 100.0
Where do you obtain information on 
genetic testing and its application in 
the context of drug therapy?
Drug labelling (package insert) p < 0.001
No 359 76.3 23 71.9 82 50.0
Yes 112 23.7 9 28.1 82 50.0
471 100.0 32 100.0 164 100.0
Colleague p < 0.001
No 429 91.1 25 78.1 113 68.9
Yes 42 8.9 7 21.9 51 31.1
471 100.0 32 100.0 164 100.0
Internet p < 0.001
No 379 80.5 26 81.2 99 60.4
Yes 92 19.5 6 18.8 65 39.6
471 100.0 32 100.0 164 100.0
Genetic testing laboratory p < 0.001
No 451 95.8 31 96.9 123 75.0
Yes 20 4.2 1 3.1 41 25.0
471 100.0 32 100.0 164 100.0
Other p < 0.001
No 446 94.7 29 90.6 126 76.8
Yes 25 5.3 3 9.4 38 23.2
471 100.0 32 100.0 164 100.0
What level of evidence is of impor-
tance to you in consideration of order-
ing a pharmacogenetic test?
Speciality guidelines p = 0.034
Important/ very important 5 1.1 0 0.0 2 1.2
Undecided 37 7.9 1 3.1 2 1.2
Unimportant/ very unimportant 429 91.1 31 96.6 160 93.0
471 100.0 32 100.0 164 100.0
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Community + other Outpatient Hospital
N % N % N %
Where do you obtain information to 
make a choice about the drug and 
dose in case of a known genotype
Drug labelling (package insert) p = 0.027
No 199 42.3 10 31.2 51 39.0
Yes 272 57.7 22 68.8 113 61.0
471 100.0 32 100.0 164 100.0
Scientific literature p < 0.001
No 223 47.3 16 50.0 39 23.8
Yes 248 52.7 16 50.0 125 76.2
471 100.0 32 100.0 164 100.0
Colleague p < 0.001
No 396 84.1 21 65.6 97 59.1
Yes 75 15.9 11 34.4 67 40.9
471 100.0 32 100.0 164 100.0
Pharmaceutical Compass p < 0.001
No 264 56.1 26 81.2 149 90.9
Yes 207 43.9 6 18.8 15 9.1
471 100.0 32 100.0 164 100.0
Were you aware that in the 
Netherlands …
dosing guidelines are available with 
information on the choice and dose 
of drugs based on the genotype of a 
patient? p < 0.001
No 154 32.7 5 15.6 14 8.5
Yes 317 67.3 27 84.4 150 91.5
471 100.0 32 100.0 164 100.0
medication surveillance based on the 
genotype of a patient in incorporated 
in the automated drug dispensing 
systems? p < 0.001
No 187 39.7 11 34.4 33 20.1
Yes 284 60.3 21 65.6 131 79.9
471 100.0 32 100.0 164 100.0
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Community + other Outpatient Hospital
N % N % N %
Do you think that your patient’s 
unfavourable test results could have 
adverse psychological consequences 
on him and his family? p = 0.002
Yes 58 12.3 7 21.9 40 24.4
No 316 67.1 21 65.6 88 53.7
Undecided 97 20.6 4 12.5 36 22.0
471 100.0 32 100.0 164 100.0
A PGx test might show there is no 
suitable drug for your patient p < 0.001
0 161 34.2 15 46.9 92 56.1
1 157 33.3 9 28.1 44 26.8
2 118 25.1 7 21.9 25 15.2
3 35 7.4 1 3.1 3 1.8
471 100.0 32 100.0 164 100.0
Which of the following health 
professionals should have access to 
the patient’s PGx test results
Nurse-practitioner p = 0.012
No 382 81.1 24 75.0 148 90.2
Yes 89 18.9 8 25.0 16 9.8
Are you worried that …
A health insurance could obtain 
information about an individual’s 
genotype based on the drug/dose 
prescribed p = 0.003
0 16 3.4 2 6.2 7 4.3
1 21 4.5 5 15.6 6 3.7
2 68 14.4 7 21.9 41 25.0
3 366 77.7 18 56.2 110 67.1
471 100.0 32 100.0 164 100.0
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Non-adopters Future adopters Past adoption
N % N % N %
Specialty p < 0.001
Community pharmacy 407 85.1 47 51.6 17 17.3
Outpatient pharmacy 56 4.8 7 7.7 2 2.0
Hospital pharmacy 48 10.0 37 40.7 79 80.6
478 100.0 91 100.0 98 100.0
Do you expect that…
PGx can prevent you patient from 
taking the wrong drug or dose
p = 0.002
0 8 1.7 3 3.3 0 0.0
1 97 20.3 8 8.8 12 12.2
2 229 47.9 37 40.7 44 44.9
3 144 30.1 43 47.3 42 42.9
478 100.0 91 100.0 98 100.0
PGx will allow detection of which drug 
or dose will cause less side effects
p = 0.002
0 9 1.9 2 2.2 0 0.0
1 97 20.3 11 12.1 16 16.3
2 235 49.2 31 34.1 47 48.0
3 137 28.7 47 51.6 35 35.7
478 100.0 91 100.0 98 100.0
Was education on PGx included in 
your postgraduate specialty training
p < 0.001
No 404 84.5 59 64.8 41 41.8
Yes 74 15.5 32 35.2 57 58.2
478 100.0 91 100.0 98 100.0
Would you like to participate in extra 
training on pharmacogenetics
p < 0.001
No 47 9.8 4 4.4 24 24.5
Yes 431 90.2 87 95.6 74 75.5
478 100.0 91 100.0 98 100.0
p < 0.001
No 41 8.6 3 3.3 1 1.0
Yes 85 17.8 28 30.8 67 68.4
Yes, after training 352 73.6 60 65.9 30 30.6
478 100.0 91 100.0 98 100.0
Supplementary Document S8.4: Comparison between responders with past adoption, future 
adopters and non-adopters (1)
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Non-adopters Future adopters Past adoption
N % N % N %
Would you feel qualified to receive 
your patient’s pharmacogenetic 
testing results, interpret them and 
advise your patient on a treatment 
choice
p < 0.001
No 41 8.6 3 3.3 1 1.0
Yes 85 17.8 28 30.8 67 68.4
Yes, after training 352 73.6 60 65.9 30 30.6
478 100.0 91 100.0 98 100.0
Would you feel comfortable to 
recommend pharmacogenetic testing 
to your patients if those tests could 
predict that a specific drug could be 
efficacious in their case
p < 0.001
No 143 29.9 13 14.3 8 8.2
Yes 183 38.3 60 65.9 80 81.6
Undecided 152 31.8 18 19.8 10 10.2
478 100.0 91 100.0 98 100.0
Do you feel that you are adequately 
informed about the availability of 
genetic testing and its application
in the context of drug therapy
p < 0.001
No 446 93.3 74 81.3 53 54.1
Yes 21 6.7 17 18.7 45 45.9
478 100.0 91 100.0 98 100.0
Do you obtain extra information on 
genetic testing and its application in 
the context of drug therapy?
p < 0.001
No 357 74.7 27 29.7 25 25.5
Yes 121 25.3 64 70.3 73 74.5
478 100.0 91 100.0 98 100.0
Where do you obtain information on 
genetic testing and its application in 
the context of drug therapy?
Drug labelling (package insert) p < 0.001
No 385 80.5 38 41.8 41 41.8
Yes 93 19.5 53 58.2 57 58.2
478 100.0 91 100.0 98 100.0
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Non-adopters Future adopters Past adoption
N % N % N %
Colleague p < 0.001
No 439 91.8 64 70.3 64 65.3
Yes 39 8.2 27 29.7 34 34.7
478 100.0 91 100.0 98 100.0
Post-academic education and 
pharmacotherapeutic meetings
p < 0.001
No 443 92.7 66 72.5 79 80.6
Yes 35 7.3 25 27.5 19 19.4
478 100.0 91 100.0 98 100.0
Internet p < 0.001
No 404 84.5 49 53.8 51 52.0
Yes 74 15.5 42 46.2 47 48.0
478 100.0 91 100.0 98 100.0
Genetic testing laboratory p < 0.001
No 463 96.9 77 84.6 65 66.3
Yes 15 3.1 14 15.4 33 33.7
478 100.0 91 100.0 98 100.0
Other p < 0.001
No 451 94.4 75 82.4 75 76.5
Yes 27 5.6 16 17.6 23 23.5
478 100.0 91 100.0 98 100.0
What level of evidence is of 
importance to you in consideration of 
ordering a pharmacogenetic test?
Speciality guidelines p = 0.041
Important/ very important 26 5.4 4 4.4 3 3.1
Undecided 197 41.2 33 36.3 26 26.5
Unimportant/ very unimportant 255 53.3 54 59.3 69 70.4
478 100.0 91 100.0 98 100.0
Scientific literature p < 0.001
No 232 48.5 25 27.5 21 21.4
Yes 246 51.5 66 72.5 77 78.6
478 100.0 91 100.0 98 100.0
Colleague p = 0.001
No 386 80.8 63 69.2 65 66.3
Yes 92 19.2 28 30.8 33 33.7
478 100.0 91 100.0 98 100.0
Supplementary Document S8.4: Continued
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Non-adopters Future adopters Past adoption
N % N % N %
Pharmaceutical Compass p < 0.001
No 290 60.7 66 72.5 83 84.7
Yes 188 39.3 25 27.5 15 34.2
478 100.0 91 100.0 98 100.0
Other p = 0.029
No 456 95.4 87 95.6 87 88.8
Yes 22 4.6 4 4.4 11 11.2
478 100.0 91 100.0 98 100.0
Were you aware that in the 
Netherlands …
dosing guidelines are available with infor-
mation on the choice and dose of drugs 
based on the genotype of a patient?
p < 0.001
No 157 32.8 9 9.9 7 7.1
Yes 321 67.2 82 90.1 91 92.9
478 100.0 91 100.0 98 100.0
medication surveillance based on the 
genotype of a patient in incorporated 
in the automated drug dispensing 
systems?
p < 0.001
No 198 41.4 18 19.8 15 15.3
Yes 280 58.6 73 80.2 83 84.7
478 100.0 91 100.0 98 100.0
Do you think that your patient’s 
unfavourable test results could have 
adverse psychological consequences 
on him and his family?
p = 0.002
Yes 64 13.4 14 15.4 27 27.6
No 312 65.3 64 70.3 49 50.0
Undecided 102 21.3 13 14.3 22 22.4
478 100.0 91 100.0 98 100.0
Are you worried that …
A PGx test might show there is no 
suitable drug for your patient
p = 0.012
0 179 37.4 34 37.4 55 56.1
1 157 32.8 28 30.8 25 25.5
2 108 22.6 25 27.5 17 17.3
3 34 7.1 4 4.4 1 1.0
478 100.0 91 100.0 98 100.0
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To benchmark knowledge and attitude of pharmacy students towards pharmacogenetics 
(PGx) and PGx-testing and compare the results to practicing colleagues. All pharmacy 
students in The Netherlands were invited to participate in a web-based survey consisting 
of 28 questions.Of the 824 invited students, 148 individuals (18.0%) completed the 
questionnaire. All responders believed in the concept of PGx and had high expectations 
towards PGx. The majority (96.6%) had received some form of education on PGx, but only 
12.8% felt adequately informed. When compared to practicing pharmacists’ differences 
were observed in the use of information and feeling qualified to recommend PGx-testing. 
More education on PGx is required in the curriculum to fill the perceived knowledge gap 
among future pharmacists.
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In recent years the field of pharmacogenetics (PGx) has developed rapidly and this has 
translated to an increasing number of drug labels containing information on genetic 
biomarkers (1, 2). In addition, the Clinical Pharmacogenetics Implementation Consortium 
(CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have created widely 
recognized guidelines with therapeutic recommendations for patients with a known 
genotype (3-5). Consequently, healthcare professionals need to develop their knowledge 
of pharmacogenetics to be able to optimize patient care based on pharmacogenetic 
markers. Previous studies have shown that physicians and pharmacists in the United States, 
Canada and the Netherlands have high expectations of PGx to improve the efficacy and 
safety of drugs. However, despite the enthusiasm of physicians and pharmacists towards 
PGx, a knowledge gap on this subject appears to be present (6-8). This knowledge gap 
potentially hinders the adoption of PGx into clinical care and may be the consequence of 
a lack of education on PGx in their curriculum (8). To solve the lack of knowledge among 
healthcare professionals additional PGx related education could be essential. Pharmacy 
students represent the next generation of pharmacists and are bound to come into contact 
with the field of PGx in their later career path. Limited knowledge among these students 
may impede PGx application in clinical care. In a statement issued in 2015 the American 
Society of Health-System Pharmacists has encouraged the embedding of education on 
PGx in college of pharmacy curricula and Specialties certification programs (9). In the 
Netherlands The Royal Dutch Pharmacist’s Association (KNMP) has incorporated PGx 
in their view of the future for care in 2020, but no clear recommendation to incorporate 
PGx in the pharmacy curricula exist (10).
Currently, it is unknown whether pharmacy students receive education on PGx and what 
their expectations and attitudes of pharmacy students towards PGx and PGx-testing are. 
In this study we set out to investigate whether pharmacy students believe in the concept of 
PGx, what expectations they have towards PGx, to research whether a knowledge gap on 
PGx is present among these students and to analyse whether there are differences between 
pharmacy students and practising pharmacists. 
Methods
Study design
Similar to a previous survey of practicing pharmacists, a web-based survey was performed 
with NetQ [101]. In brief, a list with the email addresses of all students of pharmacy in The 
Chapter_9_Paul.indd   209 21-9-2018   11:05:43
Chapter 9
210
Netherlands was obtained from the KNMP and an email with a link to the survey was sent 
to 824 students. After two weeks a reminder was sent. The students could complete the 
survey between December 15th 2014 and February 1st 2015. Participation was completely 
voluntary and no reimbursement was offered. All responses were analysed anonymously. 
For the comparison with Dutch practicing pharmacists the results of a cohort of 667 
pharmacists that completed an identical set of the questions (see below) were used (8).
Questionnaire
A questionnaire previously described in detail was used (6-8). Questions not applicable for 
students were removed (e.g. questions relating to PGx tests ordered or recommended in 
a clinical setting). In the first part of the survey a brief overview of the topics covered and 
an explanation for pharmacogenetics was provided. In total the questionnaire consisted 
of 28 questions divided among five sections. In the first section five questions were asked 
to gather baseline information on the participants. The second part of the questionnaire 
(Q6–9) surveyed the responders’ belief in the concept of PGx and their expectations towards 
PGx. In the third section (Q10–13) participants were asked questions relating to attitudes 
of toward their own abilities. Q14–20 (section 4) surveyed sources of information of PGx 
used by candidates. In the final section (Q1–28) of the survey the participants were asked 
questions relating to ethics and test coverage (see Supplementary Document S9.1).
Survey analysis
Survey responses were automatically tabulated and stored by Netq. For the analysis of the 
responses only complete questionnaires were included. In order to compare the results 
of the pharmacy students with the previously surveyed pharmacists age was recoded in a 
six-level categorical variable (≤ 29, 30–39, 40–49, 50–59, ≥ 60 years) and the answers of 
Q17 (see Supplementary Document S9.1) were condensed to a three level variable ((very) 
unimportant, undecided, (very) important) (8). The χ2 test was used to test for univariate 
associations. Binary logistic regression, multinomial logistic regression and ordinal 
logistic regression were used for the multivariate analyses using gender and age-groups 
as covariates. For the analysis of question 12 (see Supplementary Document S9.1) age was 
condensed from a six-level to a five-level categorical variable (≤ 29, 30–39, 40–49, ≥ 50 
years). Statistical analyses were performed with SPSS version 20 (SPSS, Inc., Illinois, USA) 
with p < 0.05 considered significant.
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Out of the 824 pharmacy students who received an invitation to participate in the survey 148 
students (18.0%) completed the questionnaire. Of the responders 70.3% was female and the 
median age was 24. The survey included students from the second through the sixth year 
of the study with a large majority of the responders being master students (93.9%). Of the 
students 96.6% had received some education in PGx as part of the curriculum (see Table 9.1). 
Belief in the concept of PGx & expectations towards PGx(-testing)
All students included in the analysis indicated to believe in the concept of (partially) 
hereditary drug response. To benchmark the expectation of the students towards PGx and 
PGx-testing they were asked to rate three statements on a scale from 0 (no expectation) 
to 3 (high expectation). To the question whether they expected a PGx test could prevent 
















In which year of the program do you currently follow courses?
Second year 1 0.7
Third year 8 5.4
Forth year 27 18.2
Fifth year 42 28.4
Sixth year 70 47.3
Has received education on PGx as part of their curriculum?
Yes 143 96.6
No 5 3.4
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a patient from receiving the wrong choice of drug or dose of a given treatment 86.5% of 
the students scored at least 2. For the statements “I expect that a PGx test will detect the 
most efficacious drug or dose” and “I expect that a PGx test will allow for detection the 
drug or dose that will cause less side effects” 87.2% and 73.7% of the student rated with a 
score ≥ 2 (see Figure 9.1). 
Attitude towards own expected ability to interpret PGx test results
Of the surveyed students 27.7% feels qualified to receive the PGx result of a patient, interpret 
genotype(s) and advise a treating healthcare professionals or patient on the choice of the 
drug regimen based on the results. The large majority (70.9%) see themselves qualified to 
receive and interpret a genotype and advise a patient or colleague based on the results, but 
only after receiving additional training on the subject, while 1.4% does not think this is 
part of their (future) job description. 75.0% sees him/herself qualified to recommend PGx 
testing to patients if the PGx test can reveal whether a drug is effective, whereas 8.1% does 
not feel qualified and 16.9% does not know. If the PGx test could also reveal a disease the 
patient is susceptible to in the future 20.9% would feel qualified to recommend the test and 
23.0% would feel qualified only if the disease could be treated. In contrast, 31.1% would 
not feel qualified to recommend a PGx test if that could reveal a disease and 25.0% does 
Figure 9.1: Expectations of pharmacy students towards PGx testing.
Red = I have a very low expectation that PGx …, orange = I have a low expectation that PGx …, yellow = I 
have a high expectation that PGx …, green = have a very high expectation that PGx … (the size of the bar 
is proportional to the number of respondents).
Figure 1: expectations of pharmacy students towards PGx testing












… will cause less side effects of drug / dose
…will detect the most efficacious drug / dose
… will prevent a wrong drug / dose
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not know if they would feel qualified in that case. When a PGx test would reveal that the 
only available drug therapy for a patient will not work or would lead to severe side effects 
31.1% of the surveyed student would not treat the patient with that drug and 64.2% would 
only give the treatment if the patient was suffering from a life-threatening condition. Only 
4.7% of the responders would continue with the drug even though the results of the PGx 
would indicate no efficacy.
Access to and use of PGx information
Although 96.6% of the students indicated that they had received education on PGx only 
12.8% of all students currently feels adequately informed about the availability of PGx-tests 
and how to apply PGx in treatment of patients. Among students in the final year of their 
curriculum (n = 70) 17.1% of the responders felt adequately informed about PGx testing. 
90.5% of the responders indicated they would use additional sources of information on how 
to apply PGx testing in pharmacotherapy of patients. The different sources of information 
used by students to obtain information about the use of PGx in relation to treatment or to 
support a choice in drug and dose in case of patient with an actionable phenotype predicted 
from a PGx test can be found in Supplementary Document S9.2.
Worries related toward PGx testing, privacy & coverage of PGx tests
In the last section of the questionnaire the students were benchmarked on potential worries 
towards the results of PGx testing, privacy and insurance of the PGx tests. Similar to the 
assessment of the expectations the students were asked to rate four questions on a four point 
scale from very low worries (0) to very high worries (3). To the question whether they were 
worried that a PGx might show that there is no suitable treatment for their patient 44.0% 
scored at least 2. Slightly more students (57.5%) were at least moderately worried (score ≥ 2) 
that a PGx test could show that a patient carries additional risk factors for another disease. 
71.7% scored a 2 or 3 on the question whether they were worried that PGx test results 
could fall in the hands of unauthorized individuals. Almost all of the surveyed students 
(91.2%) were at least moderately worried that insurance companies could infer a patients 
genotype based on the drug or dose a patient is prescribed (see Figure 9.2). Students also 
showed worries concerning the potential impact of unfortunate PGx test results, as 87.2% 
believed this could have negative psychological effects on the patients and their family. And 
23.0% of the responders were more worried for loss of privacy of the results of a PGx test 
compared to other diagnostic or laboratory tests. In their opinion the treating physician 
(98.0%) and pharmacist (99.3%) should have access to PGx data, whereas only a small 
portion of the surveyed students thought psychologists (8.8%), dieticians (4.7%), nurses 
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(3.4%) and social workers (1.4%) were allowed to access to results of PGx tests. Among the 
students there was no consensus on whether clinical geneticists (78.4%), clinical chemist 
(43.2%) or nurse-practitioners (16.9%) should be allowed to see a patients’ PGx-data. 
Finally, the students were asked if insurance companies should reimburse PGx-tests. All 
students were of the opinion that this indeed should be the case, but thought differently 
about the frequency in which PGx tests should be reimbursed. According to 78.4% of the 
students this should only be in certain occasions, whereas 21.6% thinks PGx tests should 
always be covered.
Differences between pharmacy students and practicing pharmacists
In a secondary analysis the responses of the pharmacy students were compared to the results 
of a previous survey among practicing pharmacists. In the univariate analyses between the 
two groups differences could be observed in multiple questions. In comparison, practicing 
pharmacists more often felt that interpreting PGx test results and advise patients and other 
healthcare professionals based on genotypes was not part of their job description (6.7% vs. 
1.4%, p = 0.038). Additionally, practicing pharmacists less often felt qualified to recommend 
PGx testing to predict the efficacy of drug treatments (48.4% vs. 75.0%, p < 0.001) and less 
Figure 9.2: Worries of pharmacy students towards PGx testing.
Green = I have very low worries that … (0), yellow = I have a low worries that … (1), orange = I have a high 
worries that PGx … (2), red = have a very high worries that PGx … (3) (the size of the bar is proportional to 




















… a health insurance could obtain information about an 
individual’s genotype based on the drug/dose prescribed
… a PGx test could reveal that your patient also has risk factors 
for another disease 
… a PGx test results could be passed to an unauthorized person
… a PGx test might show there is no suitable drug for your 
patient
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often felt qualified recommending a genetic test if that test could reveal information about 
a disease a patient was susceptible to (7.8% vs. 20.9%, p < 0.001). Practicing pharmacists 
were more likely to stop a treatment if a PGx test would indicate if the only available 
drug was not effective or would lead to severe side-effects (49.0% vs. 31.1%, p < 0.001). 
Differences were also seen in the use of information sources on how to apply PGx testing 
in pharmacotherapy of patients. In general pharmacy students more often indicated to 
use additional sources of information to determine the application of PGx in relation to 
pharmacotherapy (90.5% vs. 38.7%, p < 0.001). Pharmacy students more often believed that 
an unfavourable result from a PGx test could have negative psychological consequences 
on a patient and his/her family (87.2% vs. 63.7%, p = 0.034) and were more often at least 
moderately worried that PGx could show that there is no suitable treatment for a patient 
(44.0% vs. 28.3%, p < 0.001). Finally, a difference was observed in whether social workers 
should have access to PGx data, as pharmacy students more often agreed with this statement 
compared to practicing pharmacists (1.4% vs. 0.1%, p = 0.029). In other questions no 
significant differences were visible in the univariate analysis (Supplementary Document 
S9.3). Using gender and age groups as co-variants the multivariate analysis revealed that 
pharmacy students more often would feel qualified to recommend PGx testing to predict 
drug efficacy (odd’s ratio (OR) = 5.25 (confidence interval (CFI) = 2.47–11.16, p < 0.001), 
more often obtain extra information on genetic testing and its application in the context 
of drug therapy (OR = 12.61 (CFI = 6.42–24.77), p < 0.001) and more often think that an 
unfavourable test results could have adverse psychological consequences on him and his 
family (OR = 2.92 (1.08–7.89), p = 0.034). In contrast, pharmacy students are less often 
aware of the incorporation of medication surveillance based on genotype in electronic 
drug dispensing systems (OR = 0.12 (0.07–0.22), p < 0.001) (Supplementary Document 
S9.4).
Discussion
This study shows that pharmacy students believe in the concept of (partially) heritable drug 
response. The surveyed students had high expectations of PGx in making pharmacotherapy 
safer and more effective even though some concerns were also present among the 
responders of this survey. Despite almost all responders received some sort of education on 
PGx as part of their curriculum, the majority of students did not feel adequately informed 
about PGx. This effect remained visible in the responders who were in the last year of their 
education. Also worries that unauthorized individuals could obtain a patients’ genotype or 
that insurance companies can infer a genotype from a prescribed dose or alternate choice 
of drug scored relatively high.
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When the results of the pharmacy students are compared with the results of practicing 
pharmacists it can be seen that the results are quite similar although there are some 
differences. The differences between the students and their practicing colleagues are 
mainly present in feeling qualified to recommend PGx testing to predict efficacy of a 
specific drug, whether individuals would use additional information to support the use 
of PGx test in therapy, the sort of sources of information used to support PGx testing 
within therapy and the information sources to support changes in drug and dose in case 
of a known actionable genotype. Differences in feeling qualified to recommend PGx to 
predict efficacy of a treatment may be explained by clinical experience gained in the field 
or a degree of selection bias in the previous survey where pharmacist who had adopted a 
PGx test (and as a result had more confidence in their abilities to recommend testing) were 
more likely to respond to the survey as they were familiar with the topic. The differences 
in use sources of information may be the result of an ideal situation in case of the student 
group vs. the actual situation in practice in the group of the pharmacists. Finally, differences 
in knowledge of the incorporation of medication surveillance in electronic medication 
surveillance systems may be explained by the fact that pharmacy students do have gained 
experiences using this form of clinical decision support in clinical practice.
In this cross-sectional study of pharmacy students were benchmarked to a number of PGx-
related topics including expectations and worries towards PGx-testing. The expectations 
of the students seem to be generally high with over 80% of the students scoring at least 
≥ 2 prevent receiving a wrong regimen and predict which regimen is the most effective. 
Furthermore, 72.7% of the student scored at least ≥ 2 on the same scale to rate their 
expectation that PGx will provide the ability to predict which regimen will give the lowest 
chance of side effects. In addition to similarities to Dutch practicing pharmacists the 
expectations benchmarked in this study are also comparable with a survey of Canadian 
pharmacists where 80.0, 82.6 and 79.1% scored moderately hopeful on the three statements 
respectively and the results of a survey of Jordanian pharmacists who also have similar 
high expectations of PGx in relation to pharmacotherapy (7, 8, 11).
From Table 9.1 it can be observed that 70.3% of the responders is female compared to 29.7% 
of male responders. In a previous study among Dutch pharmacists a (M:F) ratio of 45.%7: 
54.3% was observed. Although this difference in male-female ratio can be interpreted 
as selection bias, the increase of females is in line with other research and likely a trend 
toward a more female profession (12). Additionally, as with any other questionnaire with 
no incentive for participating in the survey, there is risk for systematic bias as individuals 
with a strong opinion in both a positive or negative way are more likely to respond. In this 
survey the response rate among the pharmacy students was 18.0% which relatively high 
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compared to previous surveys (6, 7). As a result of a relatively high response rate the risk 
of systematic bias in this study will be likely be low. 
A striking finding in this survey is that only 12.8% of the students feel adequately informed 
about how to apply PGx in pharmacotherapy despite 96.6% of responders stating that PGx 
was part of their education which may result in a knowledge gap among future healthcare 
professionals. The percentage of students that felt adequately informed about PGx was 
similar to their older colleagues (14.1%) of whom only 39.7% had received education 
as part of their curriculum (8). One explanation may be found in the manner in how 
information on PGx is integrated in the curriculum. At this moment information on PGx 
and its applicability in pharmacotherapy is still taught in a traditional form using lectures. If 
the current practicing pharmacists had received any education as part of their curriculum, 
this was likely taught in a similar manner. With the decrease of the costs of sequencing 
it is anticipated that in the next years more and more patients will have a copy of their 
own genome. Pharmacogenetics is currently one of area’s within genetics that is relatively 
easy to implement in the clinic as guidelines exist providing PGx test interpretation and 
recommendations for actionable genotypes. The healthcare professionals of tomorrow 
are bound to come in contact with PGx test results and should be able to interpret these 
results and use them to improve pharmacotherapy. 
Although this survey identified a potential future knowledge gap among pharmacy 
students, the survey did not contain questions relating to the current implementation 
PGx in the curriculum (which year, which courses and credit hours etc.), the students’ 
perception on the clinical utility of PGx, their views on how PGx should be implemented 
within the PharmD curriculum and potential outcomes of a structured PGx program. 
An assessment among 715 healthcare US students, including 328 pharmacy students, 
showed that 75.3% (strongly) agreed PGx should be an important part of the curriculum, 
whereas only 13.1% (strongly) agreed that PGx had indeed been an important part of the 
curriculum Furthermore, Adams et al. developed the “Test2Learn” program in which a 
cohort of pharmacy students underwent personal genomics testing and as a result gained 
confidence in understanding PGx test and increased their self-perceived ability to empathize 
with potential patients (13). Similarly, initiatives such as reported by Weitzel et al, in which 
students genotype themselves and use this hands on experience in an educational setting 
increases understanding of PGx testing and comfort levels of student regarding acting on 
PGx data (14). Additional research should investigate whether Dutch students also would 
like hands-on experience with PGx during the Dutch pharmacy program. 
A similar elective course is present as a part of master Bio-Pharmaceutical Sciences at the 
Leiden University. In this course on clinical pharmacology students genotyped themselves, 
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interpret their own genotypes and learn how to adjust medication based on their genetic 
predicted phenotype. A similar program as part of a course on medication surveillance 
could help pharmacy students with understanding the current state of field, the clinical 
utility of PGx and their ability to interpret and act on genetic data. Further studies should 
investigate whether this form of education and/or in combination with other methods 
such as specialized residencies can reduce the PGx knowledge gap in the current pharmacy 
curriculum. 
Conclusion
This study shows that pharmacy students believe in the concept of hereditary drug response 
and have high expectations towards PGx. In a comparison with practicing pharmacists’ dif-
ferences in elements of feeling qualified to recommend PGx testing, the use of information 
on the applicability of PGx in pharmacotherapy and opinions about the possible negative 
impact of PGx tests were observed. Similar to their future colleagues the surveyed students 
perceive a knowledge gap despite having received education on the subject. 
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Section 1: Baseline information
Q1: What is your gender?  Male
 Female
Q2: What is your age? …
Q3: At which University do you currently follow your curriculum?  University of Groningen
 University of Leiden
 University of Utrecht
 Other








Q5: Has PGx been part of any course that you have followed as 
part of your curriculum
 Yes
 No
Section 2: Belief and expectations towards PGx
Q6: Do you believe that a patient’s genetic profile may influence 
his/her response to drug therapy?
 Yes
 No
Q7: Do you expect that pharmacogenetic testing will prevent your 
patient from taking the wrong medicine (or the wrong dose)? (0 = 





Q8: Do you expect that pharmacogenetic testing will allow 
detecting which drug (or which dose) will be more efficacious in 






Q9: Do you expect that pharmacogenetic testing will allow 
detecting which drug (or which dose) will cause less side effects in 
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Section 3: Attitude towards own ability to interpret PGx test results
Q10: Do you feel qualified to receive your patient’s 
pharmacogenetic testing results, interpret them and advise your 
patient on a treatment choice?
 Yes
 Yes, but after having had 
training on the subject
 No, this is not my 
responsibility
Q11: Would you feel qualified to recommend pharmacogenetic 
testing to your patients if those tests could predict that a specific 
drug could be efficacious in their case?
 Yes
 No
 I don’t know
Q12: If a pharmacogenetic test revealed that the only available 
drug to treat your patient’s disease is ineffective or leads to 




 Yes, only if he/she had a life-
threatening disease
Q13: Would you feel qualified to recommend genetic testing to 
your patients if those tests could reveal which diseases are liable 
to affect them in the future
 Yes
 Yes, but only if that disease 
could be treated
 No
 I don’t know
Section 4: Access to and use of PGx information
Q14: Do you feel that you are adequately informed about the 
availability of genetic testing and its application
in the context of drug therapy?
 Yes
 No
Q15: Would you obtain extra information on genetic testing and 
its application in the context of drug therapy?
 Yes
 No
Q16: Where do you obtain information on genetic testing and its 
application in the context of drug therapy? (select all that apply)
 Drug labelling (package 
insert)
 Colleague
 Post-academic education and 
pharmacotherapeutic meetings
 Internet
 Genetic testing laboratory
 Other …
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Q18: Where do you obtain information to make a choice about the 
drug and dose in case of a known genotype?






 Kennisbank / Informatorium 
medicamentorum
 Other …
Q19: Were you aware that in the Netherlands dosing guidelines 
are available with information on the choice and dose of drugs 
based on the genotype of a patient?
 Yes
 No
Q20: Were you aware that in the Netherlands medication 
surveillance based on the genotype of a patient in incorporated in 
the automated drug dispensing systems?
 Yes
 No
Section 5: Worries toward PGx testing & coverage of PGx testing
Q21: Do you think that your patient’s unfavourable test results 





Q22: Are you worried that a PGx test might show there is no 
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Q23: Are you worried that a PGx test could reveal that your patient 
also has risk factors for another disease that he/she does not know 





Q24: Are you worried that one of your patient’s PGx test results 






Q25: Are you more concerned about the loss of privacy of a 
patient’s genetic information from the results of pharmacogenetic 
tests than from the results of other laboratory or diagnostic tests?
 Yes
 No
Q26: Among the following health professionals, which ones 
should have access to patients’ pharmacogenetic information 










Q27: Are you worried that a health insurance could obtain 
information about an individual’s genotype based on the drug/





Q28: Do you believe that health insurers should provide full 
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Supplementary Document S9.2: Results per question
Question Answer N %
Section 1: Baseline information
Q1: What is your gender?  Male 44 29.7
 Female 104 70.3
Q2: What is your age?  20 4 2.7
 21 11 7.4
 22 15 10.1
 23 30 20.3
 24 35 23.6
 25 31 20.9
 26 15 10.1
 27 1 0.7
 28 4 2.7
 29 2 1.4
Q3: At which University do you currently follow your 
curriculum?
 University of Groningen 47 31.8
 University of Utrecht 101 68.2
 Other 0 0.0
Q4: In which year of the program do you currently 
follow courses?
 Second year 1 0.7
 Third year 8 5.4
 Fourth year 18.2 18.2
 Fifth year 28.4 28.4
 Sixth year 47.3 47.3
Q5: Has PGx been part of any course that you have 
followed as part of your curriculum
 Yes 143 96.6
 No 5 3.4
Section 2: Belief and expectations towards PGx
Q6: Do you believe that a patient’s genetic profile 
may influence his/her response to drug therapy?
 Yes 148 100.0
 No 0 0.0
Q7: Do you expect that pharmacogenetic 
testing will prevent your patient from taking the 
wrong medicine (or the wrong dose)? (0 = no 
expectations… / 3 = very high expectations …)
 0 5 3.4
 1 15 10.1
 2 73 49.3
 3 55 37.2
Q8: Do you expect that pharmacogenetic testing 
will allow detecting which drug (or which dose) 
will be more efficacious in your patient? (0 = no 
expectations… / 3 = very high expectations …)
 0 0 0.0
 1 19 12.8
 2 63 42.6
 3 66 44.6
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Question Answer N %
Q9: Do you expect that pharmacogenetic testing 
will allow detecting which drug (or which dose) 
will cause less side effects in your patient? (0 = no 
expectations… / 3 = very high expectations …)
 0 6 4.1
 1 33 22.3
 2 66 44.6
 3 43 29.1
Section 3: Attitude towards own ability to interpret PGx test results
Q10: Would you feel qualified to receive your patient’s 
pharmacogenetic testing results, interpret them and 
advise your patient on a treatment choice?
 Yes 41 27.7
 Yes, but after having 
had training on the 
subject
105 70.9
 No, this is not my 
responsibility 2 1.4
Q11: Would you feel qualified to recommend 
pharmacogenetic testing to your patients if those 
tests could predict that a specific drug could be 
efficacious in their case?
 Yes 111 75.0
 No 12 8.1
 Un-decided 25 16.9
Q12: If a pharmacogenetic test revealed that the 
only available drug to treat your patient’s disease is 
ineffective or leads to severe side effects, would you 
still advise your patient to take that medicine?
 Yes 7 4.7
 Yes, only if he/she had a 
life-threatening disease
95 64.2
 No 46 31.1
Q13: Would you feel qualified to recommend genetic 
testing to your patients if those tests could reveal 
which diseases are liable to affect them in the future
 Yes 31 20.9
 Yes, but only if that 
disease could be treated
34 23.0
 No 46 31.1
 Un-decided 37 25.0
Section 4: Access to and use of PGx information
Q14: Do you feel that you are adequately informed 
about the availability of genetic testing and its 
application in the context of drug therapy?
 Yes 19 87.2
 No 129 87.2
Q15: Would you obtain extra information on genetic 
testing and its application in the context of drug 
therapy? (if “No" proceed to Q17)
 Yes 134 90.5
 No 14 9.5
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Question Answer N %
Q16: Where would you obtain information on 
genetic testing and its application in the context of 
drug therapy? (select all that apply)
 Drug labeling (package 
insert)
102 68.9






 Internet 97 65.5
 Genetic testing 
laboratory
68 45.9
 Other 23 15.5
Q17: What level of evidence 
is of importance to you in 





 Very unimportant 0 0.0
 Unimportant 1 0.7
 Un-decided 23 15.5
 Important 75 50.7
 Very important 49 33.1
Speciality 
guidelines
 Very unimportant 0 0.0
 Unimportant 0 0.0
 Un-decided 13 8.8
 Important 88 59.5
 Very important 47 31.8
Scientific journal  Very unimportant 0 0.0
 Unimportant 1 0.7
 Un-decided 25 16.9
 Important 75 50.7
 Very important 47 31.8
Recommendation 





 Very unimportant 0 0.0
 Unimportant 12 8.1
 Un-decided 67 45.3
 Important 61 41.2
 Very important 8 5.4
Q18: Where would you obtain information to make a 
choice about the drug and dose in case of a known 
genotype?
 Drug labeling (package 
insert)
81 54.7
 Registration authority 49 33.1
 Scientific literature 115 77.7







 Other … 1 0.7
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Question Answer N %
Q19: Were you aware that in the Netherlands dosing 
guidelines are available with information on the 
choice and dose of drugs based on the genotype of 
a patient?
 Yes 115 77.7
 No 33 22.3
Q20: Were you aware that in the Netherlands 
medication surveillance based on the genotype of 
a patient in incorporated in the automated drug 
dispensing systems?
 Yes 35 23.6
 No 113 76.4
Section 5: Worries toward PGx testing
Q21: Do you think that your patient’s unfavorable 
test results could have adverse psychological 
consequences on him and his family?
 Yes 129 87.2
 No 7 4.7
 No opinion 12 8.1
Q22: Are you worried that a PGx test might show 
there is no suitable drug for your patient? (0 = not 
worried / 3 = very worried)?
 0 40 27.0
 1 43 29.1
 2 43 29.1
 3 22 14.9
Q23: Are you worried that a PGx test could reveal 
that your patient also has risk factors for another 
disease that he/she does not know about? (0 = not 
worried / 3 = very worried)?
 0 20 13.5
 1 43 29.1
 2 59 39.9
 3 26 17.6
Q24: Are you worried that one of your patient’s PGx 
test results could be passed to an unauthorized 
person? (0 = not worried / 3 = very worried)
 0 12 8.1
 1 30 20.3
 2 39 26.4
 3 67 45.3
Q25: Are you more concerned about the loss of 
privacy of a patient’s genetic information from the 
results of pharmacogenetic tests than from the 
results of other laboratory or diagnostic tests?
 Yes 34 23.0
 No
114 77.0
Q26: Among the following health professionals, 
which ones should have access to patients’ 
pharmacogenetic information (select all that apply)
 Physician 145 98.0
 Pharmacist 147 99.3
 Nurse practitioner 25 16.9
 General nurse 5 3.4
 Genetic counsellor 116 78.4
 Clinical chemist 64 43.2
 Social worker 2 1.4
 Psychologist 13 8.8
 Dietician 7 4.7
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Question Answer N %
Q27: Are you worried that a health insurance could 
obtain information about an individual’s genotype 
based on the drug/dose prescribed? (0 = not worried 
/ 3 = very worried)
 0 2 1.4
 1 11 7.4
 2 36 24.3
 3 99 66.9
Q28: Do you believe that health insurers should 
provide full coverage for pharmacogenetic tests?
 Always 32 21.6
 Sometimes 116 78.4
 Never 0 0.0
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N % N % P value
Response
Yes 148 18.0 667 18.8
p = 0.620
No 676 82.0 2883 81.2
Total 824 100.0 3550 100.0
Q1: What is your gender?
Male 44 29.7 305 45.7
p < 0.001
Female 104 70.3 362 54.3
Total 148 100 667 100.0
Q2: What is your age?
20–29 148 100.0 105 15.7
p < 0.001
30–39 0 0.0 209 31.3
40–49 0 0.0 144 21.6
50–59 0 0.0 158 23.7
≥ 60 0 0.0 51 7.6
Total 148 100.0 667 100.0
Q3: At which University do you currently follow your curriculum / did you follow your curriculum?
University of Groningen 47 31.8 221 33.1
p < 0.001
University of Leiden 0 0.0 38 5.7
University of Utrecht 101 68.2 537 53.5
University of Amsterdam 0 0.0 32 4.8
Other 0 0.0 19 2.8
Total 148 100.0 667 100.0
Q5: Did you receive education on PGx during your curriculum
Yes 143 96.6 265 60.3
p < 0.001
No 5 3.4 402 39.7
Total 148 100.0 667 100.0
Q10: Would you feel qualified to receive your patient’s pharmacogenetic testing results, interpret them 
and advise your patient on a treatment choice
No 2 1.4 45 6.7
p = 0.038Yes 41 27.7 180 27.0
Yes, after training 105 70.9 442 66.3
Total 148 100.0 667 100.0
Supplementary Document S9.3: Comparison between pharmacy students and pharmacists







N % N % P value
Q11: Would you feel qualified to recommend pharmacogenetic testing to your patients if those tests 
could predict that a specific drug could be efficacious in their case
No 12 8.1 164 24.6
p < 0.001Yes 111 75.0 323 48.4
Undecided 25 16.9 180 27.0
Total 148 100.0 667 100.0
Q12: If a pharmacogenetic test revealed that the only available drug to treat your patient’s disease is 
ineffective or leads to severe side effects, would you still advise your patient to take that medicine?
No 46 31.1 327 49.0
p < 0.001Yes 7 4.7 23 3.4
Yes, only if he/she had a life-threatening disease 95 64.2 317 47.5
Total 148 100.0 667 100.0
Q13: Would you feel qualified to recommend genetic testing to your patients if those tests could reveal 
which diseases are liable to affect them in the future
No 46 31.1 339 50.8
p < 0.001
Yes 31 20.9 52 7.8
Yes, but only if that disease could be treated 34 23.0 84 12.6
Undecided 37 25.0 192 28.8
Total 148 100.0 667 100.0
Q15: Would you obtain extra information on genetic testing and its application in the context of drug 
therapy? 
No 14 9.5% 409 61.3%
p < 0.001
Yes 134 90.5% 258 38.7%
Total 148 100.0 667 100.0
Q16: Where would you obtain information on genetic testing and its application in the context of drug 
therapy?
Drug labelling (package insert)
No 46 31.1 464 69.6
p < 0.001
Yes 102 68.9 203 30.4
Total 148 100.0 667 100.0
Colleague
No 73 49.3 567 85.0
p < 0.001
Yes 75 50.7 100 15.0
Total 148 100.0 667 100.0
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N % N % P value
Post-academic education and pharmacotherapeutic meetings
No 69 46.6 588 88.2
p < 0.001
Yes 79 534 79 11.8
Total 148 100.0 667 100.0
Internet
No 51 34.5 504 75.6
p < 0.001
Yes 97 65.5 163 24.4
Total 148 100.0 667 100.0
Genetic testing laboratory
No 80 54.1 605 90.7
p < 0.001
Yes 68 45.9 62 9.3
Total 148 100.0 667 100.0
Other
No 125 84.5 601 90.1
p = 0.046
Yes 23 15.5 66 9.9
Total 148 100.0 667 100.0
Q18: Where do you obtain information to make a choice about the drug and dose in case of a known 
genotype
Scientific literature
No 33 22.3 278 41.7
p < 0.001
Yes 115 77.7 389 58.3
Total 148 100.0 667 100.0
Other
No 147 99.3 630 945
p = 0.011
Yes 1 0.7 37 5.5
Total 148 100.0 667 100.0
Q20: Were you aware that in the Netherlands …
medication surveillance based on the genotype of a patient in incorporated in the automated drug 
dispensing systems?
No 113 76.4 231 34.6
p < 0.001
Yes 35 23.6 436 65.4
Total 148 100.0 667 100.0
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N % N % P value
Q21: Do you think that your patient’s unfavourable test results could have adverse psychological 
consequences on him and his family?
No 7 4.7 105 15.7
p < 0.001Yes 129 87.2 425 63.7
No opinion 12 8.1 137 2.5
Total 148 100.0 667 100.0
Q22: Are you worried that …
A PGx test might show there is no suitable drug for your patient
0 40 27.0 268 40.2
p < 0.001
1 43 29.1 210 31.5
2 43 29.1 150 22.5
3 22 14.9 39 5.8
Total 148 100.0 667 100.0
Q27: Which of the following health professionals should have access to the patient’s PGx test results
Social worker
No 146 98.6 666 99.9
p = 0.029
Yes 2 1.4 1 0.1
Total 148 100.0 667 100.0
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Supplementary Document S9.4: Result of the multivariate analysis of differences between 
pharmacy students and pharmacists
To determine whether other covariates as age and gender could explain possible differences in answers found 
between the two groups the significant results of the univariate analysis were analysed using a multivariate 
model including age and gender. Questions with a dichotomous (YES/NO) answer model were analysed 
using a logistic regression model (Q15, 16, 18, 20), whereas for questions with 3 or more answer options 
(Q10, 11, 13, 21) a multinomial regression model was used.
Result of logistic regression analysis
Q15: Would you obtain extra information on genetic testing and its application in the context of drug 
therapy?  
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 12.61 (6.42–24.77) < 0.001
Gender (female vs. male) 0.60 (0.43–0.83) 0.002
Age
30–39 (vs. 20–29) 0.85 (0.53–1.38) 0.510
40–49 (vs. 20–29) 0.64 (0.38–1.08) 0.098
50–59 (vs. 20–29) 0.66 (0.39–1.12) 0.123
60–69 (vs. 20–29) 0.50 (0.24–1.04) 0.064
Q16: Where do you obtain information on genetic testing and its application in the context of drug 
therapy – Drug labelling / package insert
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 3.41 (2.02–5.77) < 0.001
Gender (female vs. male) 0.77 (0.56–1.06) 0.108
Age
30–39 (vs. 20–29) 0.64 (0.39–1.05) 0.080
40–49 (vs. 20–29) 0.51 (0.30–0.89) 0.017
50–59 (vs. 20–29) 0.59 (0.35–1.02) 0.057
60–69 (vs. 20–29) 0.56 (0.27–1.18) 0.130
Q16: Where do you obtain information on genetic testing and its application in the context of drug 
therapy – Colleague
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 3.28 (1.88–5.70) < 0.001
Gender (female vs. male) 0.94 (0.64–1.38) 0.768
Age
30–39 (vs. 20–29) 0.53 (0.29–0.96) 0.037
40–49 (vs. 20–29) 0.40 (0.20–0.79) 0.009
50–59 (vs. 20–29) 0.56 (0.29–1.07) 0.077
60–69 (vs. 20–29) 0.34 (0.12–0.96) 0.042
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Q16: Where do you obtain information on genetic testing and its application in the context of drug 
therapy – Post-academic education and pharmacotherapeutic meetings
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 13.70 (6.21–30.21) < 0.001
Gender (female vs. male) 0.69 (0.46–1.04) 0.076
Age
30–39 (vs. 20–29) 1.20 (0.51–2.84) 0.678
40–49 (vs. 20–29) 1.12 (0.45–2.82) 0.808
50–59 (vs. 20–29) 2.56 (1.11–5.91) 0.028
60–69 (vs. 20–29) 1.58 (0.53–4.75) 0.411
Q16: Where do you obtain information on genetic testing and its application in the context of drug 
therapy – Internet
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 4.47 (2.59–7.69) < 0.001
Gender (female vs. male) 0.55 (0.39–0.77) 0.001
Age
30–39 (vs. 20–29) 0.72 (0.43–1.23) 0.234
40–49 (vs. 20–29) 0.56 (0.31–1.00) 0.051
50–59 (vs. 20–29) 0.61 (0.34–1.09) 0.093
60–69 (vs. 20–29) 0.42 (0.18–0.97) 0.041
Q16: Where do you obtain information on genetic testing and its application in the context of drug 
therapy – Other
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 2.46 (1.01–5.99) 0.048
Gender (female vs. male) 0.46 (0.29–0.73) 0.001
Age
30–39 (vs. 20–29) 2.29 (0.97–5.42) 0.059
40–49 (vs. 20–29) 1.09 (0.41–2.90) 0.861
50–59 (vs. 20–29) 0.61 (0.22–1.74) 0.358
60–69 (vs. 20–29) 1.01 (0.30–3.44) 0.988
Q18: Where do you obtain information to make a choice about the drug and dose in case of a known 
genotype – Scientific literature
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 1.88 (1.08–3.28) 0.027
Gender (female vs. male) 0.87 (0.64–1.18) 0.369
Age
30–39 (vs. 20–29) 0.91 (0.56–1.49) 0.709
40–49 (vs. 20–29) 0.64 (0.38–1.09) 0.098
50–59 (vs. 20–29) 0.53 (0.31–0.89) 0.016
60–69 (vs. 20–29) 0.72 (0.36–1.46) 0.364
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Q18: Where do you obtain information to make a choice about the drug and dose in case of a known 
genotype – Other
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 0.11 (0.01–0.94) 0.044
Gender (female vs. male) 0.92 (0.46–1.84) 0.823
Age
30–39 (vs. 20–29) 1.08 (0.40–2.95) 0.882
40–49 (vs. 20–29) 0.58 (0.17–1.98) 0.390
50–59 (vs. 20–29) 1.20 (0.41–3.47) 0.741
60–69 (vs. 20–29) 0.65 (0.12–3.46) 0.609
Q20: Were you aware that in the Netherlands medication surveillance based on the genotype of a 
patient in incorporated in the automated drug dispensing systems?
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 0.12 (0.07–0.22) < 0.001
Gender (female vs. male) 0.94 (0.68–1.29) 0.680
Age
30–39 (vs. 20–29) 1.29 (0.76–2.20) 0.348
40–49 (vs. 20–29) 0.66 (0.38–1.14) 0.133
50–59 (vs. 20–29) 0.49 (0.28–0.84) 0.010
60–69 (vs. 20–29) 0.32 (0.15–0.65) 0.002
Results of multinomial regression
Q10: Would you feel qualified to receive your patient’s pharmacogenetic testing results, interpret them 
and advise your patient on a treatment choice? (multinomial regression)
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 2.59 (0.47–14.26) 0.274
Gender (female vs. male) 0.27 (0.13–0.55)  < 0.001
Age
30–39 (vs. 20–29) 0.80 (0.26–2.49) 0.697
40–49 (vs. 20–29) 0.71 (0.19–2.72) 0.619
50–59 (vs. 20–29) 0.10 (0.03–0.34) < 0.001
60–69 (vs. 20–29) 0.10 (0.02–0.43) 0.002
Answer 2: Yes, after training (vs. reference no)
Cohort (students vs. pharmacist) 3.97 (0.75–21.07) 0.106
Gender (female vs. male) 0.56 (0.29–1.10) 0.090
Age
30–39 (vs. 20–29) 0.79 (0.26–2.38) 0.673
40–49 (vs. 20–29) 1.51 (0.42–5.43) 0.531
50–59 (vs. 20–29) 0.40 (0.14–1.16) 0.092
60–69 (vs. 20–29) 0.34 (0.09–1.26) 0.106
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Q11: Would you feel qualified to recommend pharmacogenetic testing to your patients if those tests 
could predict that a specific drug could be efficacious in their case?
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 5.25 (2.47–11.16) < 0.001
Gender (female vs. male) 0.57 (0.39–0.85) 0.006
Age
30–39 (vs. 20–29) 1.48 (0.82–2.66) 0.188
40–49 (vs. 20–29) 1.35 (0.72–2.53) 0.351
50–59 (vs. 20–29) 0.59 (0.32–1.09) 0.093
60–69 (vs. 20–29) 0.53 (0.23–1.20) 0.127
Answer 2: Undecided (vs. reference no)
Cohort (students vs. pharmacist) 2.33 (0.98–5.56) 0.056
Gender (female vs. male) 1.10 (0.71–1.71) 0.669
Age
30–39 (vs. 20–29) 1.46 (0.75–2.86) 0.267
40–49 (vs. 20–29) 1.40 (0.68–2.87) 0.363
50–59 (vs. 20–29) 1.26 (0.63–2.49) 0.512
60–69 (vs. 20–29) 0.90 (0.36–2.27) 0.821
Q12: If a pharmacogenetic test revealed that the only available drug to treat your patient’s disease is 
ineffective or leads to severe side effects, would you still advise your patient to take that medicine?
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 0.66 (0.20–2.19) 0.499
Gender (female vs. male) 0.30 (0.13–0.68) 0.004
Age
30–39 (vs. 20–29) 0.31 (0.09–1.01) 0.051
40–49 (vs. 20–29) 0.37 (0.12–1.19) 0.096
50–69 (vs. 20–29) 0.05 (0.01–0.25) < 0.001
Answer 2: Yes, only if he/she had a life-threatening disease (vs. reference no)
Cohort (students vs. pharmacist) 0.88 (0.50–1.54) 0.646
Gender (female vs. male) 1.42 (1.04–1.93) 0.025
Age
30–39 (vs. 20–29) 0.58 (0.35–0.98) 0.041
40–49 (vs. 20–29) 0.28 (0.16–0.49) < 0.001
50–69 (vs. 20–29) 0.30 (0.17–0.51) < 0.001
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Q13: Would you feel qualified to recommend genetic testing to your patients if those tests could reveal 
which diseases are liable to affect them in the future?
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 3.64 (1.63–8.12) 0.002
Gender (female vs. male) 0.30 (0.18–0.51) < 0.001
Age
30–39 (vs. 20–29) 0.76 (0.33–1.78) 0.532
40–49 (vs. 20–29) 0.44 (0.16–1.19) 0.107
50–59 (vs. 20–29) 0.48 (0.19–1.22) 0.124
60–69 (vs. 20–29) 0.62 (0.19–2.05) 0.434
Answer 2: Yes, but only if that disease could be treated (vs. reference no)
Cohort (students vs. pharmacist) 7.41 (2.86–19.20) < 0.001
Gender (female vs. male) 0.49 (0.31–0.77) 0.002
Age
30–39 (vs. 20–29) 2.28 (0.88–5.92) 0.090
40–49 (vs. 20–29) 2.04 (0.76–5.50) 0.158
50–59 (vs. 20–29) 2.54 (0.97–6.71) 0.059
60–69 (vs. 20–29) 2.62 (0.82–8.38) 0.105
Answer 3: Undecided (vs. reference no)
Cohort (students vs. pharmacist) 1.81 (0.97–3.39) 0.063
Gender (female vs. male) 0.90 (0.63–1.28) 0.541
Age
30–39 (vs. 20–29) 1.56 (0.90–2.71) 0.112
40–49 (vs. 20–29) 1.14 (0.63–2.06) 0.675
50–59 (vs. 20–29) 1.19 (0.65–2.18) 0.567
60–69 (vs. 20–29) 1.15 (0.50–2.66) 0.737
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Q21: Do you think that your patient’s unfavourable test results could have adverse psychological 
consequences on him and his family?
Odd’s ratio (confidence interval) P value
Answer 1: Yes (vs. reference no)
Cohort (students vs. pharmacist) 2.92 (1.08–7.89) 0.034
Gender (female vs. male) 1.41 (0.91–2.17) 0.121
Age
30–39 (vs. 20–29) 0.49 (0.24–1.02) 0.058
40–49 (vs. 20–29) 0.69 (0.31–1.51) 0.353
50–59 (vs. 20–29) 0.81 (0.36–1.81) 0.606
60–69 (vs. 20–29) 0.85 (0.29–2.46) 0.764
Answer 2: No opinion (vs. reference no)
Cohort (students vs. pharmacist) 0.86 (0.26–2.79) 0.797
Gender (female vs. male) 1.96 (1.16–3.31) 0.012
Age
30–39 (vs. 20–29) 0.52 (0.22–1.21) 0.131
40–49 (vs. 20–29) 0.58 (0.23–1.47) 0.255
50–59 (vs. 20–29) 1.02 (0.41–2.57) 0.962
60–69 (vs. 20–29) 1.17 (0.35–3.95) 0.795
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General discussion
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Chapter 10




Currently, germline pharmacogenetics (PGx) is successfully implemented within certain 
specialties in clinical care. With the integration of PGx in pharmacotherapy multiple stake­
holders are involved, which are identified in this chapter. Clinically relevant pharmacogenes 
with their related PGx test are discussed, along with diagnostic test criteria to guide clinicians 
and policy makers in PGx­test selection. The chapter further reviews the similarities and 
the differences between the guidelines of the Dutch Pharmacogenetics Working Group 
(DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) which 
both support healthcare professionals in understanding PGx test results and help guiding 
pharmacotherapy by providing evidence­based dosing recommendations. Finally, clinical 
studies which provide scientific evidence and information on cost­effectiveness supporting 
clinical implementation of PGx in clinical care are discussed along with the remaining 
barriers for adoption of PGx­testing by healthcare professionals.





In the last decade pharmacogenetics (PGx) has made the transition from a field within 
clinical pharmacology research to an integral part of pharmacotherapy. Barriers obstructing 
the integration of PGx in clinical care included a lack of clinical grade tests, a lack of 
evidence based guidelines providing interpretation and therapeutic recommendations and 
a lack of integration into the workflow of healthcare professionals (1). Currently, many 
of these barriers have been successfully addressed. Multiple genotyping tests suitable for 
clinical use have been developed. Consortia such as the Dutch Pharmacogenetics Working 
Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) 
both have provided widely acclaimed guidelines (2­4). Clinical decision support (CDS) 
integrating electronic medication surveillance based on genotype into the workflow has 
become available on institutional or national level (3­7). For several PGx genes large studies 
have provided evidence that information on germline variants in single genes can lead to 
more effective or safer therapy. The first part of this review identifies the parties that play 
a role in the wide­spread implementation of PGx in clinical care. The second part covers 
various topics regarding current implementation of PGx in clinical practice, including: 
clinically relevant tests; diagnostic criteria; guidelines containing evidence based therapeutic 
recommendations; multiple implementation programs; and barriers still hindering the full 
and widespread integration of PGx in clinical care. 
Players in the field
On the road to wide­spread integration of PGx into clinical care multiple parties play a 
role in PGx becoming a part of routine practice. These roles include making decisions to 
adopt PGx testing, enforcing research on genetic biomarkers, providing the materials for 
clinical laboratories to test patients, or reviewing available evidence to provide healthcare 
professionals the tools to optimize pharmacotherapy. Different stakeholders can be involved 
in the implementation process including the biotechnology industry, governments, 
clinicians, healthcare insurers and patients. 
Research institutions and the analytical industry are developing new methods for detection 
of genetic variants. Although this technology is mostly developed to detect mutations 
responsible for genetic diseases, clinical laboratories can optimize the developed assays to 
detect relevant (germline) PGx variants. In licensed medicine, information on PGx markers 
in drug labels increasingly will lead to ordering a PGx test before the use of the drug. However, 
the pharmaceutical industry still is somewhat divided regarding the concept of personalized 
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medicine and as long as development of “one­size­fits­all” drugs is an aim, pharmaceutical 
companies will probably consider the need for PGx markers as a disadvantage. Currently, 
PGx is mainly used by the pharmaceutical industry as a manner to salvage drugs that do 
not appear effective or safe in clinical trials. Erlotinib is an example of a drug that in the 
initial phase appeared not to show the expected results in terms of overall survival in phase 
II and III studies whereas a small subgroup performed exceptionally well. Further research 
revealed specific mutations in the EGFR receptor that could explain the gain in survival (8). 
Although mandatory genetic testing before prescribing is mainly seen in combination with 
somatic mutations, genetic testing for germline variants is required before starting certain 
treatments, such as eliglustat which requires CYP2D6 testing with an FDA­cleared test. 
For the actionable phenotype ‘poor metabolizer’ the dosage has to be halved, while for the 
phenotype ‘ultra­rapid metabolizer’ this therapy is not recommended as patients with the 
UM fenotype might not achieve adequate levels of concentrations of eliglustat (9). However, 
patents have expired for many drugs with gene interactions and producers of generic drugs 
are not interested in advancing the research in (germline) biomarkers for the drugs in 
their portfolio. For multiple gene­drug pairs the regulators had to step in and issue boxed 
warnings to enforce healthcare professionals to take gene­pairs interactions into account 
when prescribing (e.g. CYP2C19 and clopidogrel and CYP2C9/VKORC1 and warfarin). 
Additionally, because of the efforts of EMA and FDA policy innovative pharmaceutical 
companies are enforced to investigate the influence of PGx variants. As an outcome, the 
FDA reported an increase in the number of registered drugs with information on genetic 
biomarkers in corporate in drug labels (10). Similarly, in 2015 Ehmann et al. showed an 
increased uptake of information on PGx biomarkers in drug labels of drugs registered in 
the European Union in the last decades (11). 
Based on information from drug labels and guidelines, healthcare professionals are expected 
to adjust pharmacotherapy if the genotype of the patient is known and is actionable. However, 
currently the clinically relevant genotypes are not known for the majority of the patients. 
Since no solid evidence is available which supports the use of upfront panel­based (or 
pre­emptive) genotyping, the use of PGx is restricted mainly to single­gene testing mostly 
performed retrospectively in order to explain a lack of efficacy or adverse reactions. Many 
physicians and pharmacists are not yet fully aware of the potential of PGx notwithstanding 
the fact that in het last decades clinical research has generated data on the existence 
and frequencies of genetic variants in a variety of pharmacogenes. In addition, several 
multidisciplinary initiatives of healthcare professionals and researchers have translated the 
effects of aberrant phenotypes into widely acclaimed clinical guidelines providing therapeutic 
recommendations (2­4). 




Obviously, patients play an important role in the uptake of PGx in clinical care. Relative 
to secondary care, in primary care patients have a large impact on the decisions that are 
made concerning pharmacotherapy. Using a survey Haga et al. showed that the majority of 
patients are positive towards PGx as this diagnostic in the eyes of the surveyed patients can 
lead towards selecting the right drug by healthcare professionals and ultimately to safer and 
more effective pharmacotherapy. However, concerns whether third­parties can access the 
results of a PGx test result or the fear that PGx results can be used for nefarious reasons by 
employers or healthcare insurance are reasons to reject a PGx test (12).
Finally, one of the players with a large influence in primary care regarding implementation of 
PGx­testing are health insurers. This stakeholder determines whether costs of PGx and other 
laboratory test used in primary care are reimbursed, whereas in secondary care laboratory 
test are usually part of integral treatment plans that are reimbursed. Lack of coverage of 
PGx testing by insurance companies is an important demotivator in patients’ uptake of PGx 
testing. Haga et al. have shown that 81% of patient in their study are likely to decline if the 
test was not reimbursed (12). Additionally, the current (lack of) policy regarding coverage 
of PGx testing is also a major reason why the adoption of PGx testing among healthcare 
professionals is low. In a recent survey 14.0 % of the pharmacists indicate that uncertainty 
regarding the reimbursement is a reason for not having ordered or recommended a PGx 
test in the previous six months (Chapter 8).
Challenges for implementation of PGx
In the process of widespread implementation of PGx in clinical care several challenges still 
play a role. These hurdles include the answers to the question which pharmacogenes should 
be incorporated in routine care and which known variants in the gene should be tested for. 
The decision on whether genetic testing for a pharmacogene is implemented is dependent 
on several aspects including the diagnostic criteria of the assays, available therapeutic 
recommendations for patients with an aberrant phenotype and evidence whether PGx testing 
improves patient care. Additionally, in certain healthcare settings data on cost­effectiveness 
and cost­consequences also can play a role. These topics will be covered in the next sections.
Selecting clinically relevant pharmacogenes
Regarding the above­mentioned challenges, the first question to be asked is which phar­
macogenes are clinically relevant and should be tested. The answer can partially be found 
in the guidelines of the CPIC and the DPWG. Although the guidelines created by both 
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consortia are written on the premise that the genotype of the patient is already known, and 
the guidelines do not provide a recommendation who to test, the consortia have already 
selected gene­drug pairs with a clinically relevant impact on outcome of pharmacotherapy. 
Testing for genetic variants in genes other than described in these guidelines can be 
considered to be of very limited clinical use. The selection of pharmacogenes discussed 
below is based on the pharmacogenes most frequently determined in the Netherlands.
One of the examples of a clinically relevant pharmacogene where genetic variation results 
in a difference in specific treatment outcomes is CYP2D6, a gene that metabolizes 20–25% 
of the drugs that have gained market approval (13). It was described in one of the first 
reports of hereditary influence on drug metabolism (14, 15). Currently, more than 100 
variants (including single nucleotide polymorphisms, insertions and deletions) resulting 
in 113 possible combinations of genetic variations (haplotypes) have been described in 
literature. Furthermore, reports have shown that the entire gene can be deleted or duplicated 
[http://www.cypalleles.ki.se/] (16). In the last decade multiple commercial platforms have 
been developed to genotype CYP2D6. 
In addition to CYP2D6 the CPIC and DPWG guidelines have described many more 
clinically relevant pharmacogenes including CYP2C9, CYP2C19, CYP3A5, DPYD, 
TPMT, and VKORC1 (for the associated drugs with these genes see Table 10.1). For these 
pharmacogenes research has shown that the number of common genetic variants that 
have a well­known clinical relevant impact on the function of the protein are much lower 
and range from one in case of VKORC1 to four for DPYD. As a result, for the limited 
number of variants per gene it is relatively simple to design and validate assays based on 
methodologies such as Taqman, pyrosequencing or high­resolution melting. An important 
aspect with home­brew assays is quality assurance of the assay by means of the use of 
multiple techniques, controls using plasmids or reference samples from the Coriell Institute 
for Medical Research and participation in proficiency testing (17, 18). 
CYP2D6
One commercial test to genotype CYP2D6 was the Roche Amplichip (Hoffmann­La 
Roche, Basel, Swiss) which was one of the first genetic tests to receive FDA approval. The 
assay was based on the Affymetrix Genechip platform (Affymetrix, Santa Clara, CA)(19) 
and allowed for testing of 2 variant alleles of CYP2C19 and 32 variant alleles of CYP2D6 
including deletion (*5) and duplication of the gene. At the time it was on the market it was 
considered the gold standard in CYP2C19 and CYP2D6 genotyping in clinical practice. 
A disadvantage of the platform, partly a result of the FDA­approval, was that sometimes 
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10analyses resulted in a no­call (20­22). Additionally, problems with the calling of the 
CYP2D6*41 by the Amplichip have been reported in literature (18, 23) (Chapter 3). The 
miscalling of the *41 by the Amplichip can be explained by the manner that is used to call 
this allele by this platform. It uses a combination of the detected presence of 1661G>C, 
2850C>T and 4180G>C SNPs and the absence of the ­1584C>G SNP. Platforms that have 
been developed at a later stage using oligonucleotide markers for SNP detection call the 





CYP2C9 acenocoumarol†, phenprocoumon†, phenytoin, glibenclamide†, gliclazide†, 
glimepiride†, tolbutamide†, warfarin
CYP2C19 amitriptyline, citalopram, clomipramine, clopidogrel, desipramine‡, doxepin, 
escitalopram, esomeprazole†, fluvoxamine†, imipramine, lansoprazole†, 
mirtazapine† moclobemide†, omeprazole†, pantoprazole†, prasugrel†, rabeprazole†, 
sertraline, ticagrelor†, trimipramine‡, voriconazole 
CYP2D6 amiodaron†, amitriptyline, aripiprazole†, atenolol†, atomoxetine†, bisoprolol†, 
carvedilol†, citalopram†, clomipramine, clonidine†, clozapine†, codeine, 
desipramine‡, disopyramide†, doxepin, duloxetine†, eliglustat†, escitalopram†, 
flecainide†, fluphenazine†, fluoxetine†, flupentixol†, fluvoxamine, gefitinib†, 
haloperidol†, imipramine, quinidine†, methylphenidate†, metoprolol†, 
mirtazapine†, nortriptyline, olanzapine†, ondansetron‡, oxycodone†, paroxetine, 
pimozide†, propafenone†, quetiapine†, risperidone†, sertraline†, sotalol†, tamoxifen, 





DPYD capecitabine, 5-fluorouracil, tegafur
G6PD rasburicase‡
Factor V Leiden oral contraceptives containing estrogen derivatives†
HLA-A and HLA-B abacavir, allopurinol, carbamazepine, flucloxacillin†, phenytoin‡, ribavirin† 
IFNL3 peginterferon alfa-2a‡, peginterferon alfa-2b‡, ribavirin‡
MTHFR methotrexate†
SLCO1B1 atorvastatin†, simvastatin
TPMT azathioprine, 6-mercaptopurine, thioguanine
UGT1A1 atazanavir‡, irinotecan† 
VKORC1 warfarin, phenprocoumon†, acenocoumarol†
‡CPIC only; †DPWG only.
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*41 allele solely based on the 2988G>A SNP (19) (Chapter 3). After the discovery of the 
2988G>A SNP in 2004 (after the development of the Roche Amplichip) the definition of 
the *41 changed as The Human Cytochrome P450 Allele Nomenclature Committee decided 
the 2988G>A SNP was indicative of the *41 allele (16, 24, 25). As a result of the FDA 
approval, this new SNP could not be (directly) incorporated into the platform resulting in 
erroneous calling of the *41. Despite this known problem the assay was still recommended 
for genotyping CYP2D6 until Roche discontinued the platform in 2016, partly because the 
assay was not used frequently in clinical practice because of its high costs. At the moment 
xTag 2D6 assay by Luminex (Luminex Molecular Diagnostics, Austin, TX) which uses 
the Luminex® 100/200™ platform is one of the CYP2D6 assays most frequently used in the 
clinic. The third version of the assay currently on the market detects 16 variant alleles of the 
CYP2D6 gene. In this assay two separate multiplex long­range PCR reactions are carried 
out followed by a process of multiplex allele­specific primer extension.
The downside to the assays described above is that the required platforms are relatively 
expensive. The major disadvantage of using commercial assays is the limited number of 
variant alleles which can be detected. Based on the total number of variants in CYP2D6 one 
can deduce that using assays that can detect from 11 up to 32 variant alleles do not cover all 
known genetic variants in the CYP2D6 gene and patients might be designated an incorrect 
genetic predicted phenotype based on a *1 auto call by the platform (16). A solution for this 
problem is sequencing of CYP2D6 to read all nucleotides and compare it to a reference gene. 
In 2013 Dodgen et al. described a platform that combines CYP2D6 long­range PCR with 
multiple rounds of Sanger sequencing per sample. The long­range PCR were used for an 
amplicon used in Sanger sequencing as well as products to identify deletion and duplication 
of the gene (23, 26). Attempts have been made by analysing the CYP2D6 gene directly in a 
single sequencing reaction using second­generation sequencing, however due to existence 
of the pseudogenes CYP2D7 and CYP2D8 and the homology with other genes encodig for 
CYP450 enzymes this has proven difficult. Buermans et al. have circumvented this problem 
by using a long­range PCR in combination with the Pacific Biosciences RSII which allows for 
reliable full­length sequencing of CYP2D6. As result of the full­length read complete phasing 
of the sequencing data is possible resulting in calling of complete haplotype across the entire 
CYP2D6 gene which includes up­ and downstream regions, introns and exons (27). Although 
sequencing is considered an improvement upon genotyping assays, as all the genetic variants 
in the gene are uncovered, in a clinical setting this could present a problem. With sequencing 
new genetic variants within the CYP2D6 gene will be found of unknown functionality and 
unknown influence on the function of the metabolizing enzyme. Attempts have been made 
to quantify the effects of new genetic variants on the metabolizing capacity of enzymes using 
in silico prediction (28). However, with different settings of the analyses concordance for 




predicted effects of newly found variants have been low (29). In the case of implementing next 
generation sequencing in a clinical setting the discovery of novel uncharacterized variants in 
the CYP2D6 gene could present a challenge. A solution for this problem would be to limit the 
results of the sequencing analysis to known mutations that are fully characterized. 
In conclusion, despite the complexity of CYP2D6 multiple commercial assays are available 
for a broad coverage of genetic variants in this gene. Furthermore, research will likely 
lead to novel techniques which in the future can be used in the clinic for a more detailed 
analysis of this pharmacogene.
CYP2C9 + VKORC1 
The CYP2C9 gene will mostly be tested in combination with VKORC1 to guide dosing 
of cumarins or explain adverse reactions to vitamin K antagonists. Testing for CYP2C9*2 
and *3 along with the ­1639G>A mutation in the promotor of VKORC1 appears to be 
sufficient in patients of non­African ancestry to adjust the maintenance dose of cumarins 
or to determine the starting dose in case the INR is measured routinely at follow up. In 
case of patients of African descent, the additional variants of *5, *6, *8, and *11 appear 
relevant as a reduction of 15–30% of the maintenance dose is required if patients are 
carriers of these alleles (4, 30). 
CYP2C19
Currently, genetic testing for CYP2C19 is usually performed to predict response to 
clopidogrel therapy and multiple studies are ongoing to investigate whether genotyping 
of CYP2C19 can lead to an improvement in antiplatelet therapy with clopidogrel (31). The 
most frequently tested variants in the CYP2C19 gene are *2, *3 (which were also found on 
the Amplichip platform) and *17. Commercially available assays for CYP2C19 such as the 
INFINITI platform by AutoGenomics (AutoGenomics, Inc., Vista, CA), the xTag 2C19 
Mutation Detection Kit by Luminex (Luminex Molecular Diagnostics, Austin, TX) and the 
Genmark (GenMark Diagnostics, Carlsbad, CA) have a broad coverage of genetic variants, 
whereas inhouse assays developed by clinical laboratories usually include *2, *3 and *17. 
CYP3A5
The most frequent variants found among the (Caucasian) population are the *3 and *6 
alleles, encoding for a non­functional protein whereas the functional variant *1 is relatively 
uncommon in this population with a MAF of 0.078. In African Americans the *1 is more 
common than the *3 and *6 alleles (4, 32). A systematic review of the literature has shown 
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that patients that are hetero­ or homozygous carriers of the *1 variant of the CYP3A5 gene 
require a significantly higher dose (175–250%) than patient carrying two non­functional 
copies (4, 32). However, clinical studies investigating the use of the CYP3A5 genotype 
to personalize tacrolimus dosing have shown mixed results whether genotyping can 
improve pharmacotherapy with tacrolimus compared to standard care (often comprising 
of therapeutic drug monitoring) (33, 34). Currently, AutoGenomics (AutoGenomics, Inc., 
Vista, CA) and Genmark provide commercial platforms for CYP3A5 in combination with 
the CYP3A4 gene with both platforms providing a coverage of 8 alleles for CYP3A5, whereas 
the assays developed in laboratories usually include the *3 and *6 alleles.
DPYD
Although genetic testing for DPYD is widespread in routine care in some countries for 
multiple years (e.g. The Netherlands), it has only recently been incorporated into the 
Clinical Practice Guidelines of the European Society for Medical Oncology or the American 
Society for Clinical Oncology. Screening for relevant genetic variants in DPYD before 
starting capecitabine or 5­fluorouracil is increasingly becoming part of the standard­of­care 
when treating patients with fluoropyrimidine derivatives (35, 36). In recent years, literature 
has been accumulated on genetic variants in DPYD and their effects on the functionality of 
the DPD enzyme. For instance, the evidence for a 50% dose reduction among heterozygous 
carriers of the IVS14+1G>A (*2A) has been established in many studies (Chapter 6). Efforts 
by Meulendijks et al., Offer et al. and initiatives as the DPWG and CPIC have resulted in a 
consensus on the variants on the *2A, 1679T>G (*13) and the 2846A>T variants having no 
(*2A and *13) or reduced activity (2846A>T) respectively (4, 37­39). Until recently there 
was a discordance between the CPIC and the DPWG concerning the classification of the 
1236G>A/HapB3 variant. In the guidelines of the DPWG is mentioned that this variant 
leads to decreased fluoropyrimidine clearance and to increased toxicity, while in their 
2013 guideline the CPIC had not yet assigned a status to this variant (4, 39) (Chapter 7). 
However, this difference has currently been resolved by an update of the DPYD guideline 
published in February 2018 in which the gene­activity score for DPYD has also been adopted 
(40). In the Netherlands assays developed by clinical laboratories usually included the four 
SNPs described by Meulendijks et al. (35, 37).
TPMT
The first guidelines published by the CPIC covered the interpretation of genetic variations 
found in the TPMT gene to genetic predicted phenotypes and therapeutic recommendations 
for dosing of azathioprine, 6­mercaptopurine and thioguanine in case of actionable TPMT 




genotypes (41). In an update of the guideline published in 2013 a total of 33 variants in 
the TPMT gene are described, however the alleles *2, *3A, *3B and *3C appear to be the 
most relevant as this set of alleles explains 95% of the variance found in TPMT in terms 
of frequency (42). Most clinical laboratories that have developed their own assay will 
commonly use the three SNPs found in *2, *3B and *3C. As the TPMT*3A haplotype is 
comprised of both rs1800460 (*3B) and rs1142345 (*3C) this combination of SNPs can 
thus also be used to detect the *3A haplotype (42). 
Panel based approach
With the advancement of the field of biotechnology with a concurrent decrease of costs 
of techniques the screening of multiple (pharmaco)genes simultaneously (panel­based) 
approach has become available for use in a clinical setting. As multiple large implementation 
studies in secondary care have shown that patients are often (> 90–95%) carriers of at least 
one actionable phenotype, a panel based screening of multiple pharmacogenes appears 
to be the next step in PGx testing. The genes CYP2C19, CYP2C6, SLCO1B1 and TPMT 
were included in panels by all large studies, whereas CYP2C9/VKORC1 and CYP3A5 are 
included two of the three implementation projects (6, 7, 43, 44). Van Driest et al. have 
shown in the Vanderbilt Pharmacogenomic Resource for Enhanced Decisions in Care and 
Treatment (PREDICT) program that using a panel reduced the number of tests by 60% 
compared to a reactive single gene assay (7). Currently, multiple platforms can be used 
for a pre­emptive panel approach. One of the first high­throughput genotyping methods 
available for analysis of multiple pharmacogenes was the Drug Metabolizing Enzymes and 
Transporters (DMET) Plus array by Affymetrix using Genechip platform. (Affymetrix, 
Santa Clara, CA). Fernandez et al. showed that high concordance with other genotyping 
methods (45). The disadvantages of the DMET plus array include the length of a single 
run (~48 hours spread out over three days), the inability to detect certain copy­number 
variants (e.g. heterozygous carriers of the CYP2D6*5 and duplications of the CYP2D6) 
and recently discovered but clinically relevant alleles such as the 2846A>T and 1236G>A/
HapB3 in the DPYD gene are missing. In case the DMET plus platform is used to guide 
pharmacotherapy in a clinical setting this platform has to be supplemented with additional 
test depending on the genes incorporated in the desired panel (44) (Chapter 4). 
In the PREDICT program the VeraCode ADME core panel (Illumina, San Diego, CA, 
USA) was used (7). This platform detects 184 genetic markers in 34 ADME (46). Similar 
to the DMET platform the VeraCode platform is not to able to detect duplications of this 
gene (although it can detect the *5 allele). Furthermore, important SNPs in the DPYD gene 
(2846A>T and 1236G>A/HapB3 and *13) are absent in the panel of 184 genetic variants 
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and would have to be supplemented if the panel would be used for the characterization of 
CYP2D6 and DPYD (Chapter 4).
In addition to fixed selections of genetic variants found on the DMET plus and the VeraCode 
ADME core panel laboratories may choose to select the pharmacogenes and an associated 
panel of genetic variants based on their own criteria. Although Thermo Fisher (Thermo Fisher, 
Waltham, Massachusetts, USA) did offer a prefabricated array that tests for 158 variants in 
29 Phase I/II and transporter genes, a custom platform based on Taqman assays can also 
designed. A downside to the array similar to the DMET platform is that the Taqman cannot 
detect copy number variants and an additional qPCR has to be performed if genes with known 
duplication and/or deletions as CYP2D6 and UGT2B7 are included in the desired panel. 
Genome wide approaches 
In the last decade whole exome screening (WES) and whole genome screening (WGS) 
have become available for use in the clinical setting as a result of the advances in the field 
of biotechnology. Although WES and WGS are still relatively costly and therefore mainly 
used by clinical geneticists as an end­of­line method to diagnose hereditary diseases, 
information on genetic variants found in pharmacogenes can be considered a useful 
by­product of the use of these methods. Along with Genome­Wide Association (GWA) 
methods, WES and WGS are currently mostly used in a research setting to detect novel 
genetic variants in pharmacogenes.
Providing data on diagnostic criteria of PGx testing
Currently, outcomes of (genome­wide association) studies related to PGx are often reported 
as odds/hazard ratios or associations, where an individual carrying a certain genetic 
variant in a gene has a higher risk on a negative outcome of therapy or a lack of response. 
However, odds/hazards ratios and associations a do not provide information about the 
analytical validity, clinical validity and clinical utility of genetic tests or panels which are 
important objective factors in determining whether the test can lead to a clinically relevant 
improvement in healthcare (47). The analytical validity is the ability to identify the genetic 
variants of interest and is expressed as the analytical sensitivity and specificity of the test. 
The analytical sensitivity and specificity are generally required to be higher than 98% and 
99.5%, respectively (48, 49). The clinical validity concerns the correlation of the genetic 
marker with a clinical phenotype or outcome. Parameters for clinical validity are clinical 
sensitivity, clinical specificity and the amount of change in a person’s risk for a certain 




event between the wildtype genotype and a variant genotype. The final parameter for the 
reliability of a genetic marker is the clinical utility. Clinical utility relates to whether the 
genetic information would lead to change in treatment that improves drug efficacy or safety 
(i.e. the impact on healthcare) (50). Currently, relevant data concerning clinical validity 
and clinically utility is scarcely reported despite the need for this information to answer the 
question whether implementation of a specific genetic test or a panel in clinical practice can 
lead to a significant benefit of healthcare (47). A manner to obtain information regarding 
the clinical validity (such as negative and positive predicting values) is to reassess existing 
literature and extract this relevant data. With this information clinicians and other decision 
makers in healthcare can more objectively guide the decision­making process regarding 
the question whether genetic tests are useful in clinical practice (47, 51). Jansen et al. have 
shown for example that for the gene­drug pair SLCO1B1 and statins, a systematic review 
of the literature could provide the desired information on diagnostic criteria. 
Guidelines directing the clinical use of PGx test results
In 2010 the most important barrier for the implementation of PGx into clinical practice 
identified by clinicians was the translation of PGx­test results into clinical action (1, 2, 
52). Two consortia, the Clinical Pharmacogenetics Implementation Consortium (CPIC®) 
and the Dutch Pharmacogenetics Working Group (DPWG), both anticipated a near future 
where patients would confront their treating physician and pharmacists with their own 
genotype and started with the translation of information found in the scientific literature 
into tools usable by clinicians. The guidelines of both groups provide recommendations 
for treatment of patients where an actionable genetic predicted phenotype is known at 
start of pharmacotherapy, rather than indicating which gene should be tested (see Table 
10.1) (2, 3). Up to date, CPIC has published guidelines which cover 40 gene­drug pairs 
and the DPWG has reviewed 86 candidate gene­drug pairs in their guidelines and provide 
therapeutic recommendations for 47 gene­drug pairs (Chapter 7).
When guidelines of the CPIC and the DPWG on the same gene­drug pairs are compared 
there is substantial agreement between the guidelines in terms of therapeutic recommen­
dations for certain phenotypes. The most common explanation for observed discordances 
in therapeutic recommendations between the CPIC and the DPWG is the use of different 
methodologies to support dosing advices. Whereas the CPIC used a consensus based 
approach from a panel from experts on the subject, the DPWG calculates dosing advices 
with aid of pharmacokinetic data. Other explanations for differences can be found based 
on the date of literature review (Chapter 7). 
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Another important difference is the discordance in the translation of genotypes to genetic 
predicted phenotypes. Similar to the therapeutic recommendations these discordances in 
translation can be explained by a difference of interpretation of CYP2D6 genetic predicted 
phenotypes in the literature combined with the use of different model substrates by the 
CPIC and the DPWG. This in turn led to a difference in the interpretation of the CYP2D6 
intermediate metabolizer phenotype. Currently an international working group of experts 
on the subject including members from the CPIC and the DPWG has recently begun to 
standardize the translation from genotype to phenotype (Chapter 7). 
To aid in the personalization of pharmacotherapy the guidelines should not only be available 
in the form of published articles or chapters in books, but be an integral part of the workflow 
of healthcare professionals. In the Netherlands the first therapeutic dose recommendations 
of the DWPG were integrated in the national drug database (G­standard) in 2006, making 
medication surveillance based on actionable genetic predicted phenotypes available on 
a national level for healthcare professionals in both primary and secondary care through 
clinical decision support in drug prescribing and dispensing systems (3). In other nations 
where there is no national drug database available, multiple reports describe the integration 
of PGx into clinical decision support at an institutional level in both primary and secondary 
care (53­58). Alternatively, in situations where electronic medication surveillance is not 
(yet) possible a mobile enable clinical decision support could aid healthcare professionals 
in adjusting pharmacotherapy based on a patients PGx profile (59, 60). Evidence suggest 
that medication surveillance based on a patients PGx profile indeed leads to a change in 
behavior among physicians reducing the number of high PGx risk (61). 
Providing scientific evidence for improvement in patient care 
by PGx testing
The body of evidence that is required to justify the implementation of routine PGx testing 
in clinical practice has been subject of debate (62­64). The evidence­based medicine 
paradigm would require evidence to prove that a new technique or treatment would indeed 
lead to increased safety or efficacy or a same performance for lower costs before it can be 
implemented into clinical practice with a randomized controlled trial (RCT) considered 
the gold standard. The evidence­based model would require RCTs for genotype guided 
therapy for each individual gene­drug pair or a panel approach. However, there are multiple 
arguments against the demand for RCTs to deliver evidence for genotype­guided therapy 
for each gene­drug pair (Chapter 2). 




From one point of view there is no pharmacological argument to see adjustments for a 
gene­drug pair any different than adjustments for many other relevant clinical factors such 
as impaired renal function. Dosing adjustments for clinical factors are usually based on 
data from observational studies and case­reports/series, however regulatory authorities do 
not enforce a requirement of RCTs to deliver evidence that adjustments based on clinical 
parameters lead to an improvement of clinical outcomes (64). Additionally, if there is 
sufficient observational evidence available that pharmacogenetic screening can reduce 
significant morbidity or prevent mortality RCT’s can be considered unethical as patients 
with non­wildtype genotypes in the standard arm are knowingly exposed to suboptimal 
treatment which can lead to adverse events (65). Another argument against a RCT for 
each gene­drug pair is the cost aspect. As RCTs are highly expensive this would require 
an enormous investment to finance the required trials for all relevant gene­drug pairs. 
As stated earlier, in case of novel drugs RCTs are financed as part of the research and 
development by the innovative pharmaceutical companies that hold the patent for the 
marketed drug. However, many of the drugs with a known interaction with a polymorphic 
pharmacogene are drugs with a well­known pharmacology which are already produced 
by generic pharmaceutical companies which do not have any gain by financing additional 
research concerning their pharmaceutical in their portfolio (Chapter 2). 
However, despite this rationale clinicians seemed hesitant to implement this new concept of 
pharmacology in clinical practice as evidence for an improvement of pharmacotherapy by 
PGx in the previous decade was lacking (66). Fortunately, in the last years several clinical 
studies for single gene­drug pairs have already been performed providing evidence for 
implementation of genotype­guided therapy in case of these gene­drug pairs. A landmark 
RCT performed by Mallal et al. in 2008 showed that genotyping for the *5701 allele in 
the HLA-B gene could lower the incidence of abacavir­induced hypersensitivity reactions 
from 7.8% in the control group to 3.4% in the control group (p < 0.001) (67). Additionally, 
Coenen et al. studied in a multicenter study whether genotyping for the TPMT would lead 
to a reduction of hematologic adverse drug reactions (ADRs) in treatment of inflammatory 
bowel disease using thiopurines. Although the study could not detect a reduction in the 
proportion in hematologic ADRs between the screening arm and the control arm (7.4% vs. 
7.9%, 95% confidence interval: 0.57–1.52) a tenfold reduction in the hematological ADR’s 
among carriers of TPMT variants was observed in the intervention group compared to the 
same population in the control group (2.6% vs. 22.9%, 95% confidence interval 0.01–0.85) 
(68). A third example of a multicenter study to investigate the clinical utility of a PGx test 
was performed by Deenen et al. Unlike the two previous studies this group did not use a 
RCT design, but compared a prospectively genotype­guided cohort to a historical cohort 
to show that screening for the *2A variant in the DPYD gene can reduce the risk of toxicity 
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of grade 3 or higher from 73% to 28% (p < 0.001). Furthermore, the proportion of patients 
that died because of the fluoropyrimidine was reduced from 10% to 0% (69). In case of 
the gene­drug pairs HLA-B*57:01 and abacavir, DPYD and fluoropyrimidines and TPMT 
and thiopurines the results of the performed studies helped to provide evidence to justify 
implementation of routine screening in clinical practice. 
In addition to studies investigating whether routine genetic screening of a single pharma­
cogene can lead to an improvement of healthcare, a number of studies tests for a panel of 
multiple pharmacogenes simultaneously (a panel approach). Using a case­control study 
consisting of 205 genotyped patients receiving genotype­guided dosing through clinical 
decision support and 820 matched controls Brixner et al. showed that a preemptive 
screening using a panel approach resulted in a significant reduction in hospitalizations 
(9.8% vs. 16.1%, p = 0.027) and patient visits to the emergency department (4.4% vs. 15.4%, 
p = 0.0002) (70). Similar to the results of Brixner et al. a prospective pilot RCT performed 
by Elliot et al. found a reduction of in the number of rehospitalizations at 60 days in the 
intervention group compared to the group receiving regular care. In the intervention arm of 
the study patients were pre­emptively genotyped for CYP2C9, CYP2C19, CYP2D6, CYP3A4 
and CYP3A5 followed by optimization of pharmacotherapy using clinical decision support 
whereas the control population received regular care (53). In addition, the Ubiquitous PGx 
consortium is currently enrolling patients in the PREemptive PGx testing for prevention 
of Adverse drug Reactions (PREPARE) study in sites across seven European countries 
as part of a Horizon2020 funded program with the aim to provide evidence to support 
routine implementation of pre­emptive panel­based PGx screening (71). Overall, the body 
of evidence supporting the implementation of PGx in clinical practice is growing, mostly 
by the efforts of academic hospitals or specialized research institutions.
Providing information on cost-effectiveness and cost-conse-
quences of PGx testing
In addition to information about the analytical validity, clinical validity and clinical utility 
an important aspect for the implementation in clinical care is data about cost­effectiveness 
and cost­consequences of PGx tests. The information on the cost­effectiveness is especially 
relevant in the case of implementation of PGx testing in primary as health insurers will 
require this information in their decision to reimburse specific (pharmaco)genomic testing. 
In secondary and tertiary care cost­effectiveness is slightly less relevant as in a hospital 
setting a laboratory test is usually part of integral treatment plans and are not reimbursed 
directly by health insurers.




Ironically, most of the cost­effectiveness analysis (CEAs) relating to PGx tests have been 
performed for gene­drug interactions concerning drugs that are mostly initiated in a hospital 
setting. For fluoropyrimidines the studies performed by Deenen et al. and Cortejoso et al. 
show that genotyping for variants in DPYD can reduce the number of patients admitted 
to the intensive care unit with severe fluoropyrimidine induced toxicity (69, 72). Other 
gene­drug pairs where the body of evidence concerning the cost­effectiveness is growing 
are HLA-B*5701 and abacavir and CYP2C19 and clopidogrel by reducing the numbers of 
patients suffering from hypersensitivity reaction or stent­thrombosis respectively (73­76).
Up to date the evidence supporting cost­effectiveness of routine screening for genetic vari­
ants in pharmacogenes associated with prescription drugs which are frequently prescribed 
in primary care such as antidepressants (CYP2D6 and CYP2C19), statins (SLCO1B1), and 
coumarins (CYP2C9 and VKORC1) has only been shown in a number of studies despite 
the amount of literature published on these gene–drug pairs (77, 78). As a result, health 
insurance companies are not likely to reimburse routine PGx testing for these single gene­
drug pairs in primary care. However, evidence for cost­effectiveness for each individual 
gene­drug may not be necessary when using a panel approach. Brixner et al. have shown 
in their study that simultaneous screening for CYP2C19, CYP2C9, CYP2D6, CYP3A4 and 
CYP3A5 can lead to savings in healthcare as a result of a reduction in hospitalizations 
and patient visits to the emergency department (70). Similarly, the U­PGx project will 
also perform an analysis to determine whether pre­emptive screening of 50 variants in 
13 pharmacogenes will lead to a decrease in costs in the healthcare system (71). Finally, 
with the rapid developments in biotechnology and the concurrent rapid decrease in costs 
of genotyping techniques such as genome­wide screening as WES or WGS might become 
cost­efficient in the next decade.
Improving acceptance of PGx testing
In addition to the scientific evidence, the integration of any laboratory test or clinical proce­
dure is dependent on the adoption by healthcare professionals and patients. With the rapid 
progression of the field of PGx in the last decades healthcare professionals are advent of an 
era where there is a significant chance they will be confronted with (pharmaco)genomic 
information from patients and are expected to optimize the patients’ treatment based on this 
information. A survey performed among US physicians has shown that although doctors 
believe in the concept of heritable drug response only 10.3% feels adequately informed 
about the availability of PGx testing and the place of PGx testing within pharmacotherapy 
(66). Similarly, a questionnaire among Canadian pharmacists revealed a high expectation 
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of PGx to improve safety and effectiveness of drug therapy only 7.7% of the responders 
felt comfortable interpreting and advising upon PGx test results. Furthermore, virtually 
all (96.6%) of the surveyed pharmacist would like additional education on the subject 
(79). Both studies indicate a knowledge gap relating to PGx is present among healthcare 
professionals. 
With the integration of therapeutic recommendations for patients with known actionable 
genotypes into clinical decision support in electronic drug prescribing and dispensing 
systems it was anticipated that a knowledge gap relating to PGx among healthcare 
professionals would be circumvented. In contrast, a questionnaire performed among 
Dutch pharmacists showed that this was not the case. Knowledge of the guidelines of 
the DPWG and their integration in the clinical decision support was not associated with 
feeling informed about PGx testing or PGx test adoption (Chapter 8). Additionally, the 
percentages of responders that felt informed about PGx testing (14.7%), that would like 
to follow additional training on the subject (88.8%) and that had adopted a PGx test 
(14.1%) were similar to previous studies (66, 79) (Chapter 8). Further research performed 
among pharmacy students revealed a similar percentage of 12.8% of participants that felt 
adequately informed despite almost all of the students (96.6%) having followed some form 
of education on the subject (Chapter 9). The results from the latter study indicate that the 
current traditional form education on PGx as part of the curriculum is not sufficient and 
may result in a future knowledge gap.
The results from these studies indicate that a lack of knowledge on PGx testing is one of 
the remaining barriers hindering implementation. To remove this barrier more education 
on the subject for (future) healthcare professionals is required and should be presented in 
an alternate manner. In one initiative reported by Weitzel et al. students obtain their own 
pharmacogenetic profile and use this information in an education setting. This form of 
education using hands­on experience based learning appears to increase understanding 
of PGx markers and allows students to get used to the idea to act on (pharmaco)
genomic markers (80). Training on the subject for practicing healthcare professionals 
could be provided in the form of post­academic education where in addition to basic 
information about (pharmaco)genomics, the existence of guidelines containing therapeutic 
recommendations and evidence for implementation of genetic testing is discussed. One 
survey found a link between this form of education and the future use of PGx testing 
(Chapter 8).
A current challenge is that certain practicing healthcare professionals do not often receive 
the opportunity to gain experience in adjusting medication based on PGx markers. As the 
body of evidence for genetic screening for gene­drug pairs occurring in primary care is 




not as large compared to fields in secondary care (e.g. oncology) general practitioners and 
community pharmacists do not routinely use PGx markers to adjust therapy. As a result, 
they probably do not feel qualified to adjust pharmacotherapy based on PGx markers 
(Chapter 8). In the Implementation of Pharmacogenetics in to Primary care Project 
(IP3) community pharmacists were offered free ordering of a PGx panel consisting of 8 
genes (CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, SLCO1B1, TPMT and VKORC1) 
and gain experience with genotype­guided dosing of ten drugs frequently prescribed in 
primary care (Chapter 4). In line with previous implementation projects the IP3 showed 
that the majority of patients (90%) carried at least one actionable genotype in the panel 
and combinations of actionable genotypes with relevant drugs were common (31.0%). And 
although not significant (p = 0.112) there was an increase in the percentage of surveyed 
community pharmacists and general practitioners that felt qualified to interpret and act 
on PGx data (15.2% before vs. 28.3% after) (Chapter 4).
The combination of the frequencies of actionable genotypes from this panel of 8 genes 
along with prescription data from 95% of the community pharmacies in the Netherlands 
projects that 23.6% of all patients receiving incident prescriptions from a selection of 
45 drugs associated with the genes in the panel experience a gene­drug. In a possible 
future scenario where patients are routinely genotyped for this panel of clinically relevant 
pharmacogenes community pharmacists are likely required to perform an intervention 
in 5.4% of therapy and strictly monitor an additional 18.2%. To execute this role as key 
user of PGx data pharmacists will need to be comfortable with adjusting therapy based 
on genetic markers (Chapter 5).
Conclusion
In the last decades the field of PGx has provided a wealth of information from research on 
SNPs in candidate genes up to studies using hypothesis free testing in the form of GWA 
studies and next generation sequencing powered by the advances in molecular technology. 
In the last years assays have been developed that are usable in the clinical settings and by 
efforts of the CPIC and the DPWG the vast amount of scientific literature concerning 
many gene­drug pairs has been reviewed and condensed into actionable therapeutic 
recommendations usable in the clinic. Multiple studies have shown that implementation 
of PGx­testing (using a panel approach) in clinical practice is feasible and several RCTs 
have delivered evidence for the routine implementation of PGx­testing for a number of 
gene­drug pairs such as DPYD and TPMT. Currently, studies providing the clinical utility 
and cost­effectiveness of panel­based screening are ongoing which might deliver the final 
evidence required for widespread implementation of PGx in clinical care. One barrier which 
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still appears to be remaining are healthcare provides themselves which indicate that they 
hindered by a knowledge gap on the subject. A change in the current curriculum might 
prevent lack of knowledge among future healthcare professionals whereas post­academic 
education will resolve the knowledge gap among current practicing colleagues. 
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This thesis covers scientific research with the overall aim to improve clinical acceptance 
of pharmacogenetics in clinical care. Chapter 1 describes how in the last decades clinical 
studies have generated evidence that a one-size-fits-all approach to drug therapy is often 
not applicable and large inter-patient variability exists in both risk of side effects and 
efficacy of pharmaceuticals. By aid of the advancements made in biotechnology, proof was 
delivered that absorption, distribution, metabolism and excretion of pharmaceuticals (and 
endogenous substrates) is in part under control by the genome. Recent clinical studies have 
indeed shown that the use of genetic information can improve drug efficacy and toxicity. 
Additionally, the Clinical Pharmacogenetics Implementation Consortium (CPIC) and 
the Dutch Pharmacogenetics Working Group (DPWG) have provided clinicians with 
evidence-based therapeutic recommendations and in The Netherlands guidelines of the 
DPWG are incorporated in the electronic drug-prescribing and -dispensing systems. 
Currently, pharmacogenetics (PGx) is routinely used to adjust pharmacotherapy with high 
risk medication in some secondary and tertiary centers. However, in primary care PGx is 
still scarcely used, while a large majority of the drugs that are reviewed by CPIC and the 
DPWG are (primarily) prescribed and dispensed in primary healthcare centers. Moreover, 
small pilot studies and large PGx implementation projects have shown that a large majority 
of individuals carry at least one actionable phenotype. This portrays the need to implement 
a pre-emptive panel based pharmacogenetic screening in primary healthcare centers. 
The first part of this thesis provides answers to frequently asked questions by clinicians 
regarding PGx. The second part describes the clinical implementation of PGx in clinical 
practice and its impact on primary care on a national level. Harmonization of PGx 
guidelines and therapeutic recommendations are described in the third part of the thesis. 
In the fourth part knowledge, experience and attitudes towards PGx of pharmacists and 
pharmacy students are described. The final part contains the general discussion.
Part I: Answers to frequently asked question by clinicians 
regarding PGx
In Chapter 2, six frequently asked questions by clinicians are answered which can be 
applied to the implementation of PGx in clinical practice. 




Q1: Do we need pharmacogenetic markers to improve pharmacotherapy? Yes! 
As randomized clinical trials that are required for registration purposes generally include 
highly selected individuals, the efficacy and safety of prescription drugs is often lower than 
found in the clinical studies. Safety of pharmacotherapy can be increased by slowly titrating 
patients to a tolerable dose with sufficient efficacy. Using predictive pharmacogenetic 
biomarkers at the start of therapy, healthcare professionals can potentially use drugs in 
a more efficacious manner without requiring the so called ‘trial-and-error prescribing’. 
Q2: What are the sources of genetic variation that influence drug response?
Pharmacokinetics: Genetic variations come in form of single nucleotide polymorphisms, 
insertions and deletions that occur in the encoding genes, which can have consequences 
for the activity of the protein. Increased enzyme activity, by duplication of the encoding 
gene, can also occur. 
Pharmacodynamics: When genetic variation occur in the genes that encode for a receptor 
or enzymes involved in the signal-transduction this can lead to altered downstream 
signaling and associated processes and ultimately can lead to altered pharmacodynamics 
of a drug. 
Idiosyncratic drug reactions: In some cases, genetic variation can lead to altered drug 
response that does not appear to be related to exposure to the drug. These mutations are 
often found in the genetic regions that code for the Human Leukocyte Antigen (HLA) 
and seem to modulate immune-responses to drugs.
Q3: To what extent is variability in drug response explained by pharmacogenetics? 
Variable!
Using the R2 parameter, the contribution of pharmacogenetic biomarkers to an outcome 
can be compared to conventional clinical factors used to adjust therapy. Dependent on 
the studied phenotype PGx biomarkers should be combined with clinical factors, rather 
than used standalone.
Q4: Are pharmacogenetic test results actionable? Yes! 
However, the majority of drug labels do not yet contain information on how to adjust 
therapy based on genetic biomarkers, although this is increasing. If genetic biomarkers 
are to be used by clinicians as part of routine care the results form clinical studies have to 
be translated to therapeutic recommendations, scoring systems or decision trees. 
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Q5: What level of evidence is required for implementation? Still debated!
From the evidence-based paradigm the best supporting evidence for implementation of 
pharmacogenetics in clinical practice would be obtained from randomized clinical trials 
(RCT’s). However, when gene-drug interactions are considered in the same way as drug-
drug interactions or dose-adjustment for clinical factors as impaired renal or liver function, 
observational evidence should be sufficient to support implementation. In case proof of 
principle is established with a number of RCT’s investigating PGx markers providing 
positive results, additional evidence in the form of well replicated observational studies 
should be sufficient to justify implementation of PGx markers into clinical care.
Q6: Where can I find sources for up-to-date information regarding interpretation 
of PGx test results? PharmGKB!
The DPWG and CPIC both have provided clinicians with dosing recommendations 
based on systematic reviews of the literature since 2008 and 2011 respectively. With this 
information these two consortia have provided tools which facilitate physicians and 
pharmacists with the interpretation of PGx tests and adjustment of pharmacotherapy based 
on genotypes. The guidelines of both consortia can be found on pharmgkb.org.
Part II: Implementation of PGx in clinical practice and its 
impact on a national level
To ensure clinical acceptance of PGx-testing healthcare professionals should be able to order 
clinical grade tests for clinically relevant genes. One pharmacogene particularly relevant 
in pharmacotherapy is CYP2D6. At the start of this thesis the gold standard in CYP2D6 
testing in clinical practice was the Roche AmpliChip. In Chapter 3 the concordance 
between the novel GenoChip CYP2D6 macroarray and the AmpliChip was investigated. 
The study was performed by genotyping 200 samples with germline DNA samples from 
the CYPTAM study, a prospective multicenter study performed in the Netherlands and 
Belgium which includes 671 female patients with breast cancer which were screened with 
the Roche AmpliChip. Of the tested samples 99% (n = 198) of the results of the GenoChip 
were concordance with the results of the AmpliChip. In two samples the genotyping results 
from the GenoChip CYP2D6 macroarray were discordant from the results from the 
AmpliChip as the Amplichip identified a *41 allele, while the GenoChip did not. Sanger 
sequencing of the two discordant samples revealed that the 2988G>A mutation, considered 
by The Human Cytochrome P450 Allele Nomenclature Committee as the key mutation 
for *41, was not present. Based on the results of this comparison it was concluded that 




the CYP2D6 GenoChip Macroarray is a valid method for detecting 13 genetic variants 
in the CYP2D6 gene.
In addition to the development of clinical grade assays adoption of PGx test by healthcare 
professionals is an important factor in its implementation in clinical practice. At the start 
of this thesis PGx was increasingly used in hospitals, while the adoption of PGx tests by 
general practitioners and community pharmacists remained low. To further improve 
adoption of PGx-testing in primary care the Implementation of Pharmacogenetics in 
Primary care Project (IP3) was initiated. Chapter 4 describes the IP3-study in which 
general practitioners and community pharmacists could implement PGx testing in their 
own practice. Patients with an incident prescription for a drug with known gene-drug 
interactions (amitriptyline, atomoxetine, atorvastatin, (es)citalopram, clomipramine, 
doxepin, nortriptyline, simvastatin or venlafaxine) were eligible for inclusion. The patients 
were screened for 40 genetic variants in the genes CYP2C9, CYP2C19, CYP2D6, CYP3A5, 
DPYD, SLCO1B1, TPMT and VKORC1 using the DMET platform in combination with a 
qPCR Taqman to detect copy-number variation in the CYP2D6 gene. The genotypes were 
translated to predicted phenotypes and combined with a therapeutic recommendation 
from the DPWG guidelines in a written report. This report was then transferred to the 
treating general practitioner and pharmacist with the request to archive the results in 
their electronic drug prescribing and -dispensing systems in order to perform medication 
surveillance using clinical decision support (CDS). A total of 200 patients were included 
by clinicians in the period from November 2014 to July 2016, accounting to an adoption 
of PGx-testing in 18.0% of the eligible patients. The majority of the patients was included 
on an incident prescription of a statin, being atorvastatin (57.5%) or simvastatin (14.5%). 
The remainder of the patients (28.0%) was included on an antidepressant (amitriptyline, 
(es)citalopram, nortriptyline, or venlafaxine). In 90% of the patients at least one 
actionable genotype in the selected panel was found. More importantly, in 31.0% of 
the incident prescriptions a combination of one of the selected drugs of inclusion with 
the associated actionable genotype was present and a therapeutic recommendation was 
provided based on the DPWG guidelines to the clinicians to change the regimen and/
or monitor the patient more closely for ineffective or unsafe therapy. The study showed 
that genotype guided dosing in primary care is feasible and allowed general practitioners 
and community pharmacists to gain experience with PGx in the context of their own 
practice. Additionally, it demonstrated that actionable genotypes in the selected panel are 
common among the population. In Chapter 5 an estimate was made of the national clinical 
impact of implementing a preemptive panel based PGx consisting of CYP2C9, CYP2C19, 
CYP2D6, CYP3A5, DPYD, SLCO1B1, TPMT and VKORC1 in primary care throughout 
The Netherlands. The frequencies of the actionable genotypes for the selection of 8 genes 
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from the IP3-study were used a representative sample for the Dutch population and were 
combined with national prescription data in primary care obtained from the Foundation 
of Pharmaceutical Statistics (SFK). Our estimate shows that for 45 drugs associated with 
the 8 genes a gene-drug interaction as described in the guidelines of the DPWG is present 
in 23.6% of all incident prescriptions (n = 856,002 prescriptions/year). Additionally, in one 
in every 19 (= 5.4%) incident prescriptions this would result in an adjustment of the dose 
or switch to an alternate drug at the start of therapy. Based on this estimation we predict 
that in a near future where clinicians will be confronted with patients with a known PGx 
profile, general practitioners and community pharmacists will routinely have to adjust 
pharmacotherapy based on actionable genotypes. 
Part III: Harmonization of PGx-test interpretation and 
therapeutic recommendations
An important goal is to achieve a worldwide uniform interpretation of PGx-test results 
and clinical actions based on actionable pharmacogenes. However, due to of differences 
in size of studies, study population, chosen methodology and chance investigators might 
find differences in effect size of studied genotype-phenotype relationships. Chapter 6 
provides a response to Magnani et al. who proposed a further reduction of the starting 
dose of fluoropyrimidine regimens in patients who are heterozygous carriers of the DPYD 
IVS14+1G>A variant. This proposal was based on a single prospective study with 180 
patients that were candidate for therapy with a fluoropyrimidine-based regimen. Patients 
were screened for the DPYD IVS14+1G>A splice site variant as part of the study and 
were routinely evaluated for fluoropyrimidine-related toxicities. In our response, based 
on literature reviews performed by the CPIC and the DPWG and pharmacokinetic study 
performed by Deenen et al, we argue that a 50% dose reduction followed by dose titration 
based upon toxicity is the best approach to fluoropyrimidine dosing in patients who are 
heterozygous carriers of the IVS14+1G>A variant.
Despite the global availability of scientific literature different research groups interpret 
the available evidence slightly differently resulting in differences in interpretation of 
PGx test results and therapeutic recommendations. Chapter 7 describes the initiative to 
harmonize the guidelines released by the CPIC and DPWG by an inventory of existing 
differences. This was executed by a review of the methodologies incorporated by these 
two consortia, a systematic comparison of the genotype to phenotype translations and 
therapeutic recommendations for gene-drug interactions shared between the guidelines 
of both groups. The comparison shows that there is a substantial agreement between 




the therapeutic recommendations provided in the guidelines of the two consortia. The 
discordances in dosing advices or recommendations to switch to alternate drugs can be 
explained by differences in applied methodologies, the differences at which literature 
search for the recommendations for the drug-gene pairs were carried out or differences 
in clinical practices between countries. An important difference between the guidelines of 
the two consortia is the translation of genotype to phenotype in case of the gene CYP2D6. 
CPIC classifies the combination of a normal CYP2D6 allele with a null allele as a normal 
metabolizer, while according to the DWPG this is an intermediate metabolizer. Currently, 
an international group of experts in the field, including members of CPIC and DPWG is 
trying to find consensus on how CYP2D6 genotypes should be translated. 
Part IV: Knowledge, experience and attitudes towards PGx of 
pharmacists and pharmacy students
The fourth part of this thesis is dedicated to the mindset of (future) healthcare professionals 
toward PGx. 
In addition to evidence, the opinion of clinicians of a new laboratory test is also of major 
importance for its implementation in routine care. Available research done among USA 
physicians and Canadian pharmacists has shown that clinicians have found themselves 
unprepared by the swift pace of evolution of (pharmaco)genetic research driven by the 
advances in biotechnology. The adoption of PGx by clinicians can be hampered if they do 
not believe in the concept of (partially) heritable drug response, do not know where to apply 
for PGx testing or are not comfortable in their abilities to interpret PGx test results and act 
on (pharmaco)genetic data. In Chapter 8 the results of a nationwide survey among 667 
Dutch pharmacists in the context of a national CDS system are described. In this survey 
participants were asked a total of 41 questions divided among 7 themes. The results show 
that virtually all pharmacists (99.7%) believe in the concept of (partially) heritable drug 
response and have high expectations of PGx in relation to pharmacotherapy. In contrast, 
the adoption of PGx among the surveyed pharmacists was low as only 14.7% had ordered or 
recommended a PGx test in the previous 6 months. Additionally, 14.1% of the participants 
felt adequately informed about PGx testing and 88.8% would like additional training on the 
subject. Moreover, being aware of the existence of the therapeutic recommendations created 
by the DPWG or the incorporation of the DPWG guidelines in electronic medication 
surveillance systems did not have any significant effect on knowledge how to apply PGx 
or adoption of PGx-testing. From the results of this study we concluded that Dutch 
pharmacists are generally very positive toward PGx, but perceive a lack in knowledge on 
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the subject and are need of extra training. Chapter 9 provides insight in the knowledge 
and perceived abilities of pharmacy students regarding PGx testing. A survey consisting of 
28 questions performed among 148 pharmacy students revealed that like their practicing 
colleagues they all believe in the concept of PGx and have high expectations that PGx 
will lead to safer and more effective pharmacotherapy. Virtually all surveyed students 
had received some sort of education on PGx, but only 12.8% felt adequately informed on 
how to apply PGx in pharmacotherapy indicating a knowledge gap on this subject among 
future pharmacists. A comparison with the cohort of 667 surveyed pharmacists using a 
multivariate analysis revealed that there are significant differences between the students 
and their practicing colleagues. Compared to pharmacist, the students feel more qualified 
to recommend PGx testing to predict drug efficacy, would use extra information to support 
the use of PGx testing in pharmacotherapy more often and other kind of sources of 
information to support the use of PGx within pharmacotherapy and to support changes in 
dose and drug when a patients’ genotype is known. Additional research should investigate 
which type of education can reduce the PGx knowledge gap among pharmacy students.
Part V: General discussion & Summary
This dissertation is concluded with a general discussion in Chapter 10 on the implementa-
tion of pharmacogenetics in everyday clinical settings. The chapter provides an overview 
of the current players in the field who are involved with the integration of PGx into 
routine clinical care. Additionally, several challenges which currently still hinder the 
implementation are identified such as selecting of clinically relevant pharmacogenes, 
providing data on diagnostic criteria of PGx testing, guidelines directing the clinical use 
of PGx test results, the evidence supporting improve of clinical care, information on cost-
effectiveness and cost-consequences of PGx testing and the improvement of acceptance 
of PGx testing. The chapter closes with the conclusion that clinical grade assays have been 
developed, guidelines with therapeutic recommendation for actionable gene-drug pairs 
have been created and several RCT’s have delivered evidence for implementation. One 
remaining barrier still hindering implementation is currently the knowledge gap on PGx 
among healthcare professionals and future clinicians which can potentially by resolved by 
a change in the current curriculum and post-academic education. 
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In dit proefschrift wordt wetenschappelijk onderzoek beschreven welke als doel had om 
de implementatie van farmacogenetica in de gezondheidszorg te bevorderen. Hoofdstuk 
1 beschrijft hoe in de laatste decennia duidelijk is geworden dat een uniforme aanpak van 
farmacotherapie niet bruikbaar is omdat er grote inter-patiënt variabiliteit bestaat in zowel 
de effectiviteit als de bijwerkingen van geneesmiddelen. Er is inmiddels aangetoond dat 
individuele verschillen in absorptie, distributie, metabolisme en excretie van geneesmiddelen 
(en endogene substraten) deels een erfelijke oorsprong hebben. Recente klinische studies 
hebben aangetoond dat de toepassing van farmacogenetica de werkzaamheid en veiligheid 
van geneesmiddelen kan vergroten. De Nederlandse werkgroep Farmacogenetica (DPWG) en 
het Clinical Pharmacogenetics Implementation Consortium (CPIC) hebben farmacogenetica 
adviezen gebaseerd op systematische review van de wetenschappelijke literatuur opgesteld. De 
adviezen van de DPWG zijn in Nederland geïntegreerd in de voorschrijf- en afleversystemen 
van arts en apotheker. Op dit moment wordt farmacogenetica vooral toegepast in de tweede- 
en derdelijns gezondheidszorg om farmacotherapie te optimaliseren. Hoewel de meeste 
geneesmiddelen beschreven in de richtlijnen van de DPWG en CPIC door huisartsen 
veelvuldig worden voorgeschreven, wordt farmacogenetica in de eerstelijnsgezondheidszorg 
nog nauwelijks toegepast. Diverse studies hebben laten zien dat, wanneer er tegelijkertijd 
meerdere farmacogenen worden getest worden (“panel-based”), er bij de meeste patiënten 
tenminste één afwijkend genotype wordt gevonden. De hoge prevalentie van deze genetische 
variaties en de goede beschikbaarheid van farmacogenetische zijn sterke argumenten voor 
het invoeren van farmacogenetische screening in de eerstelijnsgezondheidszorg.
In het eerste deel van het proefschrift worden een zestal veelvoorkomende vragen van 
clinici over farmacogenetica beantwoord. Het tweede deel beschrijft de implementatie 
van farmacogenetica in de praktijk en de geschatte landelijke impact van farmacogenetica 
in de eerstelijnsgezondheidszorg. Het derde deel van dit proefschrift heeft als onderwerp 
het harmoniseren van de farmacogenetische adviezen van de DPWG en CPIC. In het 
vierde deel worden de kennis, ervaring en attitudes ten aanzien van farmacogenetica van 
apothekers en farmaciestudenten beschreven. Het vijfde deel bevat een algemene discussie 
van de voorgaande hoofdstukken in dit proefschrift.
Deel I: Antwoorden op door clinici veel-gestelde vragen over 
farmacogenetica
In Hoofdstuk 2 worden zes door artsen en apothekers vaak gestelde vragen behandeld 
over de implementatie van farmacogenetica.
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Vraag 1: Zijn farmacogenetische markers nodig voor de verbetering van de far-
macotherapie? Ja!
De werkzaamheid en veiligheid van geneesmiddelen blijken in de praktijk vaak aanzienlijk 
lager te zijn dan bij fase III klinische studies. Met het vaststellen van de farmacogenetische 
biomarkers aan het begin van de therapie kunnen clinici geneesmiddelen op een betere 
manier inzetten. 
Vraag 2: Wat zijn bronnen van genetische variatie die geneesmiddelrespons kun-
nen beïnvloeden?
Farmacokinetiek: Genetische variatie komt vaak voor in de vorm van een polymorfisme 
van één enkele nucleotide, inserties of deleties van één of van meerdere nucleotiden. Deze 
variaties kunnen leiden tot een verandering in activiteit van een enzym met als gevolg 
dat de afbraak van geneesmiddelen verminderd is of geheel niet plaatsvindt. Verhoogde 
enzymatische activiteit, door duplicatie van het coderende gen, kan ook voorkomen. 
Farmacodynamiek: Genetische variatie in de genen die coderen voor een receptor of 
enzymen die betrokken zijn bij de signaaltransductie, kan leiden tot veranderde signalen 
en/of veranderde processen in de cel. 
Idiosyncratische geneesmiddelreacties: In sommige gevallen kan genetische variatie 
leiden tot een reactie op een geneesmiddel die niet gerelateerd is aan de dosis of concentratie 
werkzame stof. De hypothese is dat mutaties in de genoomregio’s die coderen voor het 
Humaan Leukocyt Antigeen (HLA) de immuunrespons op het geneesmiddel moduleren.
Vraag 3: In welke mate wordt variabiliteit in geneesmiddelrespons verklaard door 
farmacogenetica? Variabel!
Met behulp van de verklaarde variantie (R2) kan de bijdrage van een farmacogenetische 
biomarker op een eindpunt worden vergeleken met de conventionele klinische factoren 
die gebruikt worden voor het aanpassen van de ingestelde therapie. Afhankelijk van het 
bestudeerde fenotype kunnen farmacogenetische biomarkers met klinische factoren 
gecombineerd worden.
Vraag 4: Zijn farmacogenetische uitslagen “actionable”? Ja!
Hoewel de meerderheid van de geneesmiddelenbijsluiters nog geen aangepaste behan-
deladviezen ten behoeve van patiënten met afwijkende genotypes bevat, worden deze 
therapeutische adviezen steeds vaker opgenomen in bijsluiters. Als genetische biomarkers 
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door clinici gebruikt gaan worden in de zorg zullen resultaten van klinische studies vertaald 
moeten worden in therapeutische adviezen, scores of beslisbomen.
Vraag 5: Welke mate van bewijs is nodig voor implementatie? Hier is nog geen 
consensus over!
Wanneer gen-geneesmiddelinteracties op dezelfde manier wordt beschouwd als reguliere 
geneesmiddelinteracties of dosisaanpassingen voor klinische factoren (zoals verminderde 
nier- of leverfunctie), dan zou observationeel bewijs genoeg moeten zijn voor de imple-
mentatie van farmacogenetica. Positieve resultaten van enkele gerandomiseerde klinische 
studies, met als focus het onderzoeken van farmacogenetische markers, kunnen als bewijs 
dienen dat het concept van farmacogenetica werkt. 
Vraag 6: Waar vind ik bronnen van up-to-date informatie met betrekking tot de 
interpretatie van farmacogenetica test uitslagen? PharmGKB!
De DPWG en CPIC hebben sinds 2008 resp. 2011 richtlijnen opgesteld voor doseer-
adviezen gebaseerd op een systematische review van de wetenschappelijke literatuur. 
Deze richtlijnen, terug te vinden op pharmgkb.org, vormen de handvatten voor artsen 
en apothekers om de farmacogenetische uitslagen van de patiënt te interpreteren en de 
therapie hierop aan te passen.
Deel II: Implementatie van farmacogenetica in de klinische 
setting en de impact op landelijk niveau
Om de implementatie van farmacogenetica in de zorg te laten slagen, moeten artsen en 
apothekers genotypes voor klinisch relevante genen kunnen laten bepalen. Omdat het 
gen CYP2D6 betrokken is bij het metabolisme van 20-25% van de geneesmiddelen die 
momenteel op de markt zijn, is dit gen zeer relevant. Bij de start van dit promotieonderzoek 
was de Roche AmpliChip de gouden standaard voor het typeren van het CYP2D6 gen. 
In Hoofdstuk 3 wordt de vergelijking tussen de nieuwe GenoChip CYP2D6 macroarray 
en de AmpliChip beschreven. De overeenkomst tussen de twee methoden is getest door, 
met de GenoChip CYP2D6 macroarray, het DNA uit witte bloedcellen afkomstig van 200 
monsters uit de CYPTAM-studie te genotyperen voor het gen CYP2D6. De CYPTAM-
studie is een prospectieve multicenter studie die is uitgevoerd in Nederland en België, 
waarin 671 vrouwen met borstkanker zijn getest met de Roche AmpliChip. De resultaten 
van de met de GenoChip 200 geteste monsters bleken voor 99% (n = 198) overeen te 
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komen met de resultaten van de AmpliChip. Bij twee monsters kwamen de uitslagen 
van de twee methoden niet overeen: de AmpliChip registreerde bij de twee monsters 
een *41 allel, terwijl met de GenoChip een *1 werd gevonden. Sanger sequencing van de 
twee afwijkende monsters toonde aan dat de 2988G>A mutatie niet aanwezig was. Deze 
mutatie wordt door de Humane Cytochroom P450 Allel Nomenclatuur Commissie gezien 
als de belangrijkste mutatie van het *41 allel. De resultaten van dit onderzoek geven aan 
dat de CYP2D6 GenoChip Macroarray een valide methode is voor het detecteren van 13 
genetische varianten in het CYP2D6 gen. 
Naast de ontwikkeling van nieuwe hoogwaardige farmacogenetische testen is de praktische 
toepassing van deze nieuwe testen door artsen en apothekers in de kliniek van belang. 
Bij de start van dit promotieonderzoek werd farmacogenetica in toenemende mate in de 
tweedelijnsgezondheidszorg toegepast, maar de implementatie ervan in de eerstelijnsge-
zondheidszorg bleef achter. Om de toepassing van farmacogenetica in de eerstelijnsge-
zondheidszorg te verbeteren, werd het Implementation of Pharmacogenetics in Primary 
care Project (IP3) geïnitieerd. In Hoofdstuk 4 wordt de IP3-studie beschreven: een studie 
waarin huisartsen en openbaar apothekers ervaring konden opdoen met farmacogenetica in 
hun eigen praktijk. Patiënten met een eerste uitgifte van een geneesmiddel met een bekende 
gen-geneesmiddel interactie (amitriptyline, atomoxetine, atorvastatine, (es)citalopram, 
clomipramine, doxepine, nortriptyline, simvastatine of venlafaxine) konden worden geïn-
cludeerd . De patiënten werden vervolgens getest op 40 genetische varianten in de genen 
CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, SLCO1B1, TPMT en VKORC1 met behulp 
van het DMET-platform. Om tevens variaties in het aantal kopieën van het CYP2D6 gen te 
kunen detecteren werd ook een kwantitatieve Polymerasekettingreactie (qPCR) Taqman 
methode toegepast. De genotypes werden vervolgens vertaald in voorspelde fenotypes en 
gecombineerd met adviezen van de DPWG in een rapport. Dit rapport werd vervolgens 
overgedragen aan de behandelend huisarts en openbaar apotheker met het verzoek om de 
resultaten in hun voorschrijf- en afleversystemen op te nemen om zo farmacogenetische 
medicatiebewaking te realiseren. In de periode van november 2014 tot en met juli 2017 
zijn 200 patiënten geïncludeerd door de deelnemende zorgverleners. Van de patiënten die 
in aanmerking kwamen voor de studie werd uiteindelijk 18.0% geïncludeerd. De meerder-
heid van de patiënten werd geïncludeerd naar aanleiding van een eerste uitgifte van een 
statine, zijnde atorvastatine (57.5%) of simvastatine (14.5%). Het resterende deel van de 
patiënten (28.0%) werd geïncludeerd naar aanleiding van een eerste uitgifte voor een anti-
depressivum (amitriptyline, (es)citalopram, nortriptyline of venlafaxine). In 90% van alle 
patiënten werd tenminste één afwijkend genotype in de 8 genen aangetoond. Wanneer de 
informatie uit het farmacogenetisch profiel van de patiënt vervolgens gecombineerd werd 
met het voorgeschreven recept, bleek er in 31.0% van de patiënten sprake te zijn van een 
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afwijking in het gen waarvan een bekende gen-geneesmiddelinteractie is beschreven met 
het voorgeschreven geneesmiddel. Bij deze groep patiënten werd er vervolgens een advies 
op basis van de richtlijn van de DPWG uitgebracht aan de behandelend arts en apotheker 
om de behandeling aan te passen en/of de patiënt strenger te monitoren op effectiviteit of 
bijwerkingen. Deze studie toont aan dat de toepassing van farmacogenetica in de eerste-
lijnsgezondheidszorg mogelijk is en bevestigt de hoge prevalentie van afwijkende genotypen 
bij patiënten in het panel van de geselecteerde 8 genen. Verder maakte dit project het voor 
huisartsen en openbaar apothekers mogelijk om ervaring op te doen met farmacogenetica 
in hun eigen praktijk. In Hoofdstuk 5 is een schatting gemaakt van de landelijke impact 
van het implementeren van een farmacogenetische screening bestaande uit een selectie van 
de genen CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, SLCO1B1, TPMT en VKORC1 in 
de eerstelijnsgezondheidszorg in Nederland. Hierbij zijn de frequenties van de afwijkende 
genotypes van deze 8 genen, zoals verkregen uit de IP3-studie, gebruikt als een represen-
tatieve steekproef uit de Nederlandse bevolking. De frequenties van de genotypen werden 
gecombineerd met nationale prescriptiedata uit de eerste lijn afkomstig van de Stichting 
Farmaceutische Kengetallen (SFK). De hieruit berekende schatting laat zien dat voor de 45 
geneesmiddelen die met de 8 genen geassocieerd zijn, er in 23.6% van de eerste uitgiftes 
(n = 856.002 uitgiftes/jaar), sprake is van een gen-geneesmiddel interactie zoals beschreven 
in de richtlijnen van de DPWG. Volgens de berekening zou er in één op de negentien (= 
5.4%) eerste uitgiftes een verandering in de dosering of de keuze van het geneesmiddel 
moeten plaatsvinden bij start van de therapie. Duidelijk wordt dat in de nabije toekomst 
huisartsen en openbaar apothekers geconfronteerd worden met patiënten waarvan het 
farmacogenetische profiel bekend is en zij routinematig farmacotherapie zullen moeten 
aanpassen aan de hand van afwijkende genotypes. 
Deel III: Harmonisatie van interpretatie van uitslagen en 
therapeutische adviezen
Een belangrijk doel is het vaststellen van een wereldwijde uniforme interpretatie van far-
macogenetische testuitslagen en het standaardiseren van de daarbij passende behandelad-
viezen voor patiënten met afwijkende farmacogenen. Hoofdstuk 6 geeft een reactie op een 
artikel van Magnani et al. In dit artikel wordt een prospectieve studie met 180 individuen 
beschreven waarin de onderzoekers de patiënten screende voor de DPYD IVS14+1G>A 
splice site variant (ofwel het *2A-allel) en routinematig evalueerde voor fluoropyrimidine-
gerelateerde toxiciteit. Vier van de 180 gescreende patiënten bleken heterozygoot drager 
te zijn van het DPYD *2A allel. Aan de hand van deze uitslag werd in één patient afgezien 
van behandeling met fluoropyrimidines en werd bij drie patiënten een dosis reductie van 
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50% toegepast op basis van de richtlijnen van de DPWG. Ondanks de toegepaste dosis-
reductie observeerden de onderzoekers ernstige toxiciteit bij de drie patiënten als gevolg 
van de fluoropyrimidine behandeling en concluderen dat er een verdere reductie van de 
startdosis van fluoropyrimidines nodig is voor patiënten die heterozygoot drager zijn van 
de DPYD IVS14+1G>A variant. In onze reactie, gebaseerd op uitgebreide review van de 
literatuur en een farmacokinetische studie van Deenen et al., wordt beredeneerd dat een 
reductie van 50% in de startdosis, gevolgd door een dosistitratie gebaseerd op toxiciteit, een 
betere benadering is voor het doseren van fluoropyrimidines in patiënten die heterozygoot 
drager zijn van de IVS14+1G>A variant. 
Verschillen in farmacogenetische richtlijnen, gebaseerd op dezelfde onderliggende litera-
tuur, kan het gevolg zijn van verschillen in interpretatie van de literatuur. Hoofdstuk 7 
beschrijft het initiatief om de richtlijnen van de DPWG en de CPIC te harmoniseren door 
de inventarisatie van bestaande verschillen in interpretatie van uitslagen en therapeutische 
adviezen. Hiervoor zijn de methodologieën van consortia systematisch beoordeeld en is 
een vergelijking gedaan van zowel interpretatie van het genotype, als de therapeutische 
adviezen voor gen-geneesmiddel interacties die beide consortia richtlijnen zijn opgesteld. 
De vergelijking laat een grote overeenkomst zien tussen de therapeutische adviezen 
opgesteld door de twee consortia. De verschillen in doseeradviezen en therapeutische 
strategieën kunnen verklaard worden door de verschillen in de gebruikte methodes, het 
verschil in de tijdstippen van het raadplegen van de literatuur of verschillen in de klinische 
praktijk tussen diverse landen of continenten. 
Een belangrijk verschil tussen de richtlijnen van de twee consortia is de vertaling van het 
genotype naar fenotype bij het gen CYP2D6. CPIC classificeert namelijk de combinatie 
van een normaal CYP2D6 allel met een nul allel als een normale metaboliseerder, terwijl 
de DPWG deze combinatie als een intermediare metaboliseerder beschouwt. Momenteel 
werkt een internationale groep van experts, waarin ook leden van CPIC en de DPWG in 
vertegenwoordigd zijn, aan een standaardvertaling van CYP2D6 genotypen. 
Deel IV: Kennis, ervaring en attitudes ten opzichte van 
farmacogenetica onder apothekers en farmaciestudenten
In het vierde deel van dit proefschrift wordt gekeken naar de attitudes van (toekomstige) 
zorgprofessionals ten opzichte van farmacogenetica. Naast klinisch bewijs, is het beeld 
dat clinici van een beschikbare moleculaire laboratoriumdiagnostiek hebben ook een 
belangrijke factor bij implementatie in de gezondheidszorg. Studies onder Amerikaanse 
artsen en Canadese apothekers tonen aan dat deze professionals zich niet voorbereid 
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voelen op de snelle evolutie in (farmaco)genetisch onderzoek. De implementatie van 
farmacogenetica in de zorg kan stagneren als clinici niet overtuigd zijn van het concept 
van farmacogenetica. Dat wil zeggen dat geneesmiddelrespons (ten dele) wordt bepaald 
door erfelijkheid. Ook spelen factoren zoals het niet weten waar farmacogenetische testen 
aangevraagd kunnen worden, of het niet kunnen interpreteren van testuitslagen, een rol. 
Hoofdstuk 8 beschrijft een landelijke enquête onder 667 Nederlandse apothekers over 
farmacogenetica in de context van beslissingsondersteuning beschikbaar in de kliniek. 
De enquête bestond uit 41 vragen verdeeld over zeven thema’s. De resultaten laten zien 
dat bijna alle apothekers (99.7%) overtuigd zijn van het concept van farmacogenetica en 
dat ze er hoge verwachtingen van hebben. Echter, de mate waarin ze farmacogenetica 
toepassen is laag, slechts 14.7% van de ondervraagden had in de afgelopen zes maanden 
een farmacogenetische test aangevraagd of aanbevolen. Verder voelde slechts 14.1% van 
de deelnemers zich voldoende geïnformeerd over farmacogenetica en wilde 88.8% aanvul-
lende scholing over dit onderwerp. Uit de analyse bleek dat er geen significante associatie 
was tussen het op de hoogte zijn van het bestaan van de therapeutische richtlijnen van de 
DPWG of van de integratie van de richtlijnen in de elektronische medicatiebewakings-
systemen met 1) de kennis over hoe farmacogenetica te gebruiken in relatie tot therapie 
of 2) de adoptie van farmacogenetische testen. Uit de resultaten van deze studie kan wor-
den geconcludeerd dat Nederlandse apothekers erg positief zijn over de mogelijkheden 
van farmacogenetica, maar een gebrek aan kennis over dit onderwerp ervaren en graag 
extra geschoold willen worden. Hoofdstuk 9 geeft inzicht in de kennis en de attitudes 
van farmaciestudenten met betrekking tot farmacogenetica. Een enquête van 28 vragen 
afgenomen onder 148 farmaciestudenten toont aan dat zij, net als hun afgestudeerde col-
lega’s, geloven in het concept van erfelijke geneesmiddelrespons en hoge verwachtingen 
hebben in farmacogenetica als hulpmiddel voor veiliger en effectiever farmacotherapie. 
Bijna alle studenten hadden enige vorm van onderwijs over farmacogenetica genoten, 
maar slechts 12.8% van de ondervraagde studenten voelde zich voldoende geïnformeerd 
om de kennis toe te passen. Een multivariaat analyse laat zien dat er significante verschil-
len bestaan tussen de studenten en de praktizerende apothekers. In vergelijking met de 
apothekers voelen de farmaciestudenten zich meer gekwalificeerd om farmacogenetische 
testen aan te bevelen. De studenten zouden vaker extra informatie opzoeken en andere 
informatiebronnen gebruiken om de toepassing van farmacogenetica binnen farmaco-
therapie te onderbouwen. Daarnaast zouden studenten andere bronnen gebruiken om 
informatie over farmacogenetica te vinden. Aanvullend onderzoek moet uitwijzen welk 
type onderwijs het meest geschikt is om farmaciestudenten voor te bereiden voor het 
gebruik van farmacogenetische informatie in hun carrière als apotheker. 
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Deel V: Algemene discussie
Dit proefschrift eindigt in Hoofdstuk 10 met een algemene discussie over de implementatie 
van farmacogenetica in de dagelijkse klinische praktijk. Het hoofdstuk geeft een overzicht 
van de belangrijkste spelers. Verder worden de volgende uitdagingen besproken die 
momenteel een rol spelen in de implementatie van farmacogenetica in de praktijk: het 
selecteren van klinisch relevante farmacogenen; data over de diagnostische criteria van 
farmacogenetica; de richtlijnen die het gebruik van farmacogenetica adviseren; het klinische 
bewijs dat deze testen tot verbetering van de therapie; informatie over kosteneffectiviteit 
en kostenconsequenties en de verbetering van de implementatie van farmacogenetische 
testen. Het hoofdstuk eindigt met de conclusie dat er hoogwaardige farmacogenetische 
testen beschikbaar zijn, er richtlijnen zijn voor gen-geneesmiddel interacties en enkele 
RCT’s het klinisch bewijs hebben geleverd dat toepassing van farmacogenetica zinvol is. 
Een barrière die momenteel nog bestaat, is een kennishiaat over farmacogenetica onder 
huidige zorgprofessionals en toekomstige artsen en apothekers die wellicht opgelost kan 
worden door een aanpassing aan het huidige curriculum en postacademisch onderwijs. 
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Na vijf jaar geduld en doorzetten is het proefschrift dan af. Graag wil ik iedereen bedanken 
die een bijdrage heeft geleverd aan dit promotieonderzoek.
Allereerst, mijn promotor en copromotor. Beste Henk-Jan, mijn dank voor de snelle 
analyses van de manuscripten. Jouw scherpe blik hielp het overzicht te bewaren en creëerde 
vaak nieuwe mogelijkheden voor het onderzoek. Beste Jesse, bedankt voor je geduld en 
feedback op experimenten en geschreven teksten. Ik ben jullie erg dankbaar voor de kans 
die jullie mij gegeven hebben.
Verder wil ik de KNMP bedanken voor het mogelijk maken van het IP3 en diverse andere 
hoofdstukken. 
Dear colleagues from CPIC, thank you for the scientific collaboration on our paper to 
identify the differences and similarities between the two PGx-consortia.
Gedurende dit promotieonderzoek heb ik hulp gekregen van de farmaciestudenten Frank, 
Rana en Valeria. Heel erg bedankt voor jullie inzet. Ook ziekenhuisapotheker Alfonso 
Pastor Cleriques wil ik graag bedanken voor zijn bijdrage aan hoofdstuk 7.
Graag wil ik alle collega’s van het KFT bedanken voor de fijne samenwerking. In het 
bijzonder Tahar en de analisten, Renee, Daniëlle en Rowena voor jullie hulp bij het 
wegdraaien van DMET’s, DPYD’s of GenoChips. Ik heb veel van jullie geleerd. Natuurlijk 
mag ik ook mijn (oud)kamergenoten niet vergeten. Dirk-Jan, Neanke, Lisanne, Marleen, 
Sofieke, Carin, Xiaoyan, Cathelijne, Maaike en Anabel erg bedankt voor de vakinhoudelijke 
gesprekken en gezelligheid op de kamer. Frank, ik ben vereerd dat je als paranimf wil 
optreden bij mijn promotie.
Ook wil ik alle apothekers en huisartsen van de eerstelijnscentra in de regio bedanken 
voor hun deelname aan de IP3-studie en het includeren van patiënten naast de gewone 
werkzaamheden.
Lieve (schoon)familie en NWZ-collega’s. Mijn dank voor jullie interesse in promotie, dit 
hielp enorm bij de laatste loodjes.
Sander, ik ben er trots op dat ik jou mijn paranimf mag noemen. Tijdens onze studies 
filosofeerden we vaak over het verder beklimmen van de academische ladder en beiden 
hebben we deze stap genomen in de vorm van een promotieonderzoek.
Lieve Leonie, jouw ambitie om geneeskunde te gaan studeren was voor mij erg inspirerend. 
Onze gesprekken over de rol van de medisch ondersteunend specialist helpen erg om ons 
lot te relativeren.
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Lieve papa en mama, dit proefschrift was zonder jullie niet mogelijk geweest. Jullie 
betrokkenheid en aanmoediging hebben ervoor gezorgd dat ik mijn huidige pad mag 
bewandelen. Mijn eeuwige dank voor jullie liefde, het luisterend oor en de wijze lessen 
die jullie mij hebben meegegeven.
Mijn allerliefste Maud, het is inmiddels bijna zes jaar geleden dat we elkaar tegenkwamen 
en als zodanig was je vanaf de start getuige van mijn gehele promotie. Dank voor je 
emotionele steun, als je opgebouwde kennis van de statistiek en je vermogen om mij af en 
toe van mijn werk weg te trekken. Elke dag prijs ik me weer gelukkig dat jij in mijn leven 
bent en dat we om zoveel dingen kunnen lachen.
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